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ABSTRACT 
The 43 kDa TAR DNA binding protein (TDP-43) has been identified as one of 
the major proteins that accumulates in the cytoplasm of brain and spinal cord from the 
patients affected with amyotrophic lateral sclerosis (ALS) and frontotemporal lobar 
degeneration (FTLD).  Under basal conditions, TDP-43 localizes in nucleus functioning 
as an RNA binding protein to regulate different aspects of RNA metabolism, such as 
alternative splicing of messenger RNA.  In ALS/FTLD brains and spinal cords, TDP-43 
forms well-defined cytoplasmic granules, the behavior very similar to stress granule (SG) 
proteins, but the mechanisms are poorly understood. 
To investigate the mechanism of TDP-43 granule formation and to identify 
potential therapeutic targets by inhibiting the granule formation, our laboratory screened 
a chemical library of 75,000 compounds using the inducible PC12 cells that express 
EGFP-tagged wild-type human TDP-43.  We used the biological effect of cycloheximide 
on SGs as a basis for the screen, since it is known to prevent the formation of SGs and 
TDP-43 granules, pointing to a novel biological pathway that regulates TDP-43 granule 
formation. 
		 vii	
One of the candidate compounds, Compound 8 (C8) and its analog C8j dose-
dependently decreased the arsenite-induced TDP-43 granules without cytotoxicity, and 
reduced the protein levels of full-length, truncated, high molecular weight and 
phosphorylated TDP-43.  In addition, we found C8j reduced the phosphorylation at 
novel, previously unknown Thr103-Ser104 amino acid residues of human TDP-43 under 
arsenite stress.  The phospho-mimetic mutations at these sites induced spontaneous 
intracellular TDP-43 granules, indicating their regulatory role in TDP-43 granule 
formation.  We also performed a series of gene expression analysis combined with the 
systems biology algorithm, mode of action by network identification (MNI), to identify 
the mode of action of C8, and found C8 potentially targets protein metabolism and 
modification processes to reduce the TDP-43 granules. 
Our study identified a family of non-cytotoxic chemical compounds that reduces 
the formation of arsenite-induced TDP-43 granules and their potential mode of action.  
Furthermore, we identified previously unknown TDP-43 phosphorylation sites Thr103-
Ser104 that are involved in the TDP-43 granule formation.  We anticipate this study will 
elucidate the biological pathways regulating TDP-43 aggregation and potential 
therapeutics for ALS/FTLD-U.  
		 viii	
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CHAPTER ONE: INTRODUCTION 
The human body is capable of performing diverse array of physical movements 
from picking up a glass of water to hit a baseball that is traveling through the air at nearly 
100 miles per hour.  Even a simple physical activity, such as bipedal walking with two 
limbs, requires the coordination of many skeletal muscles to maintain the body balance 
and propel the body forward.  The body’s voluntary movement is controlled by 
specialized neurons in the motor cortex in the brain and the spinal cord that send the 
signals to contract and relax the downstream effector muscles.  Hence, the disorder of 
these motor neurons, such as amyotrophic lateral sclerosis that involves the degeneration 
of motor neurons, results in devastating outcomes, including the paralysis of the affected 
individual’s body and the death from increased risk of upper respiratory infection. 	
Section One: Amyotrophic Lateral Sclerosis 
Amyotrophic Lateral Sclerosis is a lethal motor-neuron disease that involves the 
degeneration of upper and lower motor neurons in the brain and spinal cord.  The disease 
is also known as Lou Gehrig’s Disease, named after one of great athletes in baseball 
history who played in New York Yankees throughout his professional baseball carrier 
from 1923 to 1939, until his ability to play the sport was severely affected by the rapid 
progression of the disease.  The disease specifically affects the neurons that are 
responsible for voluntary movement, and as a result, the patients gradually lose the 
muscular control over their arms, legs and face.  As the disease progresses further, the 
patients become incapable of breathing voluntarily, leading to respiratory failure in the 
		
2	
majority of cases.  On average the life expectancy of ALS patients is 3-5 years after onset 
of the disease.  In addition, ALS is a progressive and fatal disease without a cure. 	
Subsection One: Epidemiology  
Between October 2010 and December 2011, 3.9 cases of ALS per 100,000 people 
were reported in the study performed by the Center for Disease Prevention (Mehta et al., 
2014).  Each year, ranging between 0.3 and 2.5 patients with ALS are diagnosed every 
100,000 people (Sathasivam, 2010).  Approximately 5% of all cases are familial ALS 
(fALS), ranging from 2% to 15% in different populations (Conwit, 2006; Byrne et al., 
2010) and the rest of the cases are sporadic ALS (sALS).  In some studies, the onset of 
fALS has been reported ranging between 48-52 years of age, and of sALS between 56-66 
(Mulder et al., 1986; Li et al., 1988).  Even though the regional and ethnic background 
may influence gender differences (Haberlandt, 1959; Murros et al., 1983; Worms, 2001), 
sALS has been more common among males than females (Johnston et al., 2006), 
suggesting the potential protective effect of female hormones against sALS (Abhinav et 
al., 2007). 
In addition to the higher prevalence to males, an increased risk of ALS with 
longer duration of smoking or higher number of cigarette consumption per day have been 
shown in several studies, highlighting the connection between environmental factors and 
the disease (Nelson et al., 2000; Wang et al., 2011).  Among other factors, a study has 
showed the associations of dietary fat intake and glutamate intake with an increased risk 
of ALS, but on the other hand, the dietary fiber intake with a decreased risk of the disease 
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(Nelson et al., 2000).  A high incidence of the disease among Gulf War veterans has been 
also reported (Horner et al., 2008).  Interestingly, an increased risk of ALS has been also 
reported in professional Italian soccer players, especially midfielders, but not in 
professional road cyclists or basketball players (Belli et al., 2005; Chiò et al., 2005; Chiò 
et al., 2009).  In addition to the professional soccer players in Italy, a recent study 
conducted by the National Institute for Occupational Safety and Health (NIOSH) has 
shown a higher risk of death from ALS among retired professional American football 
players (Lehman et al., 2012).  These studies highlight the undiscovered mechanism of 
the ALS pathogenesis and the involvement of environmental factors. 
 
Subsection Two: Signs and Symptoms 
The patients with ALS present upper and lower motor neuron symptoms.  Upper 
motor neurons (UMN) are located in the motor cortex of the brain and the brainstem, 
sending the signal to lower motor neurons (LMN) that are in the brainstem and spinal 
cord.  The LMNs send electrical signals to skeletal muscles to control movements of the 
arms and legs.  The UMN symptoms consist of weakness, cramps, reduced reflexes, 
spasms, and muscle wasting with possible emotional distress (Lomen-Hoerth, 2008).  
Similarly, LMN symptoms include weakness, spontaneous muscle contractions, tensed 
muscles, and muscle wasting.  In the majority of patients, the symptoms start in the 
limbs, named spinal onset, whereas about 25% of the cases the symptoms start with 
impaired speech and swallowing, called bulbar onset (Kiernan et al., 2011).  In addition 
to the physical symptoms, between 13-14% of patients represent frontotemporal dementia 
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(FTD) and 37-40% with cognitive impairment (Phukan et al., 2012; Montuschi et al., 
2014), suggesting a shared mechanism to link ALS and FTD.  The most notable 
characteristic of ALS is fast progression of the disease with loss of respiratory functions, 
leading to death from various causes, such as hypoxia, broncho-pneumonia, pneumonia, 
acute respiratory distress, heart failure and pulmonary embolism (Corcia et al., 2008; 
Kurian et al., 2009). 
 
Subsection Three: Diagnosis 
Currently there is no single clinical or laboratory test available to diagnose ALS.  
To diagnose the disease, the symptoms that are presented by the patients, together with 
the progression of the symptoms need to be closely assessed to eliminate other possible 
neuromuscular diseases with similar symptoms.  To standardize the diagnosis throughout 
the world, the El Escorial Criteria, which is a set of guidelines for ALS diagnosis, has 
been used as a widely accepted basis for ALS diagnosis (Brooks, 1994; Brooks, 2000) 
(Table 1). 
 
Table 1. Revised El Escorial Criteria for ALS diagnosis (Modified from Sathasivam, 2010). 
 
Diagnosis Criteria
Definite ALS Upper and lower motor neuron signs in at least three body regions (upper limb, lower limb, bulbar, thoracic).
Clinically Probable ALS Upper and lower motor neuron signs in at least two regions, with some upper motor neuron signs necessarily rostral to the lower motor neuron signs.
Clinically Probable ALS: 
Laboratory-Supported ALS
Clinical signs of upper and lower motor neuron dysfunction in only one region, or when upper motor neuron signs alone 
are present in one region and lower motor neuron signs defined by electromyographic criteria are present in at least two 
limbs, with proper application of neuron and clinical laboratory protocols to exclude other causes.
Clinically Possible ALS
Clinical signs of upper and lower motor neuron dysfunction are found together in only one region, or upper motor neuron 
signs are found alone in two or more regions, or lower motor neuron signs are found rostral to upper motor neuron signs 
and the diagnosis of clinically probable: laboratory-supported ALS cannot be proven by evidence on clinical grounds in 
conjunction with electrodiagnostic, neurophysiological, neuroimaging or clinical laboratory studies. Other diagnoses must 
have been excluded.
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In addition to the criteria, the diagnoses of ALS involve the elimination of other 
diseases with similar symptoms (Table 2).  A wide range of clinical laboratory tests are 
required to narrow down to the accurate diagnosis of ALS, including blood tests, urinary 
tests, spinal tap for cerebrospinal fluid (CSF), creatine kinase activity tests (Talbot, 
2009), muscle biopsy, magnetic resonance imaging (Dabby et al., 2001), 
electromyography, and nerve conduction studies (de Carvalho et al., 2008).  Other tests 
are also performed to rule out injuries such as herniated disk, spinal compression, heavy 
metal poisoning, cervical spondylitis and infections that include Lyme disease and human 
immunodeficiency virus (HIV) (Pratt et al., 2012).  Even though ALS specific biological 
markers have been actively searched, such as metabolomics analysis of ALS patients 
(Rozen et al., 2005), a lack of simple and reliable diagnostic methods has been a issue of 
ALS misdiagnosis, leading to approximately 10% of patients being diagnosed with ALS, 
even though they are affected with other disorders with ALS-like symptoms (Davenport 
et al., 1996; Ludolph et al., 1999). 
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Table 2. List of conditions or disease resembling ALS and available diagnostic tests (Modified from Sathasivam, 
2010). 
 
Subsection Four: Treatments 
Similar to the lack of the definitive diagnostic method for ALS, there is no cure 
for the disease and only a limited number of treatments are available.  The majority of the 
treatments are parietal care or only disease modifying.  Currently, 2-amino-6-
(trifluoromethoxy)benzothiazole, also know as riluzole or Rilutek® from Sanofi 
(Bridgewater, NJ), is the only pharmacological disease-modifying treatment for ALS that 
is approved by the United States Food and Drug Administration (FDA) (Bensimon et al., 
Condition Diagnostic Tests
Benign Fasciculation and Cramp 
Syndrome Electromyography
Brainstem Lesions, e.g. Syrinx, 
Stroke Magnetic resonance imaging
Cervical/Lumbar Spondylotic 
Myelopathy Magnetic resonance imaging
Chronic Inflammatory 
Demyelinating Polyneuropathy Nerve conduction studies, high protein in cerebrospinal fluid
Heavy Metal Exposure Toxicology screen
Hexosaminidase A and B 
deficiency White cell enzymes
Kennedy’s Disease (X-linked 
Spinobulbar Muscular Atrophy) Androgen receptor gene mutation
Lymphoma Full blood count, imaging of thorax, abdomen and pelvis, diagnostic biopsy
Monoclonal Gammopathy Erythrocyte sedimentation rate, serum protein electrophoresis
Multifocal Motor Neuropathy Nerve conduction studies, anti-GM1 ganglioside antibody
Multiple Sclerosis MR imaging, oligoclonal bands in cerebrospinal fluid
Myasthenia Gravis Single-fibre electromyography, anti-acetylcholine receptor antibody
Neurosyphilis Syphilis serology
Paraneoplastic Anti-neuronal antibodies, screen for underlying malignancy
Encephalomyelitis Serum creatine kinase, electromyography, muscle biopsy
Polymyositis or Inclusion body 
Myositis Post-Poliomyelitis Nerve conduction studies and electromyography
Thyrotoxicosis Thyroid function tests
Vitamin B12 and Folate Deficiency Serum vitamin B12 and folate levels 
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1994).  The compound modulates the glutamatergic transmission and reduces 
excitotoxicity by decreasing toxic glutamate level, preserving motor neuron functions 
(Mizoule et al., 1985; Martin et al., 1993).  Riluzole has been shown to inactivate sodium 
channels, inhibit glutamate release and block postsynaptic action of N-methyl-D-
aspartate (NMDA) receptors at glutamatergic nerve terminals (Doble, 1996).  The 
riluzole treatment slightly preserves limb and bulbar function, without preserving muscle 
strength, and only prolongs survival of ALS patients for about 2 to 5 months (Miller et 
al., 2007). 
In addition to riluzole, “ultra-high” dose of a vitamin B12 analog, 
methylcobalamin, which is 50- or 100-fold grater than the FDA-approved dose, has been 
shown to increase survival time in ALS patients in a small clinical trial (Izumi et al., 
2007).  In addition, methylcobalamin has been shown to protect against homocystein 
mediated excitatory toxicity in motor neuron cell line NSC-34 (Hemendinger et al., 
2011).  In wobbler mouse model of ALS, “ultra-high” dose (30 mg/kg) methylcobalamin 
treatment reduces muscle weakness and contracture in the forelimb, increases biceps 
muscles and the number of musculocutaneous nerves (Ikeda et al., 2015).  In the most 
recent phase III clinical trial sponsored by Eisai Co., Ltd. (Tokyo, Japan), intramuscular 
administration of “ultra-high” dose, 50 mg/kg methylcobalamin twice a week has 
increased survival of patients with ALS, if they are treated within 12 months the onset of 
the disease (Kaji et al., 2015).  Even though the mechanism of action is still unclear, the 
treatment with “ultra-high” dose methylcobalamin is potentially a long-awaited addition 
to riluzole, the only FDA-approved ALS treatment currently available. 
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A mixture of drugs containing dextromethorphan and the class I anti-arrhythmic 
compound quinine, which is sold as Neudexta® through Avanir Pharmaceuticals (Aliso 
Viejo, CA), has been recently approved for treating pseudobulbar affect (PBA) symptoms 
with uncontrollable crying and laughing outbursts that affect about 20% to 50% of ALS 
patients (McCullagh et al., 1999; Garnock-Jones, 2011).  The dextromethorphan is 
thought to inhibit glutamatergic signaling with an increased its bioavailability through 
quinine co-treatment, which shows modest benefit to a subset of patients (Lauterbach et 
al., 2011; Lily et al., 2015; Deutschenbaur, et al., 2015).  Interestingly, the ALS patients 
who take Nuedexta® for PBA also show improved speech and ability to swallow, 
indicating the protective effect of the treatment on bulbar control that is regulated by 
brainstem (Baldinger, et al., 2012; Pioro et al., 2014; Yang et al., 2015).  Currently, 
randomized clinical trials are conducted with Nuedexta® by Northeast ALS Consortium 
(NEALS) to test its efficacy on the speech and ability to swallow. 
Due to the lack of cure for ALS, the main treatment for the patients is palliative 
care that involves care of the patients at home and hospice.  Non-invasive ventilation is 
used to improve the quality of life and to extend the survival of non-bulbar ALS patients 
(Bourke et al., 2006).  The patient care also involves interventions for muscle spasticity, 
weariness, speech, sleep and depression.  Additionally, nutritious food with ease to 
swallow and end of life support are essential to improve the quality of patients’ life.  
Further research in understanding the mechanism of ALS pathogenesis is required to 
provide additional approaches to treat the disease and cure for ALS. 
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Subsection Five: Etiology 
Since a French neurologist Jean-Martin Charcot described the underlying 
neurological symptoms of ALS in 1874, a number of scientific studies have elucidated 
the causes of the disease.  Approximately 5% of all cases are familial ALS with a known 
family history, ranging from 2% to 15% in different populations (Conwit, 2006; Byrne et 
al., 2010) and the rest of the cases are sporadic without prominent family history.  Over a 
hundred years after Charcot’s description, a study in 1993 reported 11 missense 
mutations in the gene that encodes Cu/Zn-binding super oxide dismutase 1 (SOD1) that 
were highly linked with fALS (Rosen et al., 1993), highlighting a very first genetic cause 
of fALS.  Since the discovery of the SOD1 mutations, more genes and their mutations 
have been identified in both familial and sporadic ALS (Table 3), totaling 126 ALS-
associated genes listed by the ALS Online Database (ALSoD, http://alsod.iop.kcl.ac.uk) 
(Abel et al., 2013).  Furthermore, a number of studies have highlighted the involvement 
of those genes in biological pathways, such as ubiquitin proteasome pathway, autophagy 
and neuroinflammation, which are implicated in ALS disease progression (Figure 1) 
(Cirulli et al., 2015). 
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Table 3. List of major ALS-associated genes (Modified from Abel et al., 2013). 
Locus Chromosome Gene Gene name
ALS 1 21q22.11 SOD1 Cu/Zn superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult))
ALS 2 2q33.2 ALS2 Amyotrophic lateral sclerosis 2 (juvenile) homolog (human). Alsin
ALS 3 18q21 ALS3 Unknown
ALS 4 9q34.13 SETX Senataxin
ALS 5 15q14 SPG11 Spastic paraplegia 11 (autosomal recessive)
ALS 6 16p11.2 FUS Fusion (involved in t(12;16) in malignant liposarcoma)
ALS 7 20p13 ALS7 Unknown
ALS 8 20q13.33 VAPB Vesicle-associated membrane protein-associated protein B
ALS 9 14q11.1 ANG Angiogenin
ALS 10 1p36.22 TARDBP TAR DNA binding protein
ALS 11 6q21 FIG4 FIG4 homolog, SAC1 lipid phosphatase domain containing (S. cerevisiae)
ALS 12 10p13 OPTN Optineurin
ALS 13 12q23-q24.1 ATXN2 Ataxin 2
ALS 14 9p13 VCP Valosin-containing protein
ALS 15 Xp11.21 UBQLN2 Ubiquilin 2
ALS 16 9p13 SIGMAR1 Sigma non-opioid intracellular receptor 1
ALS 17 3p12.1 CHMP2B Chromatin modifying protein 2B
ALS 18 17p13.3 PFN1 Profilin 1
ALS 19 2q33.3-q34 ERBB4 V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4
ALS 20 12q13.1 HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1
ALS 21 5q31.2 MATR3 Matrin 3
ALS-FTD2 22q11.23 CHCHD10 Coiled-coil-helix-coiled-coil-helix domain containing 10
ALS-FTD1 9p21.2 C9orf72 Chromosome 9 open reading frame 72
ALS 19p13.12 UNC13A unc-13 homolog A (C. elegans)
ALS 12q24 DAO D-amino-acid oxidase
ALS 2p13 DCTN1 Dynactin
ALS 22q12.1-q13.1 NEFH Neurofilament, heavy polypeptide 200kDa, heavy chain
ALS 12q12 PRPH Peripherin
ALS 5q35 SQSTM1 Sequestosome 1
ALS 17q11.1-q11.2 TAF15 TAF15 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 68kDa
ALS 2p24 SPAST Spastin
ALS 8p21.1 ELP3 Elongation protein 3 homolog (S. cerevisiae)
ALS 5q23.2 LMNB1 Lamin B1
ALS 12q14.1 TBK1 TANK binding kinase 1
ALS 14q11.2 APEX1 Apurinic endonuclease
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Figure 1. Classic view of ALS-associated genes and implicated biological pathways (Adapted from Cirulli et al., 
2015). 
The protein products of the ALS-associated genes are highlighted in red.  The ALS-associated mutations 
increase the aggregation propensity of the proteins.  The protein aggregates are degraded through ubiquitin 
proteasome pathway (UPS) or autophagy.  The mutations in the genes involved in the protein homeostasis 
mechanisms can lead to aberrant accumulation of protein aggregates. 
 
In addition to the genetic mutations, environmental factors have been postulated 
to cause ALS.  One of the most well studied environmental causes of ALS is a non-
protein amino acid and neurotoxin called β-methylamino-L-alanine (BMAA), which 
causes a subset of ALS with the aggregation of a microtubule binding protein Tau with a 
potential involvement of an ALS-associated protein TDP-43.  BMAA was initially 
isolated from cycad trees in Guam in 1967 where the Chamorro people on the island were 
suffering from a neurodegenerative disease with shaking, paralysis and dementia, named 
ALS-Parkinsonism/Dementia Complex (ALS-PDC) (Vega et al., 1967).  In a later study 
showed a number of cyanobacteria strains produce BMAA, including those isolated from 
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the soil in Guam (Cox et al., 2005).  In Guam the toxin produced by the cyanobacteria 
was accumulated in cycad seeds, and the prepared cycad flour was consumed frequently 
among the endogenous people.  In addition, studies have sown the accumulation of the 
toxin throughout the food chain on the island, suggesting a high impact of the toxin on 
human population that stands atop of the food chain (Cox et al., 2003). 
Although the exact mechanism of BMAA’s neurotoxicity is not clear, it has been 
postulated that BMAA acts through activating N-methyl-D-aspartate (NMDA) and 
metabotropic glutamate receptor 5 (mGluR5) receptors, inducing oxidative stress by the 
depletion of an antioxidant glutathione and increasing extracellular glutamate level 
(Lobner et al., 2007).  The study also shows the synergistic effect of BMAA with 
amyloid-β, an Alzheimer’s disease protein, and 1-methyl-4-phenylpyridinium ion 
(MPP+), Parkinson’s disease model toxin, highlighting the involvement of underlying 
neurological conditions.  In addition, another study has shown BMAA can be 
misincorporated into proteins in place of L-serine amino acid residues (Dunlop et al., 
2013).  The treatment of the neuroblastoma cell line SH-SY5Y with BMAA increases the 
phosphorylation and high molecular weight forms of TDP-43, a RNA binding protein 
that is associated with many neurodegenerative diseases, especially ALS (Muñoz-
SaezDunlop et al., 2013).  The incorporation of BMAA into proteins is thought to lead 
proteins to misfold and aggregate, presumably through disrupting the phosphorylation of 
the serine residues, especially of proteins involved in neurodegenerative diseases, such as 
TDP-43 and Tau, suggesting the potential key role of protein homeostasis on the 
mechanism of ALS pathogenesis (Dunlop et al., 2013). 
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In addition to BMAA, other environmental causes of ALS have been postulated, 
such as organophosphates, infectious agents, smoking, physical trauma and occupational 
factors, among others, but further detailed studies are required for them to be determined 
as definitive causes of ALS. 
 
Subsection Six: Histopathology 
The distinctive features of ALS are the degeneration of motor neurons and 
astrogliosis, combined with prominent intracellular inclusions in the degenerating 
neurons and glia cells.  The degenerative process of neuronal cells involves the 
destruction of axons from the initial affected lesions that are farther away from the cell 
bodies, known as Wallerian or anterograde degeneration (Conforti et al., 2014).  In the 
process, Schwann cells catabolize the myelin sheath from the degenerating axons, leaving 
small ovoid-shaped bodies that consist with axonal debris and myelin (Waller, 1850).  
The ovoid bodies are eventually phagocytosed by macrophages. 
The degeneration of anterior horn cell body leads to the subsequent degeneration 
of the associated motor axons, and, as a result, large motor neurons are affected more 
than smaller neurons in ALS (Frey et al., 2000; Pun et al., 2000).  The degeneration of 
upper motor neurons consists of the death of Betz cells in motor cortex, variable 
astrogliosis in both the grey matter and underlying subcortical white matter of the cortex, 
and also the axonal loss within the descending pyramidal tracts (Wharton et al., 2003; 
Ince et al., 2007). 
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Brain biopsy shows the atrophy and pallor of myelinated motor axons in the 
corticospinal tract, and at late stage of the disease, the atrophy of both primary motor and 
pre-motor cortex can be observed (Isaacs et al., 2007).  The biopsy of spinal cords 
presents atrophy of anterior nerve roots with up to 50% of reduced number of motor 
neurons (Ince, 2000).  The Wallerian degeneration can further spread peripherally while 
surviving axons branch and re-innervate the denervated muscle fibers, and therefore, the 
atrophy of muscles appears as variable in biopsy.  Typically in ALS, certain motor 
neurons survive until late stage, such as oculomotor, trochlear and abducens nerves in the 
brainstem (Reiner et al., 1995).  In addition, posterior columns, spinocerebellar tracts, 
nucleus of Onuf, Clarke column are not affected in the spinal cord, even though Clarke 
column can be affected in fALS (Yoshida et al., 1995). 
In ALS the degenerating neurons in the motor cortex and spinal cord contain 
intracellular inclusions, such as Bunina bodies, hyaline conglomerate inclusions (HCI), 
and ubiquitin-positive inclusions (UBI), which are hallmarks of the disease.  Bunina 
bodies are present in 70-100% of ALS cases and they are small eosinophilic, hyaline 
cytoplasmic inclusions that are positive with the staining for cystatin, cysteine protease 
inhibitors, and transferrin, iron-binding blood plasma glycoproteins (Kato et al., 2003; 
Okamoto et al., 2008; Mizuno et al., 2006; Bunina, 1962; Piao et al., 2003).  In contrast 
with Bunina bodies, hyaline conglomerate inclusions (HCI) are associated with familial 
form of ALS, but rarely observed with sporadic form of the disease (Ince et al., 1998).  
HCI are argyrophilic inclusions with a chemical property to selectively reduce silver salts 
		
15	
to metallic silver, and they are present in spinal cord motor neurons and stained for 
phosphorylated and non-phosphorylated neurofilaments (Wharton et al., 2003). 
Ubiquitin-positive inclusions (UBI) are the most common form of protein 
aggregates in ALS and the variants can be seen up to 95% of cases (Leigh et al., 1988; 
Lowe et al., 1988; Ince et al., 2003; Leigh et al., 1991).  UBI are mainly divided into two 
different types based on their morphology: skein-like inclusions (SLI) or Lewy-body like 
inclusions (LBI).  SLI are filamentous and have more compact spherical structure with 
round appearance with 15 to 20 nm in diameter.  On the other hand LBI appear very 
similar to Lewy bodies in Parkinson’s disease with an eosinophilic dense core surrounded 
by a circle of radiating fibrils approximately 10 nm in radius.  Even though the exact 
composition of UBI is not known, many proteins have been identified as a part of the 
inclusions: ubiquitin, Cu/Zn superoxide dismutase 1 (SOD1), type III intermediate 
filament (IF) protein peripherin, and a Really Interesting New Gene (RING)-finger type 
E3 ubiquitin ligase Dorfin (Kerman et al., 2010, Shi et al., 2005, Hishikawa et al., 2003). 
In recent studies, additional protein TAR DNA-biding protein 43 (TDP-43) has 
been identified as the major component of UBI in patients with both familial and sporadic 
ALS and frontotemporal lobar degeneration with ubiquitin (FTLD-U), a major 
contributor of frontotemporal dementia (FTD) (Newmann et al.,2006, Arai et al.,2006).  
There are three main histopathologicla subtypes of FTLD: FTLD-tau, FTLD-FUS and 
FTLD-U, and based on the studies in 2006, FTLD-U is more specifically categorized as 
FTLD-TDP (Goedert et al., 2012).  Unlike the predominant association of SOD1 to the 
familial ALS, TDP-43 presents a more prominent area for the ALS and FTD research, 
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due to its wider involvement in both familial and sporadic forms of the diseases.  In 
addition, many mutations in the genes that encode ATXN2, C9ORF72, OPTN, PFN1, 
SQSTM1, UBQLN2, and VCP are associated with familial ALS/FTD and the mutations 
result in aberrant formation of TDP-43 granules, suggesting a complex combinatorial 
nature of ALS/FTD and the key role of TDP-43 in the disease process (Janssens et al., 
2013; Renton et al., 2014; Freischmidt et al., 2015; Cirulli et al., 2015). 
 
Section Two: Trans-Active Response DNA Binding Protein 43 kDa (TDP-43) 
Long before the discovery of its involvement in ubiquitin positive inclusions in 
ALS and FTLD, TAR DNA binding protein 43 kDa (TDP-43) was originally identified 
as a transcriptional repressor that binds to the trans-activating response element (TAR) of 
the HIV that was integrated into the human host cell chromosome (Ou et al.,1995).  The 
TDP-43 protein consists of 414 amino acid residues and is encoded by the TAR DNA 
binding protein (TARDBP) gene on chromosome 1, which is highly conserved between 
species and ubiquitously expressed throughout the body (Lukavsky et al., 2013). 
Subsection One: Nuclear Localization and Export Signals of TDP-43 
The TDP-43 is predominantly localized in the nucleus under normal conditions, 
but under stressed conditions or in ALS/FTLD brain and spinal cord tissues, the protein is 
found localized in the cytoplasm, often as distinct granules.  The protein contains a 
nuclear localization signal (NLS) in the amino-terminus (N-terminus) (at residues 82-98) 
and a nuclear export signal (NES) in the middle (at 239-250) (Figure 2) that allow the 
protein to shuttle between cytoplasm and nucleus depending on the biological needs 
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(Chen-Plotkin et al.,2010).  The TDP-43 NLS is a classic bipartite localization signal that 
consists with KRK (residues 82-84, NLS1) and KVKR (95-98, NLS2), and the alanine 
mutations of either subdomain are sufficient to disrupt the function of the signal, leading 
to the translocation of the protein to cytoplasm and formation of aggregate in primary 
neurons (Winton et al., 2008).  The leucine-rich NES is located at 239 to 250 of TDP-43, 
and similarly, but contrary to NLS, the alanine substitutions of hydrophobic leucine or 
isoleucine residues result in the formation of intranuclear granules (Winton et al., 2008), 
highlighting the aberrant TDP-43 localization or trafficking and the formation of 
intracellular granules. 
 
Figure 2. Domains of human TDP-43 protein with EGFP tag. 
The human TDP-43 protein consists of 414 amino acid residues with two RNA recognition motifs (RRM1 
& 2), nuclear localization and export signals (NLS and NES), and c-terminus glycine-rich (G-rich) domain.  
The protein is also enzymatically cleaved at two locations (depicted with scissors), producing C-terminus 
fragments with 35 kDa and 25 kDa molecular weights. 
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Subsection Two: RNA Recognition Motifs of TDP-43 
TDP-43 is now known to bind with both DNA and RNA with differential 
functions as transcriptional repressor, pre-mRNA splicing and translational regulation 
(Sephton et al., 2011).  In addition to the NLS and NES, the protein contains two RNA 
recognition motifs (RRM1 & 2) that are responsible for its ability to bind with 
nucleotides (Figure 2).  Both TDP-43 RRM present high affinity for single-stranded 
uracil-guanine (UG) rich RNA repeats or thymine-guanine (TG) rich DNA repeats, but 
RRM1 plays more prominent role while RRM2 plays an assisting role, mediating TDP-
43’s function as a splicing factor to regulates alternative splicing of pre-messenger RNA 
(mRNA) of cystic fibrosis transmembrane conductance regulator (CFTR) and 
apolipoprotein (apo) A-II, among others (Buratti et al., 2001, Mercado et al., 2005; Kuo 
et al., 2009; Kuo et al., 2014).  Additionally, RRM2 is involved in dimerization of TDP-
43 through protein-protein interaction of its beta-strands that was shown in the protein 
crystallography studies (Kuo et al., 2009; Kuo et al., 2014).  Furthermore, the predicted 
cleavage of the RRM2, which disrupts the beta strands and the folding of the motif, has 
been shown to increase the aggregation propensity of TDP-43 (Wang et al., 2013). 
Subsection Three: Glycine-Rich Domain and Associated Mutations of TDP-43 
The carboxy terminus (C-terminus) of TDP-43 contains a glycine-rich (G-rich) 
domain with prion-like, glutamine- and asparagine-rich amino acid composition (Figure 
2), which is an intrinsically disordered region without a well-defined structure and with a 
wide range of conformational states depending on the cellular environment (Gitler et al., 
2011; Li et al., 2013; Malinovska et al., 2013).  The G-rich domain has structural 
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similarity to other heterogenous nuclear ribonucleoprotein (hnRNP) family, and is used 
for protein-protein interaction with other RNA-binding proteins (RBP), such as hnRNP 
A2/B1 and hnRNP A1, hnRNP C1/C2, and hnRNP A3, to mediate the mRNA splicing 
function of TDP-43 (Buratti et al., 2005; Udan et al., 2011).  The domain is also required 
for the aggregation of TDP-43 that is induced by polyglutamine (polyQ)-repeat peptide, 
another neurodegeneration-associated peptide with aggregation propensity, and the TDP-
43 aggregation consequently leads to the sequestration of free TDP-43 from the nucleus 
and the loss of its splicing function (Fuentealba et al., 2010).  More than 40 mutations of 
the TDP-43 encoding gene TARDBP have been identified since the discovery of its 
involvement in the ALS/FTDL-U.  Interestingly, almost all mutations are located in the 
G-rich domain with prion-like property in the C-terminus (Figure 3), further highlighting 
the important role of this domain in the aggregation of TDP-43 and neurodegenerative 
diseases. 
 
 
Figure 3. Known ALS/FTLD-U associated TDP-43 mutations (Modified from http://bioinfo.hr/pro-
mine/Background.html). 
More than forty ALS/FTLD-U associated TDP-43 mutations have been identified in the TDP-43 encoding 
gene TARDBP.  A majority of the mutations are located in the region that encodes the G-rich domain 
(residues 274-414) in the C-terminus tail of TDP-43.  The missense mutations are highlighted in red and 
nonsense mutation is in green characters.  RRM-1 & -2, RNA recognition motifs. 
G-rich Domain
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Subsection Four: RNA Splicing by TDP-43 
Many recent studies have increased the knowledge of TDP-43’s diverse role in 
premature mRNA (pre-mRNA) processing.  A serine-arginine rich spliceosomal protein 
SC35 regulates mRNA splicing of its own transcript by binding to the 3’-UTR of its own 
pre-mRNA, forming a negative feedback loop through nonsense-mediated mRNA decay 
(NMD) machinery (Sureau et al., 2001).  TDP-43 competitively binds to the SC35 
binding site and dose-dependent regulates the transcript level (Dreumont et al., 2010).  In 
addition, TDP-43 regulates the transcript level of neurofilament light chain (NFL) 
turnover rate, stabilizing its mRNA by binding to the 3’-UTR (Strong et al., 2007).  NFL 
mRNA transcript level is also abnormally elevated in ALS spinal cord, suggesting the 
dysregulation of the transcript level by TDP-43 in the disease tissue (Ge et al., 2003).  
TDP-43 also regulates the mRNA transcript level of a protein deacetylase, histone 
deacetylase 6 (HDAC6), also known as a master regulator of autophagy.  Knocking down 
TDP-43 reduces the HDAC6 mRNA and protein levels, which increases the level of its 
substrate acetylated tubulin, increases proteotoxicity and decreases neurite outgrowth 
(Fiesel et al., 2009; Fiesel et al., 2010).  These studies highlight the widespread role of 
TDP-43 in regulating the essential biological processes through pre-mRNA splicing, and 
aberrant regulation of TDP-43 might lead to sever dysfunction of cells and their deaths. 
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Subsection Five: miRNA and lncRNA Regulation by TDP-43 
In addition to TDP-43’s role in pre-mRNA processing, TDP-43 is also involved in 
other RNA mechanisms, such as microRNA (miRNA) biogenesis, long non-coding RNA 
(lncRNA) regulation, and lariat RNA function.  TDP-43 binds to the miRNA-processing 
Drosha complex, localizing in perichromatin fibers (PF), a region in a nucleus where 
nascent pre-mRNA and splicing factors are enriched, and where the biogenesis of intron-
derived miRNA occurs (Gregory et al., 2004; Lin et al., 2006; Casafont et al., 2009; 
Kawahara et al., 2012).  In addition, TDP-43 up or down regulates the miRNA levels, 
especially of let-7b and miR-663, respectively, possibly through directly binding and 
modifying the stability of these miRNA (Buratti et al., 2010).  TDP-43 also binds with 
Dicer complex in cytoplasm, promoting the cleavage of the specific premature miRNA, 
such as pre-mi143 and pre-miR-574 (Kawahara et al., 2012).  In addition to the 
regulation of pre-mRNA splicing, TDP-43 holds the essential role in regulating the 
normal cellular functions through the regulation of gene expression by modulating 
miRNA biogenesis. 
Subsection Six: Other RNA Regulation by TDP-43 
In the context of DNA damage and cell cycle regulation, TDP-43 has been shown 
to bind with UG-rich lncRNA called growth-arrested DNA damage-inducible gene 7 
(gadd7) that is induced with ultraviolet (UV) induced DNA damage.  TDP-43 binds to 
the 3’-UTR of Cdk6 mRNA transcripts, but under UV damage, TDP-43 is bound by 
gadd7 lncRNA releasing Cdk6 mRNA leading to its transcript decay (Ayala et al., 2008; 
Liu et al., 2012). 
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In addition to the miRNA and lncRNA, TDP-43 has been shown to bind to other 
type of RNA.  In a recent study, knocking out a yeast gene debranching RNA lariats 1 
(dbr1), which encodes an enzyme that breaks down lariat introns produced during pre-
mRNA splicing, has been shown to reduce the TDP-43-induced toxicity (Figley et al., 
2012).  The predicted model shows that the deletion of dbr1 causes the accumulation of 
lariat introns and the sequestration of cytoplasmic TDP-43 aggregates though direct 
binding, preventing the protein aggregates from interfering other biologically essential 
RNA and RNA-binding proteins.  The newly discovered role of lariat introns on TDP-43 
aggregates and their reduced toxicity presents promising therapeutic approach to the 
TDP-43 proteinopathies. 
Subsection Seven: Function of TDP-43 in Neurons 
In neuronal cells, TDP-43 is found in both nucleus and cytoplasm, especially in 
the soma and dendrites, and acts as a neuronal activity-response factor to regulate 
neuronal plasticity (Wang et al., 2008).  In addition, TDP-43 has been shown to interact 
with survival motor neuron protein (SMN) and act as a scaffold for nuclear bodies that 
are known transcriptionally active sites appearing as small foci in a nucleus (Wang et al., 
2002).  Furthermore, recent high throughput studies, including cross-linking and 
immunoprecipitation, followed by high-throughput sequencing (CLIP-seq) studies, have 
showed TDP-43 binds mostly at three prime untranslated regions (3’-UTR) and long 
clusters of UG-rich area in introns down stream of TDP-43 silenced exons of more than 
6000 RNA targets in mouse and human brains.  Those RNA targets are related with 
calcium ion signaling, synaptic functions and neuronal development, highlighting the 
		
23	
important role of TDP-43 in the regulation of neuronal functions (Polymenidou et al., 
2011; Tollervey et al., 2011; Lagier-Tourenne et al., 2012). 
Subsection Eight: Phosphorylation of TDP-43 
TDP-43 is now known to be a highly modified protein; it is post-translationally 
modified by phosphorylation, ubiquitination, and protease cleavage, among others.  It has 
been shown that those modifications are responsible for the change in biochemical 
characteristics of TDP-43, including detergent solubility, protein stability and 
aggregation propensity, and they are frequently observed in the brain and spinal cord 
tissues from ALS/FTLD-U patients, suggesting the association of the post-translational 
modification with the mechanism of TDP-43 neurotoxicity and subsequent degeneration 
of neurons. 
TDP-43 from brains and spinal cord tissues affected by ALS/FTD is hyper-
phosphorylated, but is not detected in the tissues from people with normal aging, 
suggesting the hyper phosphorylation of TDP-43 is a unique process to the diseases (Arai 
et al., 2006; Neumann et al., 2006).  There are more than 30 amino acid residues within 
TDP-43 that are predicted to be phosphorylated by computational or high throughput 
analyses (Figure 4).  Two of well-studied TDP-43 phosphorylation sites are serine 
residues at 409 and 410 (Ser409-Ser410), and the antibody raised against the 
modification at those sites is able to detect the majority of TDP-43 inclusions found in 
ALS/FTLD-U tissues.  The phosphorylation of Ser409-Ser410 is thought to occur at an 
earlier stage before ubiquitination (Hasegawa et al., 2008; Neumann et al., 2009).  In 
addition, the phosphorylation at Ser379 and Ser403-Ser404 has been shown in the 
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ALS/FTLD-U brain and spinal cord tissues with increased detergent insolubility of TDP-
43 (Hasegawa et al., 2008). 
 
 
Figure 4. Known and predicted phosphorylation sites of human TDP-43 (Modified from phosphosite.org.) 
More than 30 serine (S), threonine (T) and tyrosine (Y) residues of human TDP-43 protein have been 
shown or predicted to be phosphorylated.  The phosphorylated amino acid residues, identified in mouse or 
rat, are in black.  S409 and S410 are the most studies phosphorylated residues in TDP-43 with increased 
phosphorylation in ALS/FTLD. 
 
TDP-43 can be phosphorylated by casein kinases (CK) 1 and 2, leading to the 
oligomerization and fibril formation of TDP-43 in vitro, and the modification changes 
biochemical property of the protein making the protein detergent insoluble and the half-
life longer than unmodified TDP-43 (Hasegawa et al., 2008).  The studies with TDP-43-
overexpression transgenic animal models, such as Ceanorhabditis elegans and mice, 
show increased phosphorylation of Ser409-Ser410 with aggregation of TDP-43 in the 
nuclei of expressing tissues (Liachko et al., 2010; Wils et al., 2010; Xu et al., 2010).  
Especially in the C. elegnas ALS model, the neurotoxicity of the TDP-43 protein was 
dependent on the phosphorylation at Ser409-Ser410 (Liachko et al., 2010).  Furthermore, 
the TDP-43 toxicity that is observed in the C. elegans model of ALS, is reduced by the 
genetic knockdown of AMP-activated protein kinase (AMPK), suggesting the role of the 
signaling pathway in the TDP-43 toxicity (Lim et al., 2012).  In addition to CK1, a cell-
G-rich Domain
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cycle-associated, cell division cycle kinase 7 (CDC7) strongly phosphorylates TDP-43 at 
Ser409/410 in C. elegans and knocking out the gene reduces the TDP-43 phosphorylation 
while ameliorating the toxic phenotype of TDP-43 protein (Liachko et al., 2013). 
Interestingly, the phosphorylation at amino acid residues Ser379 and Ser403-
Ser404, in addition to Ser409-Ser410, has been shown as a protective process reducing 
the TDP-43 aggregation (Li et al., 2011).  Even though, the studies have shown the 
complex involvement of various kinases in the TDP-43 phosphorylation, its mechanism 
is still unclear, especially if the hyper phosphorylation of TDP-43 is directly responsible 
for the neurotoxicity.  Furthermore, the majority of the phosphorylation sites are located 
in the G-rich domain with prion-like property in the C-terminus end of the protein where 
the disease-associated mutations are also located (Figure 3 & Figure 4), suggesting the 
possibilities in which the aberrant regulation of  phosphorylation or mutations in the 
region leads to misregulation of the protein that contributes to the pathogenesis of 
ALS/FTLD-U. 
 
Subsection Nine: Ubiquitination of TDP-43 
In addition to phosphorylation, TDP-43 has been shown to get ubiquitinated in the 
FTLD-U tissues (Neumann et al., 2006).  Even though, only a subset of TDP-43 
inclusions is ubiquitin-positive and often in a form of less dense granules, the chemical 
inhibition of ubiquitin proteasome system (UPS) leads to TDP-43 aggregation, 
suggesting the degradation of TDP-43 through UPS (Giordana et al., 2010; Ling et al., 
2010).  Additionally, the TDP-43 with disease-associated mutation is more susceptible to 
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aggregate than the wild type under this condition, further supporting the important role of 
the ubiquitin-dependent proteostasis of TDP-43 protein (Ling et al., 2010).  The ubiquitin 
E3 ligase Parkin has been shown to directly binds to and ubiquitinate TDP-43 protein, 
and the expression of Parkin ameliorates the TDP-43-induced cell death and dysregulated 
amino acid homeostasis (Hebron et al., 2013, Hebron et al., 2014).  Ubiquilin 1 
(UBQLN1), which contains N-terminus ubiquitin-like and C-terminus ubiquitin-
associated domains and belongs to a family of proteins that shuttles ubiquitinated proteins 
to the proteasome, has been shown to directly binds with poly-ubiquitinated TDP-43 
through UBQLN1’s C-terminus, further supporting the involvement of UPS and 
autophagosomal pathways in TDP-43 aggregation in ALS (Kim et al., 2009; Deng et al., 
2011).  In addition, the mutations of Ubiquilin 2 (UBQLN2), which has 76% identity 
similar to UBQLN1, have been identified in ALS, further supporting the idea that UPS 
and disruption of the system can be deleterious to the neurons (Dent et al., 2011). 
Subsection Ten: Enzymatic Cleavage of TDP-43 
In addition to its phosphorylation and ubiquitination, TDP-43 can be 
enzymatically cleaved, producing hyper-phosphorylated pathological species (Neumann 
et al., 2006; Hasegawa et al., 2008).  TDP-43 is cleaved at either close to the N-terminus 
or within RRM2 (Figure 2), each producing 35 kDa (TDP-35) and 25 kDa (TDP-25) 
fragments, respectively (Nishimoto et al., 2010).  TDP-35 has been shown to localize to 
SGs that are cytoplasmic aggregates of proteins and RNA with stalled translational 
machinery, and localize to aggresomes with aggregated proteins.  Similar to TDP-35, the 
expression of the shorter form, TDP-25, is sufficient to form TDP granules in cytoplasm 
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in cell culture and Drosophila melanogaster, similar to those observed in ALS/FTLD-U 
(Igaz et al., 2009; Li et al., 2011).  Furthermore, TDP-25	is more prone to be 
phosphorylated and to aggregate, and more toxic than full-length TDP-43, presenting a 
gain of toxicity (Zhang et al., 2009; Furukawa et al., 2011).  On the contrary, the 
overexpression of TDP-25 does not always induce apoptosis of the cells, while the 
protein still forms cytoplasmic aggregates, which suggests an additional process that is 
required for the gain of toxic phenotype of TDP-25 (Yamshita et al., 2014).  TDP-25 
presents shorter half-life than full-length TDP-43, and it is considered to be more 
susceptible for proteolysis (Zhang et al., 2007; Dormann et al., 2009, Nonaka et al., 
2009).  Even though the aggregate prone nature of TDP-25 has been shown in many 
studies, the biological function of the truncated TDP-43 spices is still not well understood 
(Saini et al., 2011; Wang et al., 2013).   Both TDP-35 and TDP-25 are more aggregate 
prone that the full length TDP-43, but TDP-35 is able to recruit the full-length TDP-43 
into cytoplasmic inclusions and alter the pre-mRNA splicing (Che et al., 2011).  The 
expression of TDP-43 is tightly regulated including autoregulation of its pre-mRNA 
(Ayala et al., 2010), and aberrant production of more aggregate prone TDP-35 and TDP-
25 species may contribute to facilitate the ALS pathogenesis. 
 
Section Three: TDP-43 and Stress Granules 
 In addition to the regulatory function of TDP-43 in transcription and splicing, the 
protein involves in post-transcriptional regulation of effectors through associating with 
SGs, cytoplasmic aggregates of proteins and RNA that are formed in response to different 
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types of cellular stress (Colombrita et al., 2009; Liu-Yesucevitz et al., 2010; Dewey et al., 
2011; McDonald et al., 2011; Meyerowitz et al., 2011).  In the spinal cord and brain 
tissues from ALS/FTLD-U patients, the increased association of TDP-43 with SG has 
been shown, suggesting the key role of this process in the ALS-FTLD-U pathology (Liu- 
Yesucevitz et al., 2010). 
Subsection One: Stress Granule  
The stress granules are dynamic cytoplasmic inclusions that consist of mRNA and 
ribonucleoprotein complexes with temporarily stalled translation of non-critical proteins, 
and they are formed when cells experience various types of stress, such as heat shock, 
oxidative stress, osmotic stress, nutrient deprivation, and a potent toxin sodium arsenite 
(Figure 5; Anderson et al., 2002).  The RNA content of SG are selective and mainly 
consists of those encoded by housekeeping genes, but excluding mRNA that encodes 
stress resistance proteins, such as heat-shock proteins (Nover et al., 1989; Stöhr et al., 
2006).  Through the formation of SG, cells adapt to the new stressful environment by re-
programming protein translational machinery and focusing the cellular resource to 
selective transcripts that encodes stress resistance proteins and essential for cell survival 
(Anderson et al., 2008).  The mRNA that are consolidated in SG are translationally 
inactive, but after the stressful environment is dissolved, the translation of those mRNA 
can resume, suggesting the SGs are temporary storage sites for non-essential mRNA 
transcripts under stress (Anderson, et al., 2008).   
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Figure 5. Stress granule formation. 
mRNA transcripts are actively translated into proteins in polysomes under normal conditions.  Under stress 
conditions, such as those induced by sodium arsenite, specialized RNA binding proteins form non-
membrane bound intracellular stress granules (SG) to consolidate the mRNA that encode non-essential 
proteins.  When the stress is removed, SGs are resolved and normal protein synthesis resumes.  When the 
stress conditions persist, the mRNA is passed along to processing body (P-body) for degradation.  
Cycloheximide prevents the formation of SGs through locking up the mRNA transcripts in polysome state.   
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Subsection Two: TDP-43 Stress Granules in ALS/FTLD-U 
One of the key regulatory proteins of SG is T-cell intracellular antigen-1 (TIA-1), 
a cytotoxic granule-associated RNA binding protein.  It is composed of three N-terminus 
RRMs and C-terminus glutamine-rich (Q-rich) motif that shows prion-like structure with 
a key regulatory role in the SG formation (Tian et al., 1991; Kawakami et al., 1992; Gilks 
et al., 2004).  A recent study from our laboratory has shown that the pathological 
mutations of TDP-43 increased the formation of SG that is marked with TIA-1 in 
neuronal cell culture (Liu-Yesucevitz et al.,2010).  Furthermore, TDP-43 co-localizes 
with TIA-1 positive SGs in brain and spinal cord of ALS and FTLD-U affected patients, 
suggesting the abnormal behavior of TDP-43 in neuronal cells may lead to dysregulation 
of its downstream effectors and eventually the death of neurons.   
The exact role of TDP-43 in SG formation is still unclear, but it is interesting to 
note that almost all of the disease-associated mutations identified thus far in TDP-43 are 
located in the C-terminus protein-protein interaction domain (Figure 3).  It is possible 
there is a link between the deleterious effect of TDP-43 mutations and the dysregulation 
of SG-like TDP-43 granule formation caused by the mutations, consequently leading to 
the pathogenesis of ALS and FTLD-U (Banks et al., 2008).  Even though the link 
between TDP-43 mutations and aggregate formation in the diseases has been indicated, 
the specific molecular mechanism of neurodegeneration in motor neurons through the 
TDP-43 aggregation is not well understood.  Moreover, a potential therapeutic agent for 
ALS and FTLD-U is yet to be discovered. 
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Cycloheximide is known to reverse the formation of SG by stabilizing polysomes, 
a complex of mRNA with multiple ribosomes, and by freezing ribosomes that are bound 
to translating mRNAs (Ballestra et al., 1991; Beelman et al., 1993; Kedersha et al., 2000; 
Cougot et al., 2004; Kedersha et al., 2005).  On the other hand, puromycin that inhibits 
the protein synthesis by destabilizing polysomes through promoting premature 
termination of translating mRNA does not inhibit SG formation, highlighting the specific 
mechanism of pharmacological inhibition of SGs (Bellestra et al., 1991; Kedersha et al., 
2000). 
Under acute arsenite-stressed conditions in cell culture system the cycloheximide 
treatment prevents the co-localization of TDP-43 with SG marker TIA-1 (Liu-Yesucevitz 
et al.,2010).  On the contrary, under a longer treatment with an oxidative stressor 
paraquat, which models chronic pathogenesis of ALS/FTLD-U in human patients, 
cycloheximide does not reverse the aggregated TDP-43, suggesting the transition of 
TDP-43 granules into more stable aggregates over time (Parker et al., 2012).   Even 
though cycloheximide is a useful chemical tool to study TDP-43 granule formation, it is 
considered as a highly toxic substance by United States Environmental Protection 
Agency (Gosselin et al., 1984; Lewis 1996), which raises a necessity of a new chemical 
agent to reverse the formation TDP-43 aggregates in vivo, and potentially to use it as a 
treatment for TDP-43-associated ALS/FTLD-U. 
Subsection Three: Inhibitors of TDP-43 Granules 
To identify new chemical agents that inhibit the formation of TDP-43 granules, a 
postdoctoral researcher in our laboratory Dr. Peter Lee-Armandt performed a large scale 
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screening of chemical compounds, using the engineered rat pheochromocytoma cell line  
(PC12) that inducibly expresses EGFP-tagged wild-type human TDP-43 (hTDP-43-
EGFP) (Boyd, Lee-Armandt, Feiler et al., 2013).  To model the pathological phenotype 
of the protein in the cells sodium a potent toxin and stress inducer, sodium arsenite was 
used to enhance formation of TDP-43 granules in the screening assay.  The arsenite-
treated cells formed the intracellular TDP-43-EGFP granules, and the inhibitory effect of 
the compounds was microscopically analyzed.  From the study we identified 22 candidate 
compounds, including Compound 8 (C8) that significantly reduced the arsenite-induced 
TDP-43 granule formation dose dependently without presenting much toxicity to the cells 
(Boyd, Lee-Armandt, Feiler et al., 2013). 
Our laboratory further tested the effect of candidate compounds on TDP-43 
induced neurodegeneration in nematodes C. elegans which expresses human ALS-
associated TDP-43 (A315T) that exhibits a movement disorder due to the expression of 
the disease protein (Liachko et al., 2010).  Among other lead compounds, 34.8µM C8 
showed the most significant improvement of the transgenic animals’ movement (Boyd, 
Lee-Armandt, Feiler et al., 2013). 
In addition to the movement disorder, the overexpression of human TDP-43 
(A315T) transgene in the nematodes induces the degeneration of the GABAergic motor 
neurons (Liachko et al., 2010).  In the compound-validation study, we observed the 
A315T-induced degeneration of motor neurons was significantly decreased when the 
transgenic nematodes were treated with C8, further supporting the bioactivity of the 
TDP-43 granule inhibitor in the ALS disease model and its neuroprotective function 
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(Boyd, Lee-Armandt, Feiler et al.,2013).  Even though the activity of C8 was shown in 
the C. elegans study, its mode of action in neuroprotection and other biological effects on 
mammalian cells are still unclear. 
In this thesis, I hypothesized the novel TDP-43 granule inhibitor C8 and its 
analogs reduce the excessive TDP-43 inclusion formation by regaining normal function 
of TDP-43 as a dynamic stress-granule protein (Figure 6).  To test our hypothesis, I 
generated the following specific aims and hypotheses. 
Aim 1: Determine whether C8 mediates the post-translational modification of 
TDP-43 and affects its granule formation to modulate the function of TDP-43. 
Hypothesis: C8 reduces the TDP-43 granule formation through the reduction of 
post-translationally modified, aggregate-prone TDP-43 proteins, including those 
modified at the novel phosphorylation sites at threonine 103 and serine 104. 
Aim 2: Determine whether the action of C8 on TDP-43 granule inhibition 
involves protein translation and proteostasis machineries, using chemo-genetic profiling 
and proteomics. 
Hypothesis: C8 reduces the TDP-43 granule formation through the proteins that 
are associated with protein translation and proteostasis machineries. 	  
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Figure 6. Hypothesis: C8 and its analog C8j reduce the excessive TDP-43 inclusion formation by regaining 
normal function of TDP-43 as a dynamic stress-granule protein. 
Under non-pathological, normal conditions the TDP-43 is localized in the nucleus.  When cells are stressed 
TDP-43 shuttles into cytoplasm and form granules that consist of other RNA binding proteins and 
untranslated mRNA.  The TDP-43 granules are degraded through proteasome and autophagy to funnel the 
cellular resources for survival, or disassembled when the stress is reduced resulting in TDP-43 to shuttle 
back in the nucleus.  On the other hand, under pathological conditions, such as disease-associated 
mutations of TARDBP, increased TDP-43 level, increased truncation and hyper phosphorylation of TDP-
43, TDP-43 aggregation may be over stimulated, resulting in the loss of nuclear TDP-43 or gain of toxicity 
from the intracellular aggregates.  C8 and its analog C8j may be reducing TDP-43 granules through 
facilitating the disassembly or degradation of the TDP-43 granules. 
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CHAPTER TWO: MATERIALS AND METHODS 
Section One: TDP-43 Granule Inhibitors 
The originally identified TDP-43 granule inhibitor C8 and 17 C8 analogs were 
provided by the Laboratory for Drug Discovery in Neurodegeneration (LDDN) 
(Cambridge, MA) and additional 132 C8 analogs were synthesized by Dr. Hrvoje Lusic 
at LDDN.  Following the screen, a necessary amount of C8 and C8j was purchased from 
ChemDiv (San Diego, CA).  The compounds were dissolved in dimethyl sulfoxide 
(DMSO) to make 30 mM of stock solution and were kept at either -80°C or -20°C for 
long or short-term storage, respectively.  C8 came in amber crystalline form and was 
continuously mixed in DMSO with vortex for at least 30 minutes to assure the compound 
was dissolved completely.  All stock solutions were protected from light with aluminum 
foil.  The compound was further diluted in cell culture media to make the final 
concentration of 5 µM with 0.1% DMSO, unless otherwise specified. 
 
Section Two: Cell Culture 
The stably transfected rat pheochromocytoma (PC12) cell line (Boyd, Lee-
Armandt, Feiler et al., 2013), which inducibly expresses the human wild type TDP-43 
protein tagged with enhanced green fluorescent protein (EGFP), was maintained in 
Dulbecco's Modified Eagle Medium (DMEM) with 4.5 g/l glucose, supplemented with 
5% fetal bovine serum (FBS) and 10 % horse serum.  The media was also supplemented 
with antibiotics 100 units/ml penicillin, 100 µg/ml streptomycin and the selection 
markers for the stably transfected cells 100 µg/ml Geneticin® and 100 µg/ml Hygromycin 
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B.  The expression of the exogenous gene was suppressed with the addition of 1 µg/ml 
doxycycline in the growth media.  The cells were maintained in collagen-coated flasks 
and incubated at 37°C with 5% carbon dioxide (CO2). 
To induce the transgene, the cells were dissociated from the flask surface with 
trypsin-ethylenediaminetetraacetic acid (EDTA), and they were transferred to a new 
collagen-coated flask with the growth media without doxycycline.  In the following day, 
the media was replaced with a fresh growth media to eliminate the residual doxycycline 
that was maintained in the cells.  One day after the replacement of the media, the cells 
were re-plated on collagen-coated 6-well plates or 10 cm plates, depending on the 
number of cells required for experiments. 
For compound treatment, 3 days after the induction of the transgene, the cells 
were treated with 5 µM of the TDP-43 granule inhibitors, unless otherwise specified, 1 
hour prior to 15 µM sodium arsenite treatment.  24 hours after the treatment of the 
inhibitors, the cells were harvested in radioimmunoprecipitation assay (RIPA) buffer 
supplemented with phosphatase and protease inhibitor cocktails (Roche, Branchburg, NJ) 
(RIPA+) for immunoblotting, or fixed with 4% paraformaldehyde (PFA) in phosphate 
buffered saline (PBS) for fixed-cell imaging. 
SH-SY5Y human neuroblastoma cell line was maintained in DMEM-F12 
(50%/50% v/v) with 1.0 g/l glucose, supplemented with 10% FBS, non-essential amino 
acids, and antibiotics Penicillin and Streptomycin.  The expression plasmids were 
transfected into the cells with Lipofectamine 2000® (Thermo Fisher Scientific, Grand 
Island, NY) in Opti-Minimum Essential Media (Opti-MEM®) reduced serum media 
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(Thermo Fisher Scientific, Grand Island, NY).  The cells were maintained at 37°C with 
5% CO2. 
The induced pluripotent stem (iPS) cells from healthy individuals and ALS 
patients with G298S TDP-43 mutation were provided by the laboratory of Dr. George 
Murphy at Center for Regenerative Medicine at Boston University School of Medicine.  
The cells were plated on Matrigel® Matrix (Corning, Corning, NY) coated plates.  The 
iPS cells were induced with the DMEDM-F12 based media, Neural Induction Medium 
(NIM) with retinoic acid, ascorbic acid, cAMP and sonic hedgehog (SHH) from Day 1 to 
Day 17, and Neural Differentiation Medium (NDM) that was supplemented with retinoic 
acid, ascorbic acid, cAMP, B-27®, BDNF, GDNF, IGF-1, CNTF from Day 17 to Day 25 
as previously described (Chambers et al., 2009, Hu et al., 2009).  The cells were 
maintained at 37°C with 5% CO2.  The differentiated cells were immunostained for a 
general neuronal marker microtubule associated protein 2 (MAP2), a functional neuronal 
marker choline acetyltransferase (ChAT), and a motor neuron marker homeobox 
transcription factor HB9.  The mouse monoclonal MAP2 antibody (1:500, Sigma-
Aldrich, St. Louis, MO) and rabbit polyclonal anti-ChAT and anti-HB9 antibodies (1:100 
and 1:1000, respectively, Millipore, Billerica, MA) were used as primary antibody.  
Donkey anti-mouse 488 nm and donkey anti-rabbit 594 nm (1:600, Jackson 
ImmunoResearch, West Grove, PA) were used as secondary antibodies.  The nuclei were 
counter stained with 30 nM of 4',6-diamidino-2-phenylindole (DAPI). 
The primary mouse hippocampal neurons were isolated from the postnatal day 0 
(P0) CD-1® pups (Charles River Laboratories, Wilmington, MA) and plated on glass 
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coverslips coated with poly-d-lysine/laminin (Sigma-Aldrich, St. Louis, MO).  On DIV1 
the neurons were transduced with adeno-associated virus serotype 1 (AAV1) viral 
particles expressing EGFP empty vector or EGFP-tagged WT, A315T, or Q331K TDP-
43.  Starting at Days in vivo (DIV) 7, the neurons were treated with 1.5 µM C8j every 48 
hours until they were fixed for immuonstaining on DIV12. 
 
Section Three: Dendritic Branching in Drosophila melanogaster  
The study in this section was conducted in collaboration with Dr. Yubin Lu at Dr. 
Fen-Biao Gao’s laboratory at the University of Massachusetts Medical School, 
Worcester, MA. 
All Drosophila melanogaster was raised at 25°C on standard food medium.  The 
transgenic D. melanogaster strains that express human full-length TDP-43 with the wild-
type or the Q331K mutation were used (Lu et al., 2009).  Their abdominal dorsal sensory 
neurons, ddaE and ddaF, were labeled with mCD8-GFP for visual observation with 
fluorescent microscopy.  The transgenic animals were feed with either DMSO vehicle 
control or 5 µM C8j containing media throughout their development. 
The images of GFP-labeled dorsal sensory neurons in Drosophila larva were 
obtained with confocal microscopy (Nikon, D-Eclipse C1).  The dendritic branching of 
ddaE and ddaF sensory neurons in the A3 dorsal cluster was manually scored. 
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Section Four: Cell Imaging and Analysis 
The cells were fixed with 4% paraformaldehyde (PFA) in PBS for 15 minutes and 
washed three times with PBS.  The cells were counterstained with 30 nM of 4',6-
diamidino-2-phenylindole (DAPI) for 5 minutes to visualize the nuclei.  High throughput 
imaging for the inducible PC12 cells was performed in collaboration with Dr. Justin 
Boyd at LDDN (Cambridge, MA) using IN Cell Analyzer 2000 high-content screening 
system (GE Healthcare, Wauwatosa, WI) as described previously (Boyd, Lee-Armandt, 
Feiler et al., 2013).  The acquired images from the cells grown in collagen-coated 96-well 
plates were further analyzed with IN Cell Workstation software (GE Healthcare, 
Wauwatosa, WI) for the detection of the cells expressing hTDP-43-EGFP with or without 
GFP granules. 
For imaging SH-SY5Y cells, the cells were cultured on 18 mm cover glasses 
(Warner Instruments, Hamden, CT) placed in 12-well plates.  Prior to the cell plating, the 
cover glasses were cleaned with 70% nitric acid overnight at room temperature with 
vigorous shaking, followed with the rigorous wash with deionized water and 70% 
ethanol.  The cleaned cover glasses were then coated with 0.1 mg/ml poly-l-lysine 
(Sigma Aldrich, St. Louis, MO) at room temperature for 2 hours, followed with washes 
with deionized water twice.  After the transfection and compound treatments, the cells 
were fixed with 4% PFA as described above.  The coverslips were mounted on glass 
slides with ProLong™ antifade mounting media (Thermo Fisher Scientific, Grand Island, 
NY) overnight and sealed with clear nail coat a day later.  The images were taken with 
Zeiss Axio Observer microscope system (Carl Zeiss, Thornwood, NY) using 20x 
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objective lens over two channels, with the excitation wavelengths 365 nm for DAPI and 
470 nm for EGFP.  The acquired images were analyzed with Fiji Is Just ImageJ (FIJI) 
image analysis software (Schindelin, Arganda-Carreras, & Frise, et al., 2012) to manually 
count the number of cells with or without EGFP granules using Cell Counter function. 
For imaging primary mouse hippocampal neurons, the cells were cultured on 18 
mm cover glasses (Warner Instruments, Hamden, CT) placed in 12-well plates.  After the 
treatment with C8j, they were fixed with 4% PFA in PBS.  The cells were permeated with 
0.1% Triton-X100 and blocked with 10% donkey serum, followed by immunestaining 
with a neuronal marker anti-microtubule-associated protein 2 (MAP2) antibody (Aves, 
Tigard, OR) at 1:1000 dilution with 5% donkey serum at 4°C overnight.  The Alexa 
Fluor® goat anti-chicken antibody was used as a secondary antibody.  The coverslips 
were mounted on glass slides with ProLong™ antifade mounting media (Thermo Fisher 
Scientific, Grand Island, NY) overnight and sealed with clear nail coat a day later.  The 
images were taken with Zeiss Axio Observer microscope system (Carl Zeiss, Thornwood, 
NY) using 20x objective lens with 6x6 tiling over three channels, with the excitation 
wavelengths 365 nm for DAPI, 470 nm for EGFP and 570 nm for MAP2.  The acquired 
images were analyzed with NeuronJ image analysis software (imagescience.org) to 
manually trace MAP2-stained dendrites. 
For live-cell imaging of the PC12 hTDP-43-EGFP cells, the induced cells were 
plated on 4-chambered 35 mm glass bottom dish with #1.5 cover glass (Cellvis, 
Mountain View, CA).  The surface of the cover glass was coated with poly-l-lysine as 
described above prior to the cell plating.  The images were captured with Zeiss Axio 
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Observer microscope system (Carl Zeiss, Thornwood, NY) with 20x and 40x objective 
lenses over the EGFP channel with the excitation wavelength 470 nm for EGFP.  To 
minimize the phototoxicity the intensity of the excitation light was reduced to 10% with 
30 ms of exposure time.  The images were captured with 10 min intervals over 18 hours 
or more.  After the live-cell imaging, the cells were fixed and counterstained with DAPI 
as described above, and their images were taken with 20x objective lens over the DAPI 
and EGFP channels. 
 
Section Five: Generation of TDP-43 (T103-S104) Expression Plasmids 
The EGFP-TDP-43 (T103-S104) phospho-mimetic and null constructs were 
generated with the help from a Ph.D. candidate Joon Y. Boon and Dr. Peter Ash of the 
Wolozin Lab.  The EGFP-tagged human TDP-43 expression plasmids with wild type or 
Q343R ALS mutation (Liu-Yesucevitz et al., 2010) were mutagenized at threonine 103 
and serine 104 (T103-S104) to aspartic acids or alanine as phospho-mimetic (T103D-
S104D) or null mutations (T103A-T104A), respectively, with QuickChange® II Site-
Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA).  After the 
mutagenesis, the protein coding sequence was confirmed with two DNA primers to cover 
the entire cDNA sequence of TDP-43: 5’-GCAGAACACCCCCATCGGCG-3’ and 5’-
GATGATCAGATTGCGCAGTC-3’.  The expression plasmids were amplified in One 
Shot® TOP10 Chemically Competent Escherichia coli (Thermo Fisher Scientific, Grand 
Island, NY) and purified with Plasmid Mini or Maxi Kit (QIAGEN, Valencia, CA). 
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Section Six: Immunoblotting 
The whole cell lysates were prepared on ice with chilled RIPA buffer 
supplemented with protease and phosphatase inhibitor cocktails as described above.  The 
cell lysates were then sonicated with Bioruptor (Diagenode, Denville, NJ), a water-bath 
based sonicator for 30 seconds on, and 30 seconds off cycles at High setting for 10 
minutes with wet ice.  After the sonication, the protein concentration was measured with 
Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, Grand Island, NY) using 
bovine serum albumin (BSA) as a standard and 20 µg of protein samples were loaded on 
NuPAGE® Novex® or Bolt® 4-12% Bis-Tris protein gels (Thermo Fisher Scientific, 
Grand Island, NY) for electrophoresis.  Following the electrophoresis, the proteins were 
transferred onto polyvinylidene difluoride (PVDF) membranes.  5% fat-free milk in Tris-
buffered saline (TBS) with 0.05% Tween 20 (TBST) was used as a blocking agent.  For 
anti-phospho antibodies, 5% BSA in TBST was used to block the membranes. 
Rabbit polyclonal anti-TDP-43 antibody (1:1000, Proteinech Group, Chicago, IL), 
rabbit polyclonal anti-phospho-TDP-43(S409-S410) antibody (1:1000, Cosmo Bio, 
Tokyo, Japan), mouse monoclonal anti-ubiquitin antibody (1:500, Thermo Fisher 
Scientific, Grand Island, NY), and mouse monoclonal anti-beta-actin antibody (1:5000, 
Millipore, Billerica, MA) were used as primary antibodies.  For immunoblotting with the 
ubiquitin antibody, the lysates were treated with 10 mM N-Ethylmaleimide to inhibit 
ubiquitin-conjugating enzymes, and the transferred PVDF membranes were incubated 
with the denaturing buffer consisting of 6 M guanidine-hydrochloride (HCl), 20 mM 
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Tris-HCl, pH 7.5, 5 mM beta- mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride 
(PMSF) for 60 minutes at 4°C. 
Horseradish peroxidase (HRP) conjugated donkey anti-rabbit and anti-mouse 
antibodies (Jackson ImmunoResearch, West Grove, PA) were used as secondary 
antibodies in 5% fat-free milk in TBST.  The blots were visualized with either Pierce™ 
ECL Western Blotting or SuperSignal™ West Pico chemiluminescence substrates 
(Thermo Fisher Scientific, Grand Island, NY).  The images of blots were acquired either 
with exposing x-ray films to the blots and scanning the films, or with imaging 
ChemiDoc™ XRS+ System (Bio Rad, Hercules, CA).  The densitometric analysis was 
performed with Image Studio™ Lite image analysis software (LI-COR, Lincoln, NE). 
 
Section Seven: Immunoprecipitation 
To immunoprecipitate the exogenous EGFP-tagged TDP-43 protein, the cells 
were lysed in RIPA+ buffer as described previously.  After the sonication, the 
immunoprecipitation was performed with the GFP-nAb™ agarose beads (Allele 
Biotechnology, San Diego, CA) at 4°C overnight.  GFP-nAb™ is a camelid-derived 
peptide that specifically binds to GFP and it is conjugated to agarose beads.  The beads 
were washed three times with chilled RIPA+ buffer, and the precipitated proteins were 
eluted from the beads by heating at 72 °C for 10 minutes with lithium dodecyl sulfate 
(LDS) sample buffer supplemented with NuPAGE® Sample Reducing Agent (Thermo 
Fisher Scientific, Grand Island, NY). 
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For immunoprecipitation with anti-TDP-43 rabbit polyclonal antibody, the cell 
lysates were prepared in RIPA+ buffer as described previously.  The protein-antibody 
complexes were isolated with Recombinant-Protein G-Sepharose® 4B beads (Thermo 
Fisher Scientific, Grand Island, NY).  The lysates were pre-cleared with the beads for 1 
hour at 4°C, and they were incubated with the anti-TDP-43 antibody overnight at 4°C.  
After extensive washes with RIPA+ buffer the immunoprecipitated proteins were eluted 
with the LDS protein sample buffer mix as described above. 
 
Section Eight: Non-Radioactive Labeling of Translated Proteins 
Prior to the TDP-43 granule inhibitor treatment, the induced PC12 cells were 
incubated with methionine-free media for 30 min.  After the deprivation of the 
methionine pool, they were incubated with the media containing Click-IT® L-
Azidohomoalanine (AHA) (Thermo Fisher Scientific, Grand Island, NY) for 1.5 hours 
where the methionine analog was incorporated into newly synthesized proteins.  The cells 
were then treated with the inhibitor as described previously, and lysed in 1% sodium 
dodecyl sulfate (SDS) in 50 mM Tris-HCl pH8.0, supplemented with phosphatase and 
protease inhibitors at time points 6, 12 and 24 hours after the inhibitor treatment.  The 
AHA-tagged proteins were biotinylated with Click-IT® Biotin Protein Analysis Detection 
Kit (Thermo Fisher Scientific, Grand Island, NY).  The biotinylated proteins were then 
pulled down with streptavidin agarose beads (Thermo Fisher Scientific, Grand Island, 
NY).  The protein samples were separated with acrylamide-gel electrophoresis and 
transferred on PVDF membranes.  The proteins that were pulled-down with streptavidin 
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beads were probed for TDP-43 and beta-actin with antibodies described previously.  
Additionally, streptavidin-HRP conjugate was used to visualize the total amount of AHA-
tagged, biotinylated proteins. 
 
Section Nine: Mass-Spectrometry 
The cell lysates from the inducible PC12 cells were prepared with RIPA+ buffer 
as described previously.  The immunoprecipitated TDP-43-EGFP protein and its protein 
complexes were visualized on acrylamide gel with SYPRO®-Ruby protein gel stain 
(Thermo Fisher Scientific, Grand Island, NY) to verify the efficacy of the 
immunoprecipitation step.  The samples for mass-spectometry analysis were separately 
run on a 4-12% Bis-Tris protein gel for 15 minutes at 120 V.  The protein bands were 
visualized with SimplyBlue™ SafeStain (Thermo Fisher Scientific, Grand Island, NY) 
and the whole well was excised from the gel for liquid chromatography (LC) with tandem 
mass spectrometry (MS) analysis (LC-MS/MS) at University of Massachusetts Medical 
School Proteomics and Mass Spectrometry Facility.  The acquired data was analyzed 
with Scaffold software (Proteome Software, Portland, OR). 
 
Section Ten: Gene Expression And MNI Analyses 
For the gene expression analysis of TDP-43 granule, the stably transfected PC12 
cells expressing hTDP-43-EGFP were cultured and treated with 5 µM C8 or DMSO and 
15 µM sodium arsenite as described previously.  The RNA was isolated based on the 
manufacturer’s protocol for the TRIzol® reagent and PureLink® RNA mini kit (Thermo 
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Fisher Scientific, Grand Island, NY).  The RNA was eluted with RNase-free water two 
times from purification columns and the purified RNA was pooled for each treatment 
group.  The nucleotide concentration and purity of the eluted samples was measured with 
NanoDrop spectrophotometer (Thermo Fisher Scientific, Grand Island, NY).  For all 
samples tested, the absorbance ratio of 260 nm/280 nm and 260 nm/230 nm were higher 
than 2.00 (between 2.07 and 2.10) and 2.2 (between 2.24 and 2.28), respectively.  The 
purified RNA samples were run with agarose gel electrophoresis to visualize the 16S and 
23S ribosomal RNA. 
The microarray analysis was performed by Coriell Genotyping and Microarray 
Center at Coriell Institute for Medical Research (Camden, NJ) using GeneChip® Rat 
Genome 230 2.0 Array (Affymetrix, Santa Clara, CA).  The obtained raw gene-
expression data was analyzed by Dr. Hu Li at Mayo Clinic (Rochester, MN).  The 
microarray data was further analyzed with the Mode of Action by Network Identification 
(MNI) algorithm by Dr. Li as described previously (Bernardo et al., 2005; Xing and 
Gardner, 2006, Brock et al., 2014).  Prior to the analysis of our microarray results, the 
MNI algorithm was trained with the publicly available 306 microarray results that were 
performed with the Rat Genome 230 2.0 microarray chip (Table 4).  This step generates a 
model of gene regulatory network and the basal gene-expression profile for rat genome.  
Our microarray data was then analyzed with this network model, highlighting the 
pathways and the immediate regulators that are potential target of C8. 
The list of genes were then analyzed for gene functional-annotation clustering 
analysis using the Database for Annotation, Visualization and Integrated Discovery 
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(DAVID), a free online analysis tool available through the Laboratory of 
Immunopathogenesis and Bioinformatics (LIB) (Huang, Sherman & Lempicki, 2009).  
The analysis was performed by inputting the list of the MNI highlighted genes with 
official gene symbols. 
 
Table 4. The list of manually curated microarray data that was used for MNI algorithm training. 
No. Series No. Series No. Series No. Series No. Series No. Series No. Series No. Series
1 GSE2275 41 GSE7323 81 GSE9387 121 GSE12066 161 GSE13802 201 GSE16899 231 GSE20259 271 GSE24878
2 GSE2870 42 GSE7441 82 GSE9445 122 GSE12132 162 GSE13810 202 GSE16981 232 GSE20344 272 GSE24879
3 GSE2872 43 GSE7479 83 GSE9480 123 GSE12153 163 GSE13883 203 GSE17384 233 GSE20358 273 GSE24982
4 GSE2875 44 GSE7491 84 GSE9537 124 GSE12196 164 GSE14269 204 GSE17661 234 GSE20388 274 GSE25144
5 GSE2880 45 GSE7493 85 GSE9570 125 GSE12260 165 GSE14337 205 GSE17859 235 GSE20635 275 GSE25196
6 GSE3110 46 GSE7584 86 GSE9788 126 GSE12289 166 GSE14402 206 GSE17959 236 GSE20659 276 GSE25612
7 GSE3298 47 GSE7623 87 GSE9789 127 GSE12296 167 GSE14484 207 GSE18055 237 GSE20935 277 GSE25752
8 GSE3866 48 GSE7625 88 GSE9797 128 GSE12304 168 GSE14505 208 GSE18162 238 GSE20967 278 GSE26066
9 GSE4031 49 GSE7640 89 GSE9833 129 GSE12343 169 GSE14562 209 GSE18260 239 GSE21006 279 GSE26138
10 GSE4037 50 GSE7697 90 GSE9918 130 GSE12457 170 GSE14666 210 GSE18753 240 GSE21075 280 GSE26316
11 GSE4038 51 GSE7891 91 GSE9976 131 GSE12481 171 GSE14676 211 GSE19106 241 GSE21417 281 GSE26350
12 GSE4130 52 GSE7955 92 GSE10376 132 GSE12483 172 GSE14723 212 GSE19210 242 GSE21476 282 GSE26363
13 GSE4286 53 GSE7970 93 GSE10408 133 GSE12596 173 GSE14724 213 GSE19290 243 GSE21573 283 GSE26660
14 GSE4753 54 GSE7999 94 GSE10409 134 GSE12639 174 GSE14725 214 GSE19354 244 GSE21681 284 GSE26730
15 GSE4776 55 GSE8077 95 GSE10411 135 GSE12724 175 GSE14848 215 GSE19366 245 GSE21806 285 GSE26936
16 GSE4865 56 GSE8078 96 GSE10412 136 GSE12725 176 GSE14903 216 GSE19380 246 GSE21937 286 GSE27393
17 GSE5033 57 GSE8132 97 GSE10527 137 GSE12752 177 GSE15041 217 GSE19537 247 GSE21938 287 GSE27625
18 GSE5034 58 GSE8134 98 GSE10557 138 GSE12754 178 GSE15074 218 GSE19589 248 GSE22118 288 GSE28058
19 GSE5131 59 GSE8184 99 GSE10608 139 GSE12755 179 GSE15184 219 GSE19652 249 GSE22299 289 GSE29247
20 GSE5282 60 GSE8238 100 GSE10641 140 GSE12817 180 GSE15223 220 GSE19653 250 GSE22321 290 GSE29299
21 GSE5350 61 GSE8252 101 GSE10669 141 GSE12966 181 GSE15243 221 GSE19658 251 GSE22515 291 GSE29885
22 GSE5509 62 GSE8302 102 GSE10748 142 GSE12978 182 GSE15407 222 GSE19701 252 GSE22531 292 GSE30526
23 GSE5606 63 GSE8310 103 GSE10775 143 GSE13268 183 GSE15415 223 GSE19820 253 GSE22537 293 GSE30532
24 GSE5680 64 GSE8314 104 GSE10919 144 GSE13269 184 GSE15498 224 GSE19830 254 GSE22553 294 GSE30851
25 GSE5849 65 GSE8316 105 GSE10923 145 GSE13270 185 GSE15563 225 GSE19909 255 GSE22638 295 GSE30964
26 GSE5996 66 GSE8318 106 GSE10949 146 GSE13381 186 GSE15652 226 GSE19948 256 GSE22647 296 GSE31117
27 GSE6104 67 GSE8341 107 GSE11097 147 GSE13413 187 GSE15727 227 GSE20214 257 GSE22791 297 GSE31307
28 GSE6119 68 GSE8421 108 GSE11133 148 GSE13414 188 GSE15737 228 GSE20219 258 GSE23004 298 GSE31399
29 GSE6208 69 GSE8485 109 GSE11137 149 GSE13428 189 GSE15841 229 GSE20245 259 GSE23179 299 GSE31430
30 GSE6299 70 GSE8491 110 GSE11334 150 GSE13524 190 GSE15856 230 GSE20246 260 GSE23432 300 GSE31503
31 GSE6342 71 GSE8700 111 GSE11465 151 GSE13535 191 GSE15887 231 GSE20259 261 GSE23643 301 GSE31668
32 GSE6497 72 GSE8880 112 GSE11478 152 GSE13537 192 GSE15944 232 GSE20344 262 GSE23668 302 GSE31678
33 GSE6701 73 GSE8911 113 GSE11542 153 GSE13538 193 GSE16231 233 GSE20358 263 GSE23748 303 GSE32125
34 GSE6718 74 GSE8978 114 GSE11722 154 GSE13539 194 GSE16232 234 GSE20388 264 GSE24047 304 GSE32156
35 GSE6929 75 GSE9062 115 GSE11730 155 GSE13550 195 GSE16233 235 GSE20635 265 GSE24104 305 GSE32890
36 GSE7002 76 GSE9076 116 GSE11829 156 GSE13594 196 GSE16624 236 GSE20659 266 GSE24110 306 GSE33973
37 GSE7041 77 GSE9121 117 GSE11842 157 GSE13624 197 GSE16695 237 GSE20935 267 GSE24363
38 GSE7193 78 GSE9263 118 GSE11851 158 GSE13668 198 GSE16710 238 GSE20967 268 GSE24515
39 GSE7253 79 GSE9281 119 GSE11987 159 GSE13669 199 GSE16792 239 GSE21006 269 GSE24672
40 GSE7267 80 GSE9293 120 GSE12007 160 GSE13747 200 GSE16849 240 GSE21075 270 GSE24877
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The publicly accessible microarray results with GeneChip® Rat Genome 230 2.0 Array were curated 
manually to ensure each dataset only contained rat microarray results, and not the results from other 
species. 
 
Section Eleven: Kinase Profiling 
5 µM of TDP-43 granule inhibitor C8j was tested with 383 wild-type kinases that 
were available through Reaction Biology Corp. (Malvern, PA).  The radioisotope filter-
binding assay was used to measure the effect of the compound on the kinase activity 
(Hastie, McLauchlan & Cohen, 2006).  C8j or DMSO was incubated with kinase, 
substrate, cofactors and radioisotope-labeled ATP, and the mixture was spotted on a filter 
paper.  The amount of catalytic product with the radioisotope-label bound on the filter 
paper was then measured.  For all kinases tested, the 10-point dose-response assay was 
performed to obtain the half-maximal inhibitory concentration (IC50) with control 
inhibitors, such as staurosporine.  The maximum enzymatic activity was calculated for 
each kinase based on the DMSO-only group and the minimum kinase activity was set 
based on the EDTA-only group. 
 
Section Twelve: Drug Affinity Responsive Target Stability (DARTS) Test 
To test whether the TDP-43 granule inhibitor C8 binds to a target protein and 
protects the protein stability against proteases under arsenite treated condition, we 
induced PC12 cells to express human wild-type TDP-43-EGFP as described previously, 
and treated with 15 µM sodium arsenite without addition of the granule inhibitors.  The 
DARTS assays were performed based on the published protocols (Lomenick et al., 2009; 
Lomenick et al., 2011).  The cells were then lysed in Mammalian Protein Extraction 
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Reagent (M-PER) (Thermo	Fisher	Scientific,	Grand	Island,	NY) supplemented with 
protease and phosphatase inhibitors.  After sonication, the lysates were incubated with 2 
µM C8 at room temperature for 1 hour before being subjected with Pronase or 
Thermolysin.  The compound concentration was chosen based on the DARTS protocol 
suggesting the use of 10-fold higher than the IC50 of C8 (~200 nM).  The enzyme-treated 
protein samples were then run on acrylamide gel, followed by SYPRO®-Ruby protein 
stain for visualization.  The gel image was taken with ChemiDoc™ XRS+ system. 
 
Section Thirteen: Bioinformatics and Statistical Analyses 
For the bioinformatics analysis of the microarray and proteomics results, the 
Database for Annotation, Visualization and Integrated Discovery (DAVID), a free online 
analysis tool available through the Laboratory of Immunopathogenesis and 
Bioinformatics (LIB) (Huang, Sherman & Lempicki, 2009).  In addition, the network of 
the highlighted genes and proteins were analyzed with Ingenuity Pathway Analysis (IPA) 
software (QIAGEN, Valencia, CA) to identify biologically relevant relationships, 
mechanisms, functions, and pathways. 
To graph the experimental results and compute statistical significance, the 
analyses were performed with One-way or Two-way ANOVA, and Tukey’s post hoc 
tests using Prism (GraphPad Software, La Jolla, CA). 
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CHAPTER THREE: THE NOVEL GRANULE INHIBITORS MEDIATE THE 
POST-TRANSLATIONAL MODIFICATION OF TDP-43 AND AFFECT ITS 
GRANULE FORMATION 
Section One: Introduction 	
In previous studies in the Wolozin Lab, we have identified chemical compounds 
that inhibit arsenite-induced TDP-43 granule formation dose dependently without 
presenting much toxicity to the PC12 mammalian cell model (Figure 7A & B; Boyd, Lee-
Armandt, Feiler et al., 2013).  In addition, we demonstrated the candidate compounds, 
including Compound 8 (C8), significantly improved the movement of transgenic C. 
elegans that expresses human TDP-43 protein with the ALS-associated A315T mutation 
exhibiting a movement disorder (Boyd, Lee-Armandt, Feiler et al., 2013).  Furthermore, 
the compound treatment ameliorated the degenerative effect of the mutant TDP-43 
protein on the C. elegans GABAergic motor neurons (Boyd, Lee-Armandt, Feiler et al., 
2013). 
This study demonstrates the effect of the novel TDP-43 granule inhibitors C8 and 
its analog C8j on the protein levels of post-translationally modified TDP-43, and the 
effect of the inhibitors on the kinetics of TDP-43 granule formation in the mammalian 
cell model system that we developed.  It also demonstrates the role of the newly 
discovered phosphorylation at the amino acid residues threonine 103 and serine 104 of 
TDP-43 on the TDP-43 granule formation.  Finally, it demonstrates the biological effects 
of C8 on the TDP-43-induced neurite shortening in primary mouse neurons and C8 on the 
TDP-43 protein function of in the Drosophila transgenic model.  
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Section Two: C8 Reduces Truncated and High Molecular Weight TDP-43 Protein 
Levels, Greater Than Full-Length Naïve Protein 	
To assess whether C8 affects the protein level of TDP-43 in mammalian cells 
under arsenite-treated conditions, we used the PC12 TDP-43 cells that inducibly express 
C-terminally EGFP-tagged human TDP-43 (hTDP-43-EGFP).  To facilitate the formation 
of intracellular TDP-43 granules, the cells were treated with 15 µM of sodium arsenite 
for 23 hours.  Under this condition, the arsenite treatment significantly increased the 
fraction of cells with TDP-43 granules as previously described (Boyd, Lee-Armandt, 
Feiler et al., 2013).  The 24-hour 5 µM C8 treatment that includes 1 hour of pre-treatment 
prior to the arsenite insult reduced the fraction of cells with TDP-43 granules by 73% 
relative to the vehicle control, DMSO (Figure 7C).  The whole cell lysates from these 
cells were prepared and subjected to immunoblotting with anti-TDP-43 antibody to 
compare the protein level of hTDP-43-EGFP with different molecular weights.  The 
immunoblot showed that the protein level of full-length hTDP-43-EGFP (70 kDa) was 
significantly reduced by 51% with the C8 treatment relative to the vehicle control (Figure 
8A Lane 4 & 5, Figure 8B, Table 6). 
TDP-43 is known to undergo post-translational modifications including the 
protein cleavage by proteases, such as caspases, producing the aggregate-prone C-
terminus fragments with 25 kDa and 35 kDa molecular weights (Zhang et al., 2007).  
Under basal conditions, the level of the truncated TDP-43 level is low (Figure 8A Lane 1 
& 2).  When the cells were under arsenite-induced stressed conditions, the cleavage 
products hTDP-25-EGFP and hTDP-35-EGFP bands with predicted molecular weight of 
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52 kDa and 62 kDa, respectively, became visible (Figure 8A Lane 3).  Under these 
conditions the TDP-43 granule inhibitor C8 significantly reduced the hTDP-25-EGFP for 
65% relative to the DMSO control (Figure 8A Lane 4 & 5, Figure 8C Top, Table 6).  The 
compound treatment also reduced the protein fragment by 91% relative to the control, 
even though the hTDP-35-EGFP fragment was not induced by the arsenite treatment as 
robust as hTDP-25-EGFP (Figure 8A Lane 4 & 5 Lower Panel, Figure 8C Middle Panel, 
Table 6).  For both truncated forms of TDP-43, the effect of C8 on reduction was larger 
than what we observed with on the full-length naïve protein; 65% and 91% reduction was 
observed with the TDP-43 fragments, as opposed to 51% with the full-length protein. 
In addition to the protein truncation, it has been shown TDP-43 forms detergent-
insoluble protein aggregates with high molecular weight in ALS/FTLD brain tissues 
(Zhang et al., 2007, Bosque et al., 2013).  Furthermore, the disease-associated mutations 
of the TARDBP gene are shown to increase the detergent-insoluble multimers (Liu-
Yesucevitz et al., 2010).  In the immunoblot of the whole cell lysates from the PC12 
hTDP-43-EGFP cells, the high molecular weight TDP-43 often appeared as a smear 
larger than 100 kDa under arsenite-treated conditions (Figure 8A Lane 3 & 4 Middle 
Panel) and the detected level of smear was significantly lowered by 73% in the C8 treated 
group than the DMSO control (Figure 8A Lane 4 & 5 Middle Panel, Figure 8C Bottom 
Panel, Table 6).  The 75% reduction of high molecular weight with C8 treatment we 
observed was more than what we observed with the full-length hTDP-43-EGFP protein 
with 51% reduction.  These data suggest C8 might reduce the TDP-43 granules through 
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reducing the protein level of high molecular weight, detergent insoluble aggregated TDP-
43. 
To test the effect of C8 on the detergent-insoluble TDP-43 aggregates that appear 
as high molecular weight smear, we further biochemically fractionated the PC12 cell 
lysates with RIPA buffer and immunoblotted with anti-TDP-43 antibody.  We normalized 
the signal intensity of the RIPA-insoluble TDP with the full-length hTDP-43-EGFP to 
compensate the reduced protein level of full-length hTDP-43-EGFP with C8.  The 
immunoblot showed the reduction of the detergent-insoluble high molecular weight TDP 
in replicated experiments (Figure 9 §, Table 7).  The degree of reduction we observed 
with C8 treatment on high molecular weight TDP in the RIPA-insoluble fraction matched 
with that of total protein samples (70% and 73%, respectively), suggesting the majority 
of the high molecular weight TDP-43 was in the detergent insoluble fraction.  In addition 
to the high molecular-weight smear, C8 reduced the truncated TDP-43 fragments in the 
RIPA-insoluble fraction (Figure 9 † & † †), suggesting the TDP-43 granule inhibitor is 
capable of reducing the amount of detergent-insoluble high molecular weight and small 
truncated TDP-43 fragments, however further investigation to show the statistical 
significance is required to draw a final conclusion. 
These results shows the TDP-43 granule inhibitor C8 significantly reduces the 
protein level of the full-length TDP-43 by 51%, the detergent insoluble, aggregated TDP-
43 by 70%, and the truncated, aggregate-prone fragments of TDP-43 by 65% and 91%.  
These effects of the compound seemed to be more robust against the aggregate-prone 
fragments and aggregated form of TDP-43, than the effect on the full-length protein.  The 
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C8 treatment significantly reduced the TDP-43 granules by 73% in the PC12 imaging 
experiments (Figure 7 & Table 5).  These results suggests what we observed with the 
reduced number of cells with TDP-43 granules is possibly due to the reduction of the 
modified protein species, and also suggesting the presence of a specific biological 
mechanism of C8 that selectively reduces the levels of TDP-43 protein with low and high 
molecular weights, for example through increasing the clearance of those proteins.  In 
addition, we observed the reduction of full-length TDP-43, and it is possible that C8 is 
also acting through another mechanism, such as reduction of protein translation 
machinery, to reduce the TDP-43 granules.  
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Figure 7. Compound 8 reduces the formation of arsenite-induced TDP-43 granules. 
The EGFP-tagged wild-type human TDP-43 was stably expressed in PC12 cells and the TDP-43 granules 
were induced with 15 µM sodium arsenite. (A) C8 inhibited the formation of TDP-43 granules dose 
dependently (Triangle) without affecting the cell count (Boyd, Lee-Armandt, Feiler et al., 2013).  (B) 
Structure of C8 is shown.  (C) The representative images of the inducible PC12 hTDP-43-EGFP cells 
treated with 15 µM sodium arsenite (Ars) and 5 µM C8.  DMSO was used as a vehicle control.  TDP-43-
EGFP is in green and the DAPI-stained nuclei are in blue channels with 20x objective lens.  Under normal 
conditions, diffused TDP-43 was nuclear localized (arrow).  The arsenite-treatment induced the formation 
of intracellular TDP-43 granules (arrow head).  Scale bar is 20 µm.  (D) % inhibition of TDP-43 granules 
was calculated based on the no-arsenite treated group as 0% and the arsenite treated group as 100%.  t-Test 
was used for statistical analysis.  *P<0.05.  
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Table 5 The quantitative analysis of C8 on the TDP-43 granule inhibition. 
The mean % inhibition from independent experiments was calculated based on the fraction of cells with 
TDP-43 granules in the no-arsenite-treated group as 0% and in the arsenite-treated group as 100%.  N, 
number of independent experiments.  SEM, standard error of the mean.  t-Test was used for statistical 
analysis to compute significance between the DMSO vehicle and C8 treatment.   
Treatment Ars Mean Inhibition SEM N
P-value 
vs. DMSO
DMSO + -0.9% 2.3% 3
C8 + 73.3% 16.4% 3 < 0.05
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Figure 8. The reduction of TDP-43 protein level with C8 treatment under arsenite treatment. 
(A) The PC12 hTDP-43-EGFP whole cell lysates were immunoblotted with anti-TDP-43.  Beta-actin was 
used as an internal loading control.  (B & C) The immunoblots was densitometrically quantified.  hTDP-
43-EGFP values were normalized to beta-actin (B) and the other TDP products were normalized to the full-
length hTDP-43-EGFP (C).  The signal intensity of DMSO treated group was set at 1.  The data was 
statistically analyzed with the one-way ANOVA and Tukey’s test.  * P<0.05, **P<0.01, ***P<0.001. 
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Table 6. The effect of C8 on TDP-43 protein levels under arsenite treatment. 
TDP-43 immunoblots were quantified by normalizing the intensity to the beta-actin level for the full-length 
hTDP-43-EGFP, or to the full-length hTDP-43-EGFP for the other TDP products.  Relative intensities were 
calculated based on the no treatment control.  Statistical analysis was performed with the one-way ANOVA 
analysis, followed with Tukey’s test to compute P-values.  N indicates the number of replicated 
experiments.  SEM, standard error of the mean. 
 
Protein MW Compound Ars Mean Intensity SEM N
P-value 
vs. DMSO
Reduction 
vs. DMSO
hTDP-43-EGFP 70 kDa
No Treatment + 1.00 0.00 3
DMSO + 1.03 0.04 3
C8 + 0.51 0.18 3 < 0.05 -51%
hTDP-25-EGFP 52 kDa
No Treatment + 1.00 0.00 3
DMSO + 0.98 0.12 3
C8 + 0.35 0.14 3 < 0.05 -65%
hTDP-35-EGFP 62 kDa
No Treatment + 1.00 0.00 3
DMSO + 0.96 0.27 3
C8 + 0.09 0.22 3 < 0.05 -91%
High MW TDP-43 > 80 kDa
No Treatment + 1.00 0.00 3
DMSO + 0.85 0.02 3
C8 + 0.23 0.15 3 < 0.01 -73%
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Figure 9. The reduction of RIPA insoluble TDP proteins with C8 under arsenite treatment. 
(A) The PC12 hTDP-43-EGFP lysates were biochemically fractionated with RIPA buffer and 
immunoblotted with anti-TDP-43 antibody.  Beta-actin was used as internal loading control.  (B) The 
immunoblots were densitometrically quantified and the signal intensity from detergent-insoluble TDP 
spices was normalized to that of full-length hTDP-43-EGFP from the total protein sample.  The signal 
intensity of DMSO treated group was set at 1.  Error bars are SEM. 
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Table 7. The effect of C8 on RIPA insoluble TDP-43 protein levels under arsenite treatment. 
Immunoblots were quantified by normalizing the intensity to the RIPA-insoluble TDP protein level with 
the full-length hTDP-43-EGFP from the total protein for each group.  Relative intensities were calculated 
based on the DMSO treated control.  t-test was used to analyze statistical significance between DMSO and 
C8 for each TDP spices.  N indicates the number of replicated experiments.  SEM, standard error of the 
mean.   
Protein MW Compound Ars Mean Intensity SEM N
Reduction 
vs. DMSO
hTDP-43-EGFP 70 kDa
DMSO + 1.00 0.00 2
C8 + 1.02 0.10 2 2%
hTDP-25-EGFP 52 kDa
DMSO + 1.00 0.00 2
C8 + 0.42 0.20 2 -58%
hTDP-35-EGFP 62 kDa
DMSO + 1.00 0.00 2
C8 + 0.46 0.09 2 -54%
High MW TDP-43 > 80 kDa
DMSO + 1.00 0.00 2
C8 + 0.30 0.25 2 -70%
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Section Three: C8 Analog C8j Reduces Arsenite-Induced TDP-43 Fragmentation 
and Multimerization 	
The TDP-43 granule inhibitor C8 was one of the candidate compounds that were 
identified in the original large-scale compound screen (Boyd, Lee-Armandt, Feiler et al., 
2013).  To ask if other chemical compounds with a structurally similarity to C8 can also 
reduce the arsenite-induced TDP-43 granules in the inducible PC12 cell model, we 
further tested 17 preexisting C8 analogs and additional 132 newly synthesized analogs 
that were provided by Dr. Hrvoje Lusic at the Laboratory for Drug Discovery in 
Neurodegeneration (LDDN) (Cambridge, MA).  In the experiment, we identified C8j that 
inhibited the arsenite-induced TDP-43 granules dose dependently, among other analogs 
with weaker inhibitory effect (Figure 10A).  At 5 µM C8j significantly reduced the 
fraction of cells with the TDP-43 granules with 71.7% inhibition rate (Figure 10B, Table 
8). 
In addition to the imaging based analysis for TDP-43 granule inhibition by the 
newly identified C8j, we tested the effect of C8j on the protein level of TDP-43 under 
arsenite treatment using the whole cell lysates from the inducible PC12 cells, as described 
in the previous immunoblotting experiments.  The lysates were immunoblotted with anti-
TDP-43 antibody to detect all of the TDP-43 species, including the full-length, truncated 
and high molecular weight proteins.  As with C8, the analog C8j significantly reduced the 
protein level of full-length, truncated and high molecular weight TDP-43 relative to 
DMSO under arsenite-induced stressed conditions (Figure 11, Table 9). 
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To further test the effect of the TDP-43 granule inhibitors on the TDP-43 protein 
level, we utilized induced pluripotent stem (iPS) cells that were isolated from healthy 
individuals and ALS patients with G298S mutation of TDP-43 mutation that were 
provided by Dr. George Murphy’s laboratory at the Center for Regenerative Medicine at 
Boston University School of Medicine.  G298S has been reported to cause familial form 
of ALS, and the iPS cells allow us to study the effect of the TDP-43 granule inhibitors on 
the endogenous level of TDP-43 protein with the disease-associated mutation (Benajiba 
et al., 2009). 
First we tested if the longer duration of differentiating the iPS cells will increase 
the detergent insoluble fraction of TDP-43, which is a hallmark of ALS pathology and 
TDP-43 aggregates (Arai et al., 2006; Liu-Yesucevitz et al., 2010).  The patient-derived 
and control iPS cells were induced for 17 days in Neural Induction Medium (NIM) and 
Neural Differentiation Medium (NDM) for additional 8 days (Chambers et al., 2009, Hu 
et al., 2009).  First, to test if the cells expressed neuronal markers, they were 
immunostained with a neuronal marker microtubule associated protein 2, MAP2, and 
motor neuron markers	choline acetyltransferase (ChAT) and homeobox transcription 
factor HB9  (Figure 12).  The immunostaining showed that the induced cells were 
positive for the neuronal markers MAP2.  The MAP2 positive cells also expressed the 
ChAT in the neurites and also HB9 in nuclei, even though some cells were 
immunostained with the markers without distinct neuronal morphology.  The cells were 
lysed at the day of differentiation 0, 14, 21 and 25 and biochemically fractionated with 
RIPA buffer.  Immunoblotting of the RIPA-insoluble fraction showed increased level of 
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detergent-insoluble, high molecular weight and low molecular weight TDP-43 species 
after 21 and 25 days of differentiation, that were absent at earlier stage (Figure 13).  At 
the day 25 of differentiation, TDP-43 seemed to accumulate in the detergent insoluble 
fraction suggesting the sensitivity of the protein to conditions and providing the 
possibility of the biochemical change of TDP-43 from more detergent soluble to 
detergent insoluble state over time. 
Next we tested if C8 and C8j reduce the detergent insoluble species of TDP-43 
using the ALS-patient derived iPS cells 25 days after differentiation.  The 
immunoblotting of the RIPA insoluble fraction showed the decreased level of 
immunoreactivity to anti-TDP-43 antibody with the treatment of C8 and C8j (Figure 14).  
With the treatment of C8 and C8j, the detergent insoluble TDP-43 with high molecular 
weight were reduced in two independent ALS patient lines, and also the control line from 
healthy individual.   
These data suggest the detergent solubility of TDP-43 is influenced by condition 
and decreased over time, and C8 and C8j seem to increase the detergent solubility of 
TDP-43.  However, we observed variability between lines and experiments on the 
amount of detergent insoluble TDP-43, which could be due to the differences in genetic 
background of each human-derived cell line and sensitive nature of endogenous TDP-43 
protein to experimental conditions in iPS cells.  In future experiments, it will be essential 
to use the control lines from the ALS-patient cells that are genetically edited from G298S 
to the wild type, and test if increase in the detergent-insoluble TDP-43 is higher with the 
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mutation with extended differentiation time and the effect of C8 on the insoluble TDP-43 
in iPS cells. 
These data suggest the TDP-43 granule inhibitor C8 and its analog with similar 
chemical structure are able to reduce the TDP-43 protein levels with different molecular 
weights, in addition to reducing the formation of the intracellular granules in the 
mammalian cells.  Additionally, the effect was consistently more prominent on the 
fragmented or high molecular weight TDP-43 than the full-length, supporting the similar 
observation in the previous experiments, even though the effect of the C8 and C8j on 
reducing the TDP-43 protein levels seemed to vary between experiments.  In addition, the 
solubility of TDP-43 seems to be sensitive to conditions in the iPS cells, suggesting the 
dysregulation or chronic change in neuronal environment might affect its dynamic, 
liquid-like TDP-43 into more aggregated, detergent-insoluble in ALS/FTLD-U.  
		
65	
 
Figure 10. C8 analog C8j also reduces the arsenite-induced TDP-43 granules. 
The inhibitory effect of C8 analog, C8j on TDP-43 granule formation was tested with the stably transfected 
PC12 hTDP-43-EGFP cells.  (A) % inhibition was calculated based on the no-arsenite and arsenite-treated 
groups as 0% and 100% inhibition, respectively, and plotted over different concentrations of C8j.  (B) % 
inhibition at 5 µM C8j treatment is shown and result was statistically analyzed with t-test.  *** P<0.001.  
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Table 8. Inhibitory effect of C8j on the arsenite-induced TDP-43 granules. The	inhibitory	effect	of	5	µM	C8j	24	hour	treatment	was	calculated	for	the	arsenite-induced	TDP-43	granules	in	the	inducible	PC12	hTDP-43-EGFP	cells.		The	result	was	statistically	analyzed	with	t-test.		SEM,	standard	error	of	the	mean.			  
Treatment Ars Mean Inhibition SEM N
P-value 
vs. DMSO
DMSO + 5.0% 2.3% 3
C8j + 71.7% 5.5% 3 < 0.001
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Figure 11. The reduction of TDP-43 protein level with C8j treatment under arsenite treatment. 
(A) The PC12 hTDP-43-EGFP cell lysates were immunoblotted with anti-TDP-43.  Beta-actin was used as 
protein loading control.  ** indicates the unstripped endogenous TDP-43.  (B & C) The immunoblot was 
densitometrically quantified.  hTDP-43-EGFP values were normalized to beta-actin (B) and the other TDP 
products were normalized to the full-length hTDP-43-EGFP (C).  The signal intensity of DMSO treated 
group was set at 1.  The data was statistically analyzed with the one-way ANOVA and Tukey’s test.  
**P<0.01, ***P<0.001, ****P<0.0001. 
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Table 9. TDP-43 granule inhibitors affect TDP-43 protein levels under arsenite treatment. 
TDP-43 immunoblots were quantified by normalizing the intensity to the beta-actin level.  Relative 
intensities were calculated based on the no treatment control.  Statistical analysis was performed with the 
one-way ANOVA analysis, followed with Tukey’s test to compute P-values.  N indicates the number of 
replicated experiments.  SEM, standard error of the mean.  
Protein MW Compound Ars Mean Intensity SEM N
P-value 
vs. DMSO
Reduction 
vs. DMSO
hTDP-43-EGFP 70 kDa
DMSO + 1.00 0.00 9
C8 + 0.63 0.11 6 < 0.01 -37%
C8j + 0.50 0.11 6 < 0.001 -50%
hTDP-25-EGFP 52 kDa
DMSO + 1.00 0.00 9
C8 + 0.51 0.12 6 < 0.001 -49%
C8j + 0.42 0.07 6 < 0.0001 -58%
hTDP-35-EGFP 62 kDa
DMSO + 1.00 0.00 9
C8 + 0.23 0.20 6 < 0.001 -77%
C8j + 0.37 0.12 6 < 0.01 -63%
High MW TDP-43 >100 kDa
DMSO + 1.00 0.00 9
C8 + 0.25 0.10 6 < 0.0001 -75%
C8j + 0.37 0.17 6 < 0.001 -63%
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Figure 12 Human induced pluripotent stem cells were differentiated into neuron-like cells that were positive for 
neuronal markers. 
The induced pluripotent stem cells from healthy individual (Ctrl) and two independent isolates of ALS 
patient lines C6.2 and C7 with G298S TDP-43 mutation were differentiated with the Neural Induction 
Medium (NIM) between Day 1 to Day 17 and the Neural Differentiation Medium (NDM) for the rest of the 
maturation period.  NIM contained retinoic acid, ascorbic acid, cAMP and sonic hedgehog (SHH), and 
NDM was supplemented with retinoic acid, ascorbic acid, cAMP, B-27®, BDNF, GDNF, IGF-1 and 
CNTF.  The cells were immunostained for a neuronal marker MAP2, and motor neuron markers ChAT and 
HB9.  The scale bar is 10 µm.	  
MAP2 ChAT Overlay (MAP2/ChAT/DAPI)
ALS C6.2
MAP2 HB9 Overlay (MAP2/HB9/DAPI)
ALS C7
ALS C6.2
ALS C7
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Figure 13. The detergent insoluble TDP-43 in ALS-patient-derived iPS cells (Published in Liu-Yesucevitz et 
al, 2014). 
The induced pluripotent stem cells from healthy individual (Ctrl) and ALS patient (Isolate C6.2) with 
G298S TDP-43 mutation were differentiated with neural growth factors, and harvested for biochemical 
fractionation with RIPA buffer.  The total protein and RIPA-insoluble fractions were immunoblotted with 
anti-TDP-43 antibody.  Beta-actin was used as a loading control.  The RIPA-insoluble TDP-43 proteins 
increased over time during 14, 21 and 25 days of differentiation process.	  
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Figure 14. The effect of C8 & C8j on detergent insoluble TDP-43 in ALS-patient-derived iPS cells. 
The induced pluripotent stem cells from healthy individual (Ctrl) or two independent isolates of ALS 
patient lines C6.2 and C7 with G298S TDP-43 (ALS1 & ALS2, respectively) were differentiated with 
neural growth factors for 25 days, and harvested for biochemical fractionation with RIPA buffer.  The total 
protein and RIPA insoluble fractions were immunoblotted with anti-TDP-43 antibody.  Beta-actin was used 
as a loading control.  C8 and C8j reduced the RIPA-insoluble TDP-43 in all cell lines relative to the DMSO 
vehicle control (D).	  
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Section Four: C8 and C8j Reduce Arsenite-Induced TDP-43 (S409-S410) 
Phosphorylated Proteins 	
It has been shown that TDP-43 is hyper-phosphorylated at multiple locations in 
the brain tissues of ALS/FTLD patients (Arai et al., 2006; Neumann et al., 2006).  
Among other phosphorylation sites, it has been shown that the serine residues at 409 and 
410 (S409-S410) of TDP-43 are prominently phosphorylated under stress conditions 
(Hasegawa et al., 2008; Neumann et al., 2009).  Furthermore, the antibody that detects 
the phosphorylation at the amino acid residues also detects detergent-insoluble TDP-43 
and intracellular TDP-43 inclusions in the disease tissues. 
In the immunoblot experiments above, an additional band was detected right 
above the full-length hTDP-43-EGFP (Figure 8 Lane 3 & 4, Figure 11 Lane 3) that is 
presumably a post-translationally modified form of the protein with slightly higher 
molecular weight than the naive, full-length hTDP-43-EGFP.  Based on the small shift on 
the molecular weight, it is possible that the protein right above 70 kDa band could be 
from the phosphorylation at S409-S410, and C8 and C8j reduce the phosphorylated TDP-
43 (S409-S410).  Since the protein level of the top band is significantly weaker than the 
full-length hTDP-43-EGFP with 70 kDa molecular weight when the lysates were 
immunoblotted with anti-TDP-43 antibody, it was not possible to reliably separate the 
two bands for quantitation. 
To accurately measure the TDP-43 protein level with S409-S410-p modification, 
the stably-transfected PC12 cells were treated with the TDP-43 granule inhibitors and 15 
µM of sodium arsenite, and their whole cell lysates were immunoblotted with anti-TDP-
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43 (S409-S410-p) antibody.  Under basal conditions, the anti-phospho antibody did not 
detect the modified hTDP-43-EGFP (Figure 15A Lanes 1 & 2).  As previously described 
(Higashi et al.,2013), the arsenite treatment induced the phosphorylated hTDP-43 (S409-
S410)-EGFP with molecular weight around 75 kDa (Figure 15A Lane 3).  Under this 
condition, C8 and C8j significantly reduced the protein level relative to DMSO (Figure 
15A Lanes 4 & 5, Figure 15C, Table 10). 
Even though the amount of full-length hTDP-43-EGFP protein was reduced by 
the inhibitor treatments (Figure 15B), the inhibitors also reduced the phosphorylated 
protein regardless of the change in the full-length TDP-43 (Figure 15C).  These data 
shows that in addition to reducing the protein level of full-length, cleaved and high 
molecular weight TDP-43, C8 and C8j also reduce the TDP-43 that is phosphorylated at 
S409-S410.  
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Figure 15. The reduction of 409/410-phosphorylated TDP-43 protein level with C8 and C8j treatment 
under arsenite insults. 
(A) The PC12 hTDP-43-EGFP lysates were immunoblotted with anti-TDP-43 (S409-S410p) and anti-TDP-
43 antibodies.  Beta-actin was used as loading control.  * putative phosphorylated hTDP-43-EGFP.  ** 
non-specific bands.  (B & C) The immunoblot was densitometrically quantified.  The hTDP-43-EGFP 
signal was normalized to beta-actin (B), and S409p-S410p signals were normalized to the full-length 
hTDP-43-EGFP signal (C).  The intensity of DMSO treated group was set at 1.  The data was statistically 
analyzed with the one-way ANOVA and Tukey’s test.  * P<0.05, **P<0.01, ***P<0.001. 
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Table 10. C8 and C8j reduces TDP-43 protein levels under arsenite treatment. 
TDP-43 (S409-S410p) immunoblots were quantified by normalizing the intensity to the full-length hTDP-
43-EGFP.  Relative intensities were calculated based on the DMSO vehicle control.  Statistical analysis 
was performed with one-way ANOVA analysis, followed with Tukey’s test to compute P-values.  N 
indicates the number of replicated experiments.  SEM, standard error of the mean.	  
Protein MW Compound Ars Mean Intensity SEM N
P-value 
vs. DMSO
hTDP-43(S409/410p)-EGFP ~70 kDa
DMSO + 1.00 0.00 3
C8 + 0.52 0.13 3 <0.05
C8j + 0.36 0.11 3 <0.01
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Section Five: TDP-43 Is Phosphorylated at Multiple Amino Acid Residues, 
Including the Previously Unknown Sites T103-S104 	
In addition to the phosphorylation at serine residues Ser409 and 410, TDP-43 is 
predicted to be phosphorylated at other amino acid residues (Figure 4), such as serines 
403 and 404 (Hasegawa et al., 2008), although the biological role of those 
phosphorylation sites on the TDP-43 granule formation and ALS/FTLD pathogenesis is 
yet to be elucidated.  To test if C8 affect other phosphorylation sites of TDP-43 under 
arsenite-treated conditions, we utilized non-quantitative mass-spectrometry to detect the 
post-translational modifications of TDP-43. 
The lysates were harvested from the inducible PC12 hTDP-43(WT)-EGFP cells 
that were treated with either 5 µM C8j or the vehicle control, DMSO and 15 µM sodium 
arsenite for 24 hours (Figure 16A).  In addition to the 24-hour compound treatment, we 
included 1-hour acute C8j treatment group to see the short-term effect of the compound 
treatment on the arsenite-induced post-translational modification.  Furthermore, to 
identify the natural response of cells to recover from the arsenite-stressed condition and 
the role of phosphorylation sites during the recovery process, we included a group in 
which the toxic stressor was removed for 1 hour before harvesting the cells.  The 
immunoprecipitation condition was validated by SYPRO Ruby protein stain that 
visualized the isolated hTDP-43-EGFP band with 70 kDa molecular weight (Figure 16B).  
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Figure 16. The immunoprecipitation of hTDP-43-EGFP and associated proteins. 
The inducible PC12 hTDP-43-EGFP cells were treated with DMSO vehicle control, 5 µM C8j with 15 µM 
sodium arsenite according the time table (A), and they were lysed after 24 hours.  hTDP-43-EGFP and 
associated proteins were immunoprecipitated with camelid-derived GFP-nAb™ conjugated beads that 
specifically bind with GFP.  The input and immunoprecipitated proteins were separated with acrylamide 
gel electrophoresis and they were visualized with SYPRO Ruby protein stain (B).	 	
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Interestingly LC-MS/MS analysis showed that hTDP-43-EGFP was 
phosphorylated at S409-S410 in all treatment conditions, including the no arsenite 
control, arsenite-treated and C8j-arsenite co-treated groups (Figure 17A, Table 11), 
highlighting those residues can be phosphorylated more readily under basal conditions.  
On the other hand, other previously known phosphorylation sites S379 and S403/404 
were not phosphorylated in any conditions.  In addition to those previously known 
phosphorylation sites, the mass spectrometry detected phosphorylation at previously 
unidentified another set of amino acid residues at threonine 103 and serine 104 (T103-
S104) under arsenite-treated conditions (Figure 17B, Table 11).  Furthermore, the 
phosphorylation at those residues was undetected when the cells were treated with C8j 
(Table 11).  The analysis also identified the phosphorylation at other amino acid residues, 
including previously known residues at threonine 25 (T25), serine 29 (S29), serine 292 
(S292) and previously unknown phosphorylation site at threonine 30 (T30) (Table 11). 
Even though the mass spectrometry detected phosphorylation at multiple residues 
throughout TDP-43 protein, the phosphorylation at T103-S104 seemed to be the only 
sites that were responding to the two sets of C8j treatments, suggesting the reduction of 
the phosphorylation at these sites might be important in the action of C8j on TDP-43 
granule inhibition. 
In addition to the phosphorylation, the mass spectrometry detected unique di-
glycine signature at lysine residues mainly within the RNA recognition motif (RRM), 
indicating the ubiquitination at those locations (Table 11).  It is interesting to see the 
detected ubiquitination sites were localized near the RRMs, but further studies are 
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required to elucidate the role of the modification in regulating RNA/DNA binding and 
subsequent functional changes of the TDP-43 protein.  Among all the detected 
ubiquitination sites, the modification at lysine residue 102 (K102) was right adjacent to 
the newly identified T103-S104 phosphorylation sites, suggesting the possible interplay 
between the phosphorylation and ubiquitination at the residues (Table 11), especially in 
the context of regulating the formation of intracellular TDP-43 granules.   
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Figure 17. Post-translational modification of TDP-43 detected by LC-MS/MS. 
The representative spectra for phosphorylation at (A) S409 and (B) T103 of TDP-43 are shown.  The 
detected peptide fragments for SSGW (A) and AVQKTSDKI (B) are highlighted in red and the 
phosphorylation at the residues is indicated with +80 in the spectra.  
S  S  G  W
b2 b3
A.
B. A  V  Q  K  T  S  D  L  I
b2 b7 b8
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Table 11.	Previously known and newly discovered phosphorylation and ubiquitination sites of TDP-
43. 
The total number of unique peptides that were detected by LC-MS/MS is listed.  The previously known or 
studied phosphorylation sites are highlighted with blue and the newly identified phosphorylation sites are in 
red background.  The number of peptides detected without (-) or with (+) modification was listed for each 
treatment group.  The peptides with phosphorylation or ubiquitination with treatment were highlighted in 
red (increased) or blue (decreased).  The amino acid residues of lysine (K) with two serine (S) or threonine 
(T) in tandem were highlighted in black boxes.	  
Protein Features
Amino Acid Residue &
Position
Known Mutation
Type of Modification
Known Kinase
Sample Modification
1 No Ars +  DMSO
-
+
2 Ars + DMSO
-
+
3 ArsC8j 24h
-
+
4 Ars + C8j 1h
-
+
5
Ars 1h Off 
+
DMSO
-
+
hTDP-43
EGFP35 kDa 86-414
25 kDa 216-414
RRM1 105-169 RRM2 193-257 Gly-Rich Domain 274-414
T S T K T S K T T K K K K S S S S K S S S T
25 29 30 102 103 104 114 115 116 121 145 160 263 292 379 403 404 408 409 410 416 606
C/P
PO4 PO4 PO4 Ub PO4 PO4 Ub Ub Ub Ub Ub PO4 PO4 PO4 PO4 PO4 PO4 PO4 PO4
CK1 & 2? CK1ε
4 4 4 1 10 10 10 37 0 3 6 4 3 3 3 33 34 34 23
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 1 0
6 7 7 3 9 9 9 33 0 3 6 5 4 4 4 29 29 30 13
1 0 0 1 1 1 1 0 0 1 0 1 0 0 0 2 2 1 1
4 4 4 1 8 8 7 25 0 2 4 2 2 2 2 24 23 24 11
0 0 0 1 0 0 1 0 1 1 0 0 0 0 0 1 2 1 0
6 5 5 1 10 10 9 37 0 2 6 4 2 2 2 45 44 45 10
0 1 1 1 0 0 1 0 0 0 0 1 0 0 0 1 2 1 1
5 5 5 3 7 7 8 28 0 2 7 5 2 2 2 30 29 30 12
0 0 0 1 1 1 0 2 1 1 2 1 0 0 0 1 2 1 1
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Section Six: The Novel Phosphorylation Sites T103-S104 of TDP-43 Regulate The 
Protein’s Granule Formation 	
To validate our finding of new TDP-43 phosphorylation sites and to test the 
functional role of the phosphorylation on the TDP-43 granule formation, the plasmid 
constructs that encode EGFP-tagged human TDP-43 protein harboring either phospho-
mimetic, aspartic acid (T103D-S104D) or phospho-null, alanine (T103A-S104A) 
mutations were generated with site-directed mutagenesis.  The expression plasmids were 
transiently transfected to the human neuroblastoma cell line SH-SY5Y cells and the TDP-
43 granule formation was observed under fluorescent microscope. 
Preliminary studies showed the wild type EGFP-hTDP-43 and the phospho-null 
(T103A-S104A) proteins were localized to the nucleus in diffused pattern with no or a 
small number (≤7) of speckles or puncta under basal conditions (Figure 18A).  On the 
other hand, in 12% of the cells expressing the EGFP-hTDP-43 protein with the T103D-
S104D phospho-mimetic mutations spontaneously formed high-intensity aggregates in 
nucleus or cytoplasm (Figure 18A Arrows & B, Table 12), even though in a majority of 
the cells the phospho-mimetic protein was localization to the nucleus similar to the wild 
type and phospho-mimetic proteins. 
The formation of consolidated aggregate was further facilitated with the treatment 
of arsenite in all three forms of TDP-43 and the effect was statistically significant with 
two-way ANOVA analysis (p<0.001), and the arsenite induced the granules at similar 
extent with 20% increase from the no-arsenite treatment groups, regardless of the 
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genotype background at 103-104, suggesting there was no synergistic effect of the 103-
104 and the arsenite treatment (Figure 18C, Table 13). 
We further tested if the TDP-43 granule inhibitor C8j is able to reduce the TDP-
43 granules in the T103D-S104D phospho-mimetic background with the SH-SY5Y cells.  
In a preliminary experiment we scored the fraction of cells with nuclear TDP-43 puncta 
and intense intracellular aggregates.  The results from the preliminary experiment showed 
that the C8j did not reduce the fraction of cells with TDP-43 aggregates that were 
spontaneously induced with the T103D-S104D phospho-mimetic mutations under basal 
conditions, even though the statistical analysis with Chi square test showed C8j 
significantly changed the distribution of cells population with nuclear TDP-43 puncta 
(Figure 19C, Table 14).  The arsenite treatment increased the fraction of cells with the 
TDP-43 intracellular aggregates in the phospho-mimetic background from 4% to 29%, 
and the C8j reduced the fraction of the cells to 8% (Figure 19C, Table 14).  Statistical 
analysis with Chi square test showed the arsenite significantly changed the population of 
cells with the TDP-43 aggregate or nuclear puncta, and C8j further shifted back the 
population with less cells with aggregates. 
These data suggest that the phosphorylation at the newly identified residues T103-
S104 is sufficient to induce the TDP-43 granules, but not necessary to regulate the 
formation of the granules under stressed conditions, shown by the formation of granules 
with phospho-null mutation under arsenite treatment.  Further studies are required to test 
if the modification at those residues has a role in the action of C8 and C8j on reducing the 
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aggregate formation of TDP-43 (T103D-T104) variant, since we have not tested C8 in 
replicated experiments.  
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Figure 18. The effect of phospho-mimetic and null mutations at S103/T104 of TDP-43 on TDP-43 
granule formation. 
SH-SY5Y cells were transiently transfected with the plasmid constructs harboring GFP-tagged phospho-
mimetic or -null form of TDP-43(S103/T104), and they were treated with 10 µM sodium arsenite for 24 
hours.  The nuclei were counterstained with DAPI.  (A) The representative images of GFP expression 
pattern are shown.  (B & C) The quantitative analysis was performed by calculating the fraction of GFP-
positive cells with intracellular TDP-43-EGFP granules.  Scale bars are 10 µm for smaller images and 5 µm 
for magnified images.  TS, wild type, AA, phospho-null, and DD, phospho-mimetic.  The data was 
statistically analyzed with the one-way ANOVA with Tukey’s test (B), or two-way ANOVA (C).  **, P < 
0.01 & ****, P < 0.0001.    
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Table 12. The effect of phospho-mimetic and null mutations at T103-S104 of TDP-43 on its granule 
formation. 
The human neuroblastoma SH-SY5Y cells were transiently transfected with the plasmid constructs 
expressing the wild type, phospho-mimetic or null TDP-43 tagged with EGFP.  The fraction of cells with 
GFP intracellular granules was calculated.  Statistical analysis was performed with the one-way ANOVA 
analysis, followed with Tukey’s test to compute P-values for no-arsenite or arsenite treated groups.  TS, 
wild type, AA, phospho-null, and DD, phospho-mimetic.  Total n indicates the total number of cells scored.  
SEM, standard error of the mean.  n.s. not significant.   
103/104 Ars Compound Mean % + SEM Total n P value vs. DMSO
TS - DMSO 1.5% 0.9% 284
AA - DMSO 0.7% 0.5% 384 P < 0.0001
DD - DMSO 12.1% 1.5% 254 P < 0.0001
TS + DMSO 24.7% 3.6% 101
AA + DMSO 21.7% 6.3% 109 n.s.
DD + DMSO 30.5% 3.6% 99 n.s.
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Table 13. Statistical analysis of the effect of arsenite and T103-S104 phenotype on TDP-43 granule 
formation. 
The fraction GFP-positive cells with TDP-43 granules from the T103-S104 expression experiments was 
statistically analyzed with the two-way ANOVA to compute P-values. 
  
Source of 
Variation
Degrees 
of 
Freedom
Sum of 
Squares
Mean 
square P value
Arsenite 
Treatment 1.0 0.6533 0.6533 P < 0.0001
T103/S104 
Phenotype 2.0 0.1154 0.5770 P = 0.0095
Interaction 2.0 0.005768 0.002884 P = 0.7765
Residual (error) 54.0 0.6129 0.01135
Total 59.0 1.387
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Figure 19. The effect of C8j on the arsenite-induced TDP-43(T103-S104) granules in human neuroblastoma cells. 
SH-SY5Y cells were transiently transfected with wild-type (A), phospho-null (B), or phospho-mimetic (C) 
EGFP-TDP-43(T103-S104) expression plasmids.  The cells were co-treated with sodium arsenite and C8j.  
Fraction of cells with small nuclear puncta and intracellular aggregate was plotted and Chi-square analysis 
was performed between no-arsenite and arsenite treated groups, and between DMSO and C8j treated 
groups for each genetic background.  * P < 0.05, ** P < 0.01, **** P < 0.0001.  
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Table 14. Statistical analysis of C8j’s effect on the arsenite-induced TDP-43(T103-S104) granule 
formation in human neuroblastoma cells. 
SH-SY5Y cells were transiently transfected with the plasmid constructs expressing the wild type, phospho-
mimetic or null TDP-43(T103-S104) tagged with EGFP.  The fraction of cells with GFP nuclear and 
intracellular granules was calculated.  Statistical analysis was performed with the Chi squre analysis, to 
compute P-values between no-arsenite and arsenite treated groups, and between DMSO and C8j treated 
groups for each genetic background.  TS, wild type, AA, phospho-null, and DD, phospho-mimetic.  Total n 
indicates the total number of cells scored.  n.s. not significant. 
 
  
103/104 Ars Compound Agg >7 Puncta ≤7 Puncta No Puncta Total n P value vs. DMSO
P value vs.
No Ars
P value vs. 
Ars+DMSO
TS - DMSO 0% 5% 67% 28% 117
TS + DMSO 0% 27% 73% 0% 15 n.s.
TS + C8j 9% 29% 59% 3% 124 n.s.
AA - DMSO 0% 4% 71% 24% 143
AA + DMSO 0% 27% 73% 0% 41 n.s.
AA + C8j 9% 46% 44% 1% 91 <0.05
DD - DMSO 4% 9% 59% 29% 246
DD - C8j 3% 21% 66% 9% 107 <0.0001
DD + DMSO 29% 21% 50% 0% 28 <0.0001
DD + C8j 8% 58% 25% 8% 24 <0.01
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Section Seven: C8 Does Not Affect The Total Ubiquitinated Protein Level 	
Ubiquitinated proteins are major components of intracellular TDP-43-positive 
inclusions in ALS/FTLD affected brain and spinal cord tissues.  In the PC12 hTDP-43-
EGFP cell model, arsenite induces intracellular TDP-43 granules that are similar to those 
observed in the disease tissues.  We hypothesized C8 and its analogs reduce the 
formation of TDP-43 granules by reducing the ubiquitinated protein level in the cells.  To 
assess whether C8 and its analogs affect the level of ubiquitinated proteins under 
arsenite-treated conditions in mammalian cells, the whole cell lysates from the inducible 
PC12 cells expressing hTDP-43-EGFP were immunoblotted with anti-ubiquitin antibody.  
The treatment with sodium arsenite significantly increased the amount of ubiquitinated 
proteins, but the compounds C8 and C8j had no effect on the level of total ubiquitinated 
protein under arsenite-treated conditions in replicated experiments (Figure 20, Table 15).   
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Figure 20. The effect of C8 and C8j on the total ubiquitinated protein level under arsenite treatment. 
The inducible PC12 hTDP-43-EGFP cells were treated with C8 or C8j for 24 hours including 23-hour co-
treatment with 15 µM sodium arsenite.  DMSO (D) was used as vehicle control.  (A) The whole cell lysates 
were immunoblotted with anti-ubiquitin, anti-TDP-43 or anti-beta-actin antibodies.  ** unstripped Ubb 
bands.  (B) The immunoblot was densitometrically quantified.  The signal intensity was calculated relative 
to the DMSO treated group.  The data was statistically analyzed with the one-way ANOVA and Tukey’s 
test.  n.s. not significant.  
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Table 15. C8 and C8j do not have effect on total ubiquitinated protein level under arsenite treatment. 
TDP-43 immunoblot was quantified by normalizing the intensity to the beta-actin level.  Relative 
intensities were calculated based on the DMSO vehicle control.  Statistical analysis was performed with 
ANOVA analysis, followed with Tukey’s test to compute P-values.  N indicates the number of replicated 
experiments.  SEM, standard error of the mean.  n.s. No statistical significance. 	 	
Protein MW Compound Ars Mean Intensity SEM N
P-value 
vs. DMSO
Ub >50 kDa
DMSO + 1.00 0.00 4
C8 + 0.83 0.09 4 n.s.
C8j + 0.91 0.11 4 n.s.
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Section Eight: C8 Transiently Reduces Ubiquitinated TDP-43 	
TDP-43 is ubiquitinated in the brain tissues from FTLD-U affected patients, 
where the TDP-43 is localized in the ubiquitin-positive intracellular inclusions (Neumann 
et al., 2006).  In addition to the global ubiquitinated protein level, we asked if C8 reduces 
the ubiquitinated TDP-43 level to inhibit the TDP-43 granule formation.  To investigate 
the effect of TDP-43 granule inhibitors C8 and C8j on the ubiquitinated TDP-43, total 
TDP-43 was immunoprecipitated with polyclonal anti-TDP-43 antibody, and the 
precipitated samples were immunoblotted with anti-ubiquitin antibody. 
In the input lysates, sodium arsenite significantly increased the total ubiquitinated 
proteins as observed in the previous experiments (Figure 20), and in these conditions the 
C8 and C8j treatments did not reduce the total ubiquitinated protein level (Figure 21).  
The immunoprecipitation of TDP-43 pulled down the ubiquitin-positive smear with high 
molecular weight (Figure 21A IP Lane 3).  In the samples that were treated with C8 or 
C8j, the quantitative analysis showed the slight reduction in the ubiquitin-positive 
proteins in the TDP-43-immunoprecipitated samples, but the changes were not 
statistically significant in replicated experiments (Figure 21A & B, Table 16).   
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Figure 21. The effect of C8 and C8j on the TDP-43 immunoprecipitated ubiquitin protein level under 
arsenite treatment. 
The inducible PC12 hTDP-43-EGFP cells were treated with C8 or C8j for 24 hours including 23-hour co-
treatment with 15 µM sodium arsenite.  DMSO (D) was used as vehicle control.  (A) The PC12 hTDP-43-
EGFP lysates were immunoprecipitated with anti-TDP-43 antibody, followed by immunoblotting with anti-
ubiquitin or anti-TDP-43 antibodies.  Beta-actin was used as a loading control for the total protein samples.  
(B) The immunoblot was densitometrically quantified.  The immunoprecipitated ubiquitin level was 
normalized to the immunoprecipitated full-length hTDP-43-EGFP.  The signal intensity was calculated 
relative to the DMSO treated group.  Round, square and triangle marks are data points from independent 
experiments.  Error bars are standard error of the mean.  
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Table 16 The effect of C8 and C8j on the TDP-43 immunoprecipitated ubiquitin protein level under 
arsenite treatment. 
The TDP-43 immunoprecipitated samples were probed with anti-ubiquitin or anti-TD-re antibodies.  The 
quantified by normalizing the intensity to the beta-actin level.  The immunoprecipitated ubiquitin level was 
normalized to the immunoprecipitated full-length hTDP-43-EGFP.  Relative intensities were calculated 
based on the DMSO vehicle control.  SEM, standard error of the mean.  N, the number of replicated 
experiments.	  
Sample Protein MW Compound Ars Mean Intensity SEM N
Reduction 
vs. DMSO
IP: TDP-43 Ub >80 kDa
DMSO + 1.00 0.00 2
C8 + 0.72 0.03 2 -28%
C8j + 0.83 0.25 2 -17%
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In addition to the immunoprecipitation with anti-TDP-43 antibody, we selectively 
immunoprecipitated the exogenous human TDP-43-EGFP with anti-GFP beads and 
tested the effect of C8j on ubiquitinated TDP-43 by probing the precipitated samples with 
anti-ubiquitin antibody or anti-TDP-43 antibodies.  The signal intensity of ubiquitinated 
TDP-43 was normalized with the immunoprecipitated full-length hTDP-43-EGFP level 
for each treatment group.  In agreement with the results with the anti-TDP-43 antibody, 
the GFP immunoprecipitation for hTDP-43-EGFP pulled down ubiquitin-positive 
proteins in smear with high molecular weight under arsenite-treated groups (Figure 22A 
IP Lane 3).  Even though the 24 hour C8j treatment seemed to reduce the ubiquitinated 
TDP smear, after normalization with the immunoprecipitated hTDP-43-EGFP level, the 
reduction was not statistically significant relative to the DMSO vehicle control in 
repeated experiments (Figure 22A & B, Table 17). 
Even though the immunoprecipitated ubiquitin-positive smear seemed to be 
higher in the 1 hour C8j treatment group in the immunoblot, after the normalization 
mentioned above the level of immunoprecipitated ubiquitinated-TDP was 44% less than 
that of DMSO control (Figure 22A & B, Table 17).  At 1-hour time point, the 
ubiquitinated TDP-43 smear was reduced for 44% with C8 treatment, but in the total 
protein or RIPA-insoluble samples C8 reduced the high molecular weight TDP-43 smear 
for approximately 70% after 24 hours.  These data suggest that the C8j might transiently 
reduce the ubiquitinated TDP-43 for short period of time, but the effect is transient and 
does not persist for longer period.  It is also possible that the immunoprecipitated, 
ubiquitin-positive smear might contain not only TDP-43, but also other proteins that were 
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not reduced by the C8j treatment, masking the reduction of the TDP-43 protein level that 
was reduced by C8j.  
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Figure 22. The effect of C8 and C8j on the GFP immunoprecipitated ubiquitin protein level under 
arsenite treatment. 
The inducible PC12 hTDP-43-EGFP cells were treated with C8 or C8j for 24 hours including 23-hour co-
treatment with 15 µM sodium arsenite.  DMSO (D) was used as vehicle control.  (A) The PC12 hTDP-43-
EGFP lysates were immunoprecipitated with the camelid-derived GFP-nAb™ conjugated beads to enrich 
hTDP-43-EGFP proteins.  The immunoprecipitated samples were probed with anti-ubiquitin or anti-TDP-
43 antibodies.  Beta-actin was used as a loading control in the input samples.  (B) The immunoblot was 
densitometrically quantified.  The immunoprecipitated ubiquitin level was normalized to the 
immunoprecipitated full-length hTDP-43-EGFP.  The signal intensity was calculated relative to the DMSO 
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treated group.  The data was statistically analyzed with the one-way ANOVA and Tukey’s test.  n.s. not 
significant, * P<0.05.  
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Table 17. The effect of C8 and C8j on the TDP-43 immunoprecipitated ubiquitin protein level under 
arsenite treatment. 
The hTDP-43-EGFP PC12 cell lysates were TDP-43 immunoprecipitated with camelid-derived GFP-
nAb™ conjugated beads.  The samples were probed with anti-ubiquitin or anti-TDP-43 antibodies.  The 
immunoprecipitated ubiquitin level was normalized to the immunoprecipitated full-length hTDP-43-EGFP.  
The signal intensities were calculated relative to the DMSO vehicle control.  Statistical analysis was 
performed with the one-way ANOVA analysis, followed with Tukey’s test to compute P-values.  N 
indicates the number of replicated experiments.  SEM, standard error of the mean.  n.s. no statistical 
significance. 
  
Sample Protein Compound Ars Mean Intensity SEM N
P-value 
vs. DMSO
IP: GFP-nAb Ub
DMSO + 1.00 0.00 4
C8j 24h + 0.94 0.09 4 n.s.
C8j 1h + 0.56 0.13 4 <0.05
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Section Nine: Preliminary Effect of C8 on Degradation Rate of TDP-43 Protein 	
The study in this section has not been replicated in multiple experiments.  TDP-43 
with the ALS-associated mutations, such as G298S, is found in aggregates in the brain 
and spinal cord motor neurons, and the mutations have been shown to increase the half-
life of TDP-43 protein (Pesiridis et al., 2009; Ling et al., 2010).  In earlier experiments 
we have shown that the treatment with the TDP-43 granule inhibitors significantly 
reduced the protein level of hTDP-43-EGFP, including the full-length, truncated, high 
molecular and the phosphorylated species.  Based on these results we asked if the 
compounds increase the rate of TDP-43 protein turnover to reduce the TDP-43 granules. 
To investigate the effect of TDP-43 granules inhibitor C8j, we used non-
radioactive, Click-IT® chemistry-based labeling of translated proteins.  The newly 
synthesized proteins in the stable PC12 hTDP-43-EGFP cells were labeled with a 
methionine analog L-Azidohomoalanine (AHA) prior to the compound and arsenite 
treatment.  0, 6, 12 and 24 hours after the beginning of the compound treatment under 
arsenite insults, the cell lysates were prepared for biotinylation with AHA and the biotin-
tagged proteins were subsequently pulled down with streptavidin beads.  Following the 
purification process, the samples were immunoblotted for TDP-43 and β-actin. 
As observed in previous experiment with C8j, the TDP-43 granule inhibitor 
reduced the total full-length hTDP-43-EGFP after 24-hour treatment in the input samples 
(Figure 23A Top Panel, Input).  The preliminary results suggest the AHA-labeled 
endogenous TDP-43 and β-actin protein levels were decreased by half approximately in 
10 hours under the conditions tested (Figure 23A, B).  Furthermore, C8j did not affect the 
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rate of protein turnover of these endogenous proteins relative to the DMSO vehicle 
control.  In contrast, the amount of AHA-labeled hTDP-43-EGFP decreased slightly with 
DMSO and C8j treatment at time points 6 and 12 hours, but the reduction seemed to stop 
in both treatment groups (Figure 23B Lower Panel).  At this stage, it is not clear whether 
the rate of reduction in C8j treated group is faster than the DMSO treated group. 
Next, we asked if the TDP-43 granule inhibitor reduces the protein level of 
cleaved TDP-43 products with lower molecular weights more efficiently than the full-
length protein.  Since the cleaved species can be produced from the full-length protein, 
the values for each cleaved fragment were normalized to the full-length hTDP-43-EGFP 
protein for each time point.  The AHA-labeled protein level of hTDP-25-EGFP was 
steady over 24 hours with DMSO treatment and did not decrease over time (Figure 23C).  
On the other hand, the C8j treatment lowered the protein level after 24 hours.  The AHA-
labeled hTDP-35-EGFP protein level steadily decreased with both DMSO and C8j 
treatments and did  (Figure 23).  Even though the signal level seems to be weaker with 
DMSO treatment for the hTDP-35-EGFP fragments, it is not clear if the difference is 
statistically significant at this stage. 
These preliminary results suggest that even though the endogenous TDP-43 
degrades at the rate of 10 hours half-life, the exogenous TDP-43 protein seems to have 
increased stability than the endogenous protein.  In addition, the C8j treatment appeared 
to increase the rate of clearance of the truncated hTDP-25-EGFP protein based on the 
difference of the slopes between DMSO and C8j, but not the full-length protein. hTDP-
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35-EGFP variant, or other endogenous proteins, however further studies are necessary to 
statistically analyze the results and draw a conclusion.  
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Figure 23. The effect of C8j on the protein turnover with pulse-chase approach. 
The newly synthesized proteins in PC12 hTDP-43-EGFP cells were non-radioactively labeled and the 
reduction of those proteins were observed over 24 hours with or without C8j treatment under arsenite 
treatment.  The non-degraded proteins were isolated by streptavidin-conjugated beads.  (A) The isolated 
samples were probed with anti-TDP-43 and anti-beta-actin antibodies.  The vehicle treated controls are 
indicated with D.  (B & C) The immunoblot was densitometrically quantified.  The signal intensity was 
calculated relative to the time point 0 of the DMSO vehicle treated group and plotted over time. The signals 
for TDP-25 and TDP-35 fragments were normalized to the Streptavidin pulled down full-length hTDP-43-
EGFP.	 	
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Section Ten: C8j Enhances Dissociation of Arsenite-Induced TDP-43 Granule 
Formation 	
In previous experiments we have observed the reduction of cells with TDP-43 
granules by C8 and C8j in 24 hours time frame.  In addition, we tested the effect of C8j 
on the protein turnover of TDP-43 proteins with different molecular weights.  To further 
understand the kinetics of TDP-43 granule formation and to test the inhibitors’ 
mechanism of action on the granule inhibition, we used the live-cell microscopy imaging 
to observe the inducible PC12 hTDP-43-EGFP cells under arsenite-induced stressed 
conditions over time with C8j treatment. 
At the time point 0, approximately 20-30% of cells were positive with the TDP-43 
granules (Figure 24, Table 18), indicating the overexpression of TDP-43 itself can induce 
the low level of TDP-43 granule formation.  Within 3 hours from the beginning of the 
arsenite treatment, the PC12 responded to the arsenite treatment by forming the TDP-43 
granules mainly localized in the nuclei.  In the DMSO control treated group, the fraction 
of the GFP-positive cells with TDP-43 granules reached a plateau at 70% and did not 
further increase or decrease over time (Figure 24B, Table 18).  On the other hand, in the 
C8j treated group the cells responded to the arsenite within 3 hours by forming TDP-43 
granules, which was similar to the DMSO treated group, but the fraction of GFP-positive 
cells with the granules steadily decreased over time afterward and the effect of was 
statistically significant (Figure 24B, Table 18, Table 19).  In both groups, the total 
number of cells did not change dramatically over time. 
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These results suggest that even though the arsenite insult induces the TDP-43 
granules acutely, the C8j is able to reduce those granules over time.    
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Figure 24. The effect of C8j on the arsenite-induced TDP-43 granule formation over time. 
The arsenite-induced TDP-43 granule formation was observed with live-cell imaging of the hTDP-43-
EGFP cells over time.  (A) The representative images of the same field for each treatment over time are 
shown.  The TDP-43 granules appear with intense GFP signals shown by the arrows.  The cells with 
diffused nuclear GFP expression are indicated with arrowheads.  The scale bars are 15 µm.  The fraction of 
GFP-positive cell with TDP-43 granules (B) and total number of cells (C) are plotted over time.  Two-way 
ANOVA with Sidak post-hoc test, **** P < 0.0001. 
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Table 18. The formation of arsenite-induced TDP-43 granule formation over time. 
The TDP-43 granules were induced in hTDP-43-EGFP cells with arsenite and the formation of the granules 
was observed over time using live-cell imaging.  The fraction of GFP-positive cells with the granules was 
calculated for each time point.  n, total number of GFP-positive cells scored.  SEM, standard error of the 
mean. 
 
 
Table 19. Statistical analysis of the effect of arsenite over time on TDP-43 granule formation. 
The live cell imaging data from arsenite-treated PC12 hTDP-43-EGFP cells was statistically analyzed with 
the two-way ANOVA with Sidak post-hoc test to compute P-values.	 	
Ars Compound 0h 3h 6h 9h 12h 15h 18h
+ DMSO
Fraction + 0.21 0.63 0.68 0.68 0.71 0.68 0.70
SEM 0.004 0.031 0.024 0.016 0.028 0.016 0.012
n 121 151 154 166 167 167 157
+ C8j
Fraction + 0.30 0.63 0.56 0.53 0.50 0.43 0.42
SEM 0.025 0.041 0.029 0.029 0.034 0.014 0.023
n 130 132 139 137 129 133 129
DF Sum of Squares
Mean 
Square
Mean 
square P value
C8j 
Treatment 1 0.1913 0.1913 P = 0.0060
Time 6 0.6417 0.1069 P < 0.0001
Interaction 6 0.1663 0.0277 P < 0.0001
Subjects 
(matching) 4 0.0269 0.0067
Residual 
(Error) 24 0.0261 0.001088
Total 41 1.0520
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Section Eleven: C8j Reverses the TDP-43-Induced Dendrite Shortening  
The study in this section was conducted by Dr. Tara Vanderweyde at Aquinnah 
Pharmaceuticals (Cambridge, MA). 
In primary neurons, the overexpression of TDP-43 protein with ALS-associated 
mutations becomes toxic to the neurons over time (Barmada et al., 2010).  To test if the 
TDP-43 granule inhibitors ameliorate the toxic effect of the mutant protein, we isolated 
the primary mouse hippocampal neurons from prenatal day 0 (P0) pups.  One day after 
isolation (DIV1) the neurons were transduced with the adeno-associated virus serotype 1 
(AAV1) expressing empty vector, wild type (WT), A315T or Q331K TDP-43 proteins 
tagged with EGFP.  The overexpression of the wild type TDP-43 shortened the total 
dendrite length of the primary mouse neurons significantly (Figure 25A).  In addition to 
the wild type protein, the exogenous TDP-43 with ALS-associated mutations shortened 
the total dendrite length of the neurons relative to the EGFP control (Figure 25A). 
With the 5-day treatment of C8j starting from DIV7 up until the fixation of the 
neurons at DIV12, the total dendritic length of neurons that express exogenous TDP-43 
was significantly increased in all three genetic backgrounds (Figure 25A & B).  These 
data suggest that the TDP-43 granule inhibitor C8j was biologically active in the primary 
mammalian neurons and was able to reverse the toxicity caused by the overexpression of 
exogenous TDP-43 proteins, including the mutant form of the protein, however we did 
not observe significant difference in the toxicity between the wild type and mutant 
proteins.  It is possible the enhanced toxicity with the ALS-mutation on the primary 
neurons would be more prominent in older cultured neurons (Barmada et al., 2010).    
		
110	
 
Figure 25. C8j reverses the shortened neurite length that was induced by exogenous TDP-43 in primary mouse 
neurons. 
Primary neurons were dissected from P0 pups of the DC1 wild type mice.  At DIV1 the neurons were 
transduced with AAV1 viral particles expressing EGFP empty vector, wild type, A315T or Q331K TDP-43 
that are tagged with EGFP.  At DIV7, the neurons were treated every 48 hours with 1.5 µM of C8j or a 
vehicle DMSO.  (A) The total dendritic length of 15 neurons in two independent experiments (total 30 
neurons) was measured.  (B) The % rescue of the total dendritic length by C8j was calculated as follows—
the effect of C8j (TDP+C8j minus TDP+DMSO) divided by the effect of TDP on dendritic length 
(EGFP+DMSO minus TDP+DMSO).  Statistical analysis was performed with one-way ANOVA with 
Tukey test.  Error bars are SEM.  ** P < 0.01, *** P < 0.001.  The experiment was performed by Dr. Tara 
Vanderweyde at Aquinnah Pharmaceuticals (Cambridge, MA). 
 	  
0"
500"
1000"
1500"
2000"
2500"
To
ta
l&D
en
dr
ite
&L
eg
nt
h&
(u
m
)&
DMSO"
Compound"8J"
EG
FP
"
W
T"
TD
P9
43
"
EG
FP
"
A3
15
T"
TD
P9
43
"
EG
FP
"
Q
33
1K
"T
DP
94
3"
EG
FP
"
***" **" ***"
0"
20"
40"
60"
80"
100"
%
"R
es
cu
e"
to
"E
GF
P"
Ba
se
lin
e"
"
To
ta
l"D
en
dr
ite
"L
eg
nt
h"
WT"TDP,43"
A315T"TDP,43"
Q331K"TDP,43"
W
T"
TD
P,
43
"
EG
FP
"
A3
15
T"
TD
P,
43
"
EG
FP
"
Q
33
1K
"T
DP
,4
3"
EG
FP
"
A. B.
DMSO
C8j
EG
FP
W
T
 T
D
P-
43
EG
FP
A
31
5T
 T
D
P-
43
EG
FP
Q
33
1K
 T
D
P-
43
EG
FP
W
T
 T
D
P-
43
EG
FP
A
31
5T
 T
D
P-
43
EG
FP
Q
33
1K
 T
D
P-
43
EG
FP
To
ta
l D
en
dr
ite
 L
en
gt
h 
(µ
m
)
%
 R
es
cu
e 
to
 E
G
FP
 B
as
el
in
e
To
ta
l D
en
dr
ite
 L
en
gt
h
0"
500"
1000"
1500"
2000"
2500"
To
ta
l&D
en
dr
ite
&L
eg
nt
h&
(u
m
)&
SO"
Compound"8J"
EG
FP
"
W
T"
TD
P9
43
"
EG
FP
"
A3
15
T"
TD
P9
43
"
EG
FP
"
Q
33
1K
"T
DP
94
3"
EG
FP
"
***" **" ***"
		
111	
Section Twelve: C8 Ameliorates Hypomorphic Effect of Mutant TDP-43 on 
Dendritic Branching in Fly Sensory Neurons 
 
The study in this section was conducted in collaboration with Dr. Yubin Lu at Dr. 
Fen-Biao Gao’s laboratory at the University of Massachusetts Medical School, 
Worcester, MA. 
In Drosophila melanogaster it has been shown that the expression of TDP-43 
protein in the dorsal sensory neurons promote dendritic branching (Lu et al., 2009, Figure 
26).  In addition, the disease associated mutant form of TDP-43, such as Q331K variant 
lessens the ability of the protein to promote the dendritic branching relative to the wild 
type form.  To test if the TDP-43 granule inhibitor C8j ameliorates the dendritic 
branching in the Q331K Drosophila model system, Dr. Lu at Dr. Gao’s laboratory 
utilized the transgenic D. melanogaster expressing the human TDP-43 (Q331K) in the 
abdominal dorsal multidendritic sensory neurons ddaE and ddaF feeding them with either 
DMSO vehicle control or 5 µM C8j containing media throughout their development. 
In the GFP-labeled ddaE and ddaF neurons of larva, the expression of the wild 
type human TDP-43 protein increased the branching of ddaE and ddaF neurons in vivo, 
and the effect on branching of TDP-43 was less in the Q331K background (Figure 26B, C 
and D).  The preliminary results showed that 5 µM C8j treatment increased the number of 
dendritic branching relative to the vehicle-treated group in the Q331K background 
(Figure 26B, C and D).  C8j did not have an effect in the wild-type, non-transgenic 
background ((Figure 26A, C and D).  These data suggest that the TDP-43 granule 
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inhibitor is biologically active in Drosophila, and it is able to modulate the protein 
function of TDP-43 on dendritic branching of fly sensory neurons.  Furthermore, the data 
suggest the compound is able to ameliorate the reduced function of the mutant TDP-43 
protein in those neurons, and its effect is specific to the mutant protein.    
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Figure 26. The effect of C8j on the dendritic branching of Drosophila sensory neurons. 
The D. melanogaster expressing Q331K variant of TDP-43 was fed with the media containing C8j.  The 
dendritic branching of mCD8-GFP-labeled dorsal sensory neurons, ddaE and ddaF, in the abdomen of 
Drosophila larva in vivo was observed under microscope for the vehicle (DMSO) or C8j treated animals 
(A).  (B) The larva expressing the wild type or Q331K mutant hTDP-43 were treated with DMSO or C8j.  
Scale bar is 100 µm.  The dendritic ends of ddaE (C) and ddaF (D) were quantified and are plotted.  The 
experiment was performed by Dr. Yubin Lu at Dr. Fen-Biao Gao’s laboratory at the University of 
Massachusetts Medical School (Worcester, MA). 
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CHAPTER FOUR: UNBIASED SYSTEMS BIOLOGY AND PROTEOMICS 
APPROACHES HIGHLIGHTING THE PUTATIVE C8-MODULATED 
BIOLOGICAL PATHWAYS 
Section One: Introduction 
 
Since the discovery of TDP-43 protein as a major component of ubiquitin positive 
inclusions in the brain and spinal cord tissues from ALS and FTLD (Neumann et al., 
2006), a number of mechanisms have been postulated as potential biological mechanisms 
of TDP-43 granule formation, including the discovery of TDP-43 as a dynamic stress-
granule protein (Liu-Yescevitz et al., 2010; Buratti et al., 2012).  However, other proteins 
and surrounding biological mechanisms that are responsible for the TDP-43 granule 
formation are still unclear.  Furthermore, non-cytotoxic methods to prevent or reverse the 
formation of TDP-43 granules are yet to be discovered. 
In previous experiments, we demonstrated the effect of the novel TDP-43 granule 
inhibitors on the post-translational modifications of TDP-43, including its truncation and 
phosphorylation.  This study highlights the putative biological pathways, such as protein 
homeostasis and mRNA metabolism, that are targeted by the novel TDP-43 granule 
inhibitors C8 and C8j, based on the unbiased systems biology approaches.  In addition, it 
demonstrates the effect of the inhibitors on the TDP-43-protein complexes with mass-
spectrometry.  
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Section Two: Identification of C8-Targeted Biological Pathways by Mode of 
Action by Network Identification (MNI) 	
The work in this section was performed in collaboration with Dr. Hu Li of Dr. 
James Collins laboratory at Boston University Department of Medical Engineering. 
The TDP-43 aggregate formation is thought to be a multifactorial process and 
many biological processes related to TDP-43 protein metabolism are involved, such as 
protease cleavage, phosphorylation, protein translation and ubiquitin proteasome system 
(UPS) and autophagy (Buratti et al., 2012).  In previous studies, we showed the biological 
effects of the novel TDP-43 granule inhibitors C8 and C8j in different model organisms, 
potentially acting through the reduction of post-translational modification and protein 
level of TDP-43 with different molecular weights.  To better understand the mechanism 
of the granule inhibition by those compounds, it is essential to know if the inhibitors 
mediate a specific biological pathway to reduce TDP-43 granule formation. 
A chemical compound resveratrol has been shown to be protective against 
neuronal death through binding to a nicotinamide adenine dinucleotide (NAD)-dependent 
protein deacetylase sirtuin-1 (SIRT1) and promoting the clearance of amyloid-beta 
peptide in Alzheimer’s disease model (Bastianetto et al., 2015; Marambaud et al., 2005).  
There are many known transcription factors that are regulated by SIRT1 and resveratrol 
can affect global gene expression through regulating those downstream targets of SIRT1  
(Deng, 2009; Viswanathan et al., 2005).  We questioned if the TDP-43 granule inhibitor 
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C8 changes the gene expression of specific genes that are responsive for the clearance of 
aggregated proteins in a similar manner to resveratrol. 
To identify the putative biological process that is targeted by C8, we used the 
inducible TDP-43 granule model of rat pheochromocytoma, PC12 hTDP-43-EGFP cells 
that were originally used in the large-scale compound screening (Boyd, Lee-Armandt, 
Feiler et al., 2013).  The cells were treated with C8 under arsenite-induced stress and we 
performed time course gene expression analysis for 3, 6, 9, 12 and 24 hours (t3, t6, t9, t12 
and t24, respectively) using GeneChip® Rat Genome 230 2.0 Array.  Following the 
microarray analysis by Dr. Hu Li at Mayo Clinic (Rochester, MN) the gene-expression 
data was processed with the Mode of Action by Network Identification (MNI) algorithm 
by Dr. Li.  The MNI is a systems biology method to isolate the targets or immediate 
mediators of a treatment from the secondary or downstream cellular responses, which 
was previously used to predict the mode of action of treatments on eukaryotic cells or 
organisms, such as 1-phenyl-1H-tetrazol-5-ylsulfonyl-butanenitrile (PTSB) a growth 
inhibitory compound for eukaryotic cells (Bernardo et al., 2005; Xing and Gardner, 2006; 
Brock et al., 2014).  Prior to the analysis of our microarray data, the MNI algorithm was 
trained with the publicly available 306 gene-expression results performed with the rat 
microarray chip to generate a model of gene-regulatory network and to set the baseline 
gene-expression pattern for the rat genome. 
For each C8-treated time points the MNI algorithm provided a list of genes that 
are potential targets or immediate mediators of C8 in the inducible PC12 hTDP-43-EGFP 
cells, but absent in the DMSO-treated control groups for each time points (Table 20).  
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Among the list of proteins products of MNI-highlighted genes, many them were detected 
in multiple time points as C8 targets.  In addition, 18 candidates were known TDP-43 
binding proteins.  We further analyzed the listed candidates with the gene-annotation 
enrichment analysis to identify biological pathways that were highlighted with MNI 
using the Database for Annotation, Visualization and Integrated Discovery (DAVID), a 
free online analysis tool available through the Laboratory of Immunopathogenesis and 
Bioinformatics (LIB) (Huang, Sherman & Lempicki, 2009).  At the earliest time point 
after 3 hours of C8 treatment, the MNI-highlighted candidates were enriched with the 
genes involved in proteasome and protein homeostasis (Table 21).  The analysis further 
showed that those targets were enriched in other time points, t6, t9, t12 and t24, 
indicating the protein homeostasis can be the immediate target of the TDP-43 granule 
inhibitors in mammalian cells and the effect of the compounds persists over time. 
In addition to protein homeostasis, the MNI and gene-annotation enrichment 
analyses also highlighted other biological pathways as potential targets of C8 in the cell 
model.  6 hours after the beginning of the C8 treatment, the analysis indicated the genes 
involved in mRNA metabolism were enriched in the compound treated group, but absent 
in the vehicle control (Table 21).  Those candidates were also enriched in the later time 
points, t12 and t24. 
In addition to the MNI analysis, we further analyzed the highlighted candidate 
genes to identify biologically relevant relationships, mechanisms, functions, and 
pathways using Ingenuity Pathway Analysis (IPA) software.  The analysis generated 
networks of genes involved in RNA metabolism and protein homeostasis, also 
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highlighting the known protein-protein interactions between those candidates and TDP-
43 protein (Figure 27).  These results further support the potential targets of the TDP-43 
granule inhibitor C8 are associated with RNA metabolism and protein homeostasis, and 
they are biologically closely associated to each other forming a tight network.  
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Table 20. The list of potential immediate targets or mediators of C8 that were identified with MNI analysis. 
The microarray results from the inducible PC12 hTDP-43 cells were further analyzed with MNI algorithm 
and the protein products of the encoding genes that were highlighted with MNI were listed.  The algorithm 
isolated the candidate target genes that responded only to the C8 treatment, but absent in the DMSO vehicle 
controls for time points 3, 6, 9, 12 and 24 hours (t3, t6, t12 and t24, respectively).  The recurring gene 
products were highlighted with bold face and the immediate TDP-43 interactors were highlighted in 
magenta.  The MNI analysis was performed by Dr. Hu Li at Mayo Clinic (Rochester, MN). 
t3 t6 t9 t12 t24
ADM PPP1CC ADM MED10 ACSL5 NUP93 AP3D1 PSMD5 AKT1S1 PPP2CA
ANAPC1 PRIM1 ALG13 MID1 ADM PIKFYVE ATIC RABEP1 ATF3 PRKAA1
ARFIP2 PRPF3 APEX1 MLF1IP AGPAT5 PLRG1 ATP6V1F RASA2 ATP6V1F PRKX
ATG5 PRPF38B ARFGEF1 MYO9B AP1S3 POLR2C AZI2 RHEB ATP6V1H PRPF3
BCAS2 PSMC1 ARSG NHP2 APEX1 PRKAG2 B3GNT7 RPS6KA6 BCL2L11 PSMB1
BECN1 PSMD5 CARS NUPL2 ARFGAP1 PSMB1 CACYBP RRAS2 BET1L PSMB3
BUD31 PSMD6 CCNH ORC2L ATP6V1C1 PSMB3 CANX SETD2 BRF2 PSMB4
CACYBP PTK2 CCT4 PAN3 AZI2 PSMD4 CHMP4B SF3B2 BUD31 PSMC1
CANX PUM1 CCT7 PEX3 BAX RAB22A CHRNB1 SGMS2 CARD9 PSMC2
CCDC99 RAB22A CD28 PFKFB2 CARD9 RABEP1 COBRA1 SIN3B CCT3 PTGES3
CCT3 RAN CEP152 PIP5K1A CARS RHOV DPM1 SLC16A8 CDC27 PTPN11
CDK7 RFWD2 CHRNB1 POLH CCT3 RICTOR DSN1 SLC20A1 CDK7 RHOQ
CLIP1 RPL3 CLDN6 POLR3E CHRNA5 RPS6KA6 DYNC1H1 SNUPN CDKN1A RICTOR
CLTC RPL39 CPSF2 PROK1 CLIP1 SERPINE1 EEA1 SPAG9 CEP152 RQCD1
COBRA1 SARS CSNK1A1 PRPH COX4I2 SF3B2 EIF2B1 TAF1 CRNKL1 SART1
CREB3 SEC24B DCTN6 PSMD14 CSNK2A2 SH3GL1 ELL THOC2 CSNK1A1 SFRS7
DAAM1 SERPINE1 DDIT3 PSMD4 DSN1 SLC16A8 FBXW11 TINF2 CTDP1 SLC30A6
DIAPH3 SFRS1 DOT1L RABEP1 EIF3A SLC5A5 FGF11 TXK DCTN6 SLC38A1
EEF1A1 SGOL2 DPM1 RAD17 EIF6 SLC6A3 FPGT UAP1 DHX8 SLK
EEF1B2 SNAP29 DUSP4 RAN ETF1 SLK FRS2 UBB EIF4A1 SRP19
EIF3A SNAPC1 DUSP5 RARS FASLG SMN1 HTT UBC EIF6 STX3
EIF3I SPCS1 DUSP9 RHOV FGF11 SMURF2 IL4 UBE2H EPHB3 SUGT1
EXOSC8 STX18 EEF1B2 RNMT FUCA2 SNAPC1 IL5 UBE2O ERCC1 TAF5
FGF11 SUMO1 EIF2B1 RPS6KA6 FZD6 SPTLC2 ITGA3 UNC5C EXOSC6 TCERG1
FTH1 TAF9 EIF3A SAT1 GMDS SSRP1 JAG1 VAPA FGF22 THOC4
FUCA2 TBCA ERCC6 SEMA6A GPD2 STIP1 KIF18A VIM GNG8 TRIB3
FUT1 TBCC FASLG SEMA6C GTF2H2 SUGT1 LPAR6 VPS37C GSK3B UAP1
GFRA4 TOB1 FGF11 SF3B2 GTF3C4 TBK1 MAP3K10 XRN2 GTF2A2 UBC
GOSR1 TSG101 GAS6 SFRS2 GTSE1 TBKBP1 MAP3K7 HAND1 UBE2D2
GTSE1 TTK GATA3 SLC16A8 HBEGF TCERG1 MAPK8 HBEGF UBE2J1
HNRNPU TYMS GIPR SMAD5 HMOX1 TJP2 MID1 HDAC3 VAPA
ITGA3 UBA52 GRK4 SQSTM1 HSPA1A TMSB4X MPP5 HNRNPH2 VDAC2
KDSR VDAC2 GTF2E1 SRP19 IL5 TPR PFKFB2 HRH1 VPS37C
KIF23 VDAC3 GTF2IRD1 TAF1 KIF18A TRAF3 PIGA HS3ST5 WDR77
MED13 WDR61 GTF3C4 TBKBP1 KPNA1 TRIB3 PIGS HSPA1A WNT9A
NAE1 XRN1 HBEGF TBX2 LPAR2 TXK PIGX HTT XYLT1
NDEL1 ZFYVE16 HCRT TCERG1 LSM6 UBE2B PIK3C2A MED15
NME1 HGS THOC1 MED1 UBE2D2 PIP4K2C MED4
NPC2 HIST1H3F THOC3 MED6 UBE2E2 POLR3E MRE11A
PCNA IL4 TRH MLF1IP UBE2O PPCDC P4HA1
PIGA JAM3 TSG101 MYO9B VCL PRPH PDE7A
PIGK LPAR2 TYMS NOSIP ZFYVE16 PSMA5 PFKFB2
POLH MAFG UAP1 NTRK1 PSMB6 PGM3
PPP1CB MAP3K7 WNT9A NUP160 PSMC2 POLR3F
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Table 21. The list of GO terms that were highlighted by the MNI analysis of C8 for each time point. 
The gene-annotation enrichment analysis was performed with the MNI highlighted candidate targets for the 
potential biological processes that was specifically affected by C8 treatment.  The genes were analyzed by 
the gene functional annotation clustering.  To rank the biological significance, enrichment score in a 
corresponding annotation cluster is calculated based on the geometric mean of member's p-values in log 
scale.  The number of genes involved in each annotation is listed in the Count column.  A modified Fisher 
Exact P-value was used for statistical analysis.  
t3 Category Enrichment Score: 9.66 Count P-value
SP_PIR_KEYWORDS proteasome 14 1.32E-17
GOTERM_CC_FAT proteasome	complex 15 3.63E-17
GOTERM_BP_FAT negative	regulation	of	ubiquitin-protein	ligase	activity	during	mitotic	cell	cycle 15 7.62E-17
KEGG_PATHWAY Proteasome 14 6.88E-13
COG_ONTOLOGY Posttranslational	modification,	protein	turnover,	chaperones 6 1.40E-04
t6 Category Enrichment Score: 6.50 Count P-value
GOTERM_BP_FAT regulation	of	ubiquitin-protein	ligase	activity 12 1.82E-11
SP_PIR_KEYWORDS proteasome 10 3.08E-11
GOTERM_CC_FAT proteasome	complex 10 7.86E-10
KEGG_PATHWAY Proteasome 10 3.14E-08
t6 Category Enrichment Score: 1.53 Count P-value
SP_PIR_KEYWORDS mrna	splicing 6 7.30E-03
GOTERM_CC_FAT nuclear	speck 5 8.05E-03
GOTERM_BP_FAT RNA	splicing 7 2.32E-02
KEGG_PATHWAY Spliceosome 6 4.74E-02
t9 Category Enrichment Score: 4.03 Count P-value
GOTERM_BP_FAT regulation	of	protein	modification	process 15 7.07E-08
SP_PIR_KEYWORDS proteasome 7 9.19E-07
GOTERM_CC_FAT proteasome	complex 7 7.29E-06
KEGG_PATHWAY Proteasome 5 8.14E-03
COG_ONTOLOGY Posttranslational	modification,	protein	turnover,	chaperones 4 2.85E-02
t9 Category Enrichment Score: 1.73 Count P-value
INTERPRO Dual	specificity	protein	phosphatase	(MAP	kinase	phosphatase) 3 8.25E-04
PIR_SUPERFAMILY dual	specificity	protein	phosphatase	(MAP	kinase	phosphatase) 3 1.60E-03
GOTERM_MF_FAT MAP	kinase	phosphatase	activity 3 4.25E-03
SP_PIR_KEYWORDS protein	phosphatase 5 7.28E-03
GOTERM_BP_FAT dephosphorylation 5 3.28E-02
t9 Category Enrichment Score: 1.62 Count P-value
SP_PIR_KEYWORDS mRNA	transport 5 9.47E-04
GOTERM_BP_FAT mRNA	transport 5 4.82E-03
SP_PIR_KEYWORDS mrna	processing 6 1.87E-02
t12 Category Enrichment Score: 4.58 Count P-value
GOTERM_BP_FAT negative	regulation	of	protein	modification	process 12 9.44E-09
SP_PIR_KEYWORDS proteasome 8 8.21E-08
GOTERM_CC_FAT proteasome	complex 8 9.13E-07
KEGG_PATHWAY Proteasome 8 2.17E-05
COG_ONTOLOGY Posttranslational	modification,	protein	turnover,	chaperones 4 3.49E-02
t12 Category Enrichment Score: 1.95 Count P-value
GOTERM_BP_FAT RNA	elongation	from	RNA	polymerase	II	promoter 5 9.02E-04
GOTERM_CC_FAT DNA-directed	RNA	polymerase	II,	holoenzyme 4 3.34E-02
t24 Category Enrichment Score: 1.96 Count P-value
GOTERM_BP_FAT cellular	response	to	stress 14 1.03E-03
SP_PIR_KEYWORDS dna	repair 5 3.10E-02
t24 Category Enrichment Score: 1.88 Count P-value
GOTERM_BP_FAT positive	regulation	of	cellular	protein	metabolic	process 10 1.65E-04
SP_PIR_KEYWORDS proteasome 5 3.99E-04
GOTERM_CC_FAT proteasome	complex 5 1.31E-03
KEGG_PATHWAY Proteasome 4 5.25E-02
t24 Category Enrichment Score: 1.46 Count P-value
SP_PIR_KEYWORDS mrna	processing 7 5.61E-03
GOTERM_BP_FAT mRNA	processing 8 1.97E-02
GOTERM_CC_FAT spliceosome 5 1.99E-02
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Figure 27. The MNI identified C8-candidate genes and their encoded proteins are closely related with TDP-
43/TARDBP in a biological network. 
A representative network from IPA analysis is shown for the potential C8 targets that were highlighted in 
MNI with the 3-hour C8 treatment (t3).  TDP-43 (TARDBP) and the proteins that are known to directly 
bind to TDP-43 are highlighted in magenta.	 	
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Section Three: Effect of C8 On TDP-43 Protein Complex 	
Since TDP-43 protein was initially identified as a DNA/RNA binding protein, it 
has been shown the protein not only binds to nucleotides, but also binds with proteins, 
such as other heterogeneous nuclear ribonucleoproteins (hnRNPs) and RNA binding 
proteins, including itself forming a homo dimer.  In addition, many protein products from 
ALS-associated genes, such as HNRNP-U and ATXN2, are shown to directly bind with 
TDP-43 (Freibaum et al., 2010, Kim et al., 2013).  To ask if C8 affect the interaction of 
TDP-43 with other proteins and if the compound affects the binding of TDP-43 to its 
specific partner, we conducted non-quantitative mass spectrometry analysis with the 
GFP-immunoprecipitated hTDP-43-EGFP complex from the inducible PC12 cells. 
The TDP-43 complexes were isolated from the lysates of the PC12 hTDP-43-
EGFP cells that were treated with C8j for 24 hours or acute 1-hour treatments under 
arsenite-induced stress conditions.  In addition to the inhibitor treated groups, to identify 
the natural response of cells to recover from the arsenite-stressed condition, we added a 
group in which the toxin was removed for 1 hour before the harvesting the cells.  The 
comparison of the 1-hour arsenite-off group with 1-hour C8j treatment group will allow 
us to isolate the molecular change that is specific to the C8j treatment. 
First, the immunoprecipitation condition was validated by running the purified 
protein samples on SDS-PAGE gel, followed by the visualization with SYPRO Ruby 
protein stain.  The staining visualized the well-defined hTDP-43-EGFP band around 70 
kDa and other co-purified protein complexes (Figure 16).  The purified samples that were 
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run on a separate protein gel from whole lane were excised for LC-MS/MS analysis at the 
UMass Mass Spectrometry and Proteomics facility. 
The mass spectrometry detected 1327 proteins in 1177 families based on the 
criteria of Scaffold proteomics software that is similar, but more stringent algorithm than 
Mascot.  We used the thresholds higher than 90% probability of correct protein 
identification and 80% probability of correct peptide identification to eliminate false 
positives.  To isolate the proteins that associate with TDP-43 in the complex, we used the 
criteria in which minimum of 2 unique peptides for one protein in order to consider the 
protein to be identified.  Among 1327 proteins, we detected 158 out of 278 (57%) 
previously known TDP-43 protein binding partners, validating that hTDP-43-EGFP can 
form protein complexes with other proteins in the inducible PC12 cell model. 
We further analyzed the list of TDP-43 binding proteins to test if they were 
involved in specific biological processes or functions, such as translation and protein 
post-translational modification, by performing bioinformatics analysis for the function 
categories (KEYWORDS), gene ontology (GO), pathways (KEGG Pathway) and protein 
domains (INTERPRO) with the online bioinformatics resource Database for Annotation, 
Visualization and Integrated Discovery (DAVID) that was developed by the Laboratory 
of Immunopathogenesis and Bioinformatics (LIB).  As we expected, the analysis showed 
that the TDP-43 binding proteins were enriched with those involved in translation, 
protein folding and polymerization, glucose metabolism and tRNA metabolism (P=5E-
06) (Table 22).   In addition, the proteins, which are involved in post-translational 
modification, protein turnover, chaperone (P=5.98E-05) and signal transduction 
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mechanisms were also enriched in the list (P=1.07E-02).  These data confirms that the 
TDP-43 forms protein complexes that are enriched with translation machinery and 
protein homeostasis, and also the signal transduction mechanism that is essential for 
normal neuronal functions.   
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Table 22. The list of GO terms that were highlighted by the Database for Annotation, Visualization and 
Integrated Discovery (DAVID). 
The proteins that were detected by mass-spectrometry were analyzed by the gene functional annotation 
clustering.  To rank the biological significance, enrichment score in a corresponding annotation cluster is 
calculated based on the geometric mean of member's p-values in log scale.  The number of proteins 
involved in each annotation is listed in the Count column.  A modified Fisher Exact P-value was used for 
statistical analysis.	 	
Annotation Cluster 1 Enrichment Score: 24.06 Count P-value Annotation Cluster 7 Enrichment Score: 11.36 Count P-value
GOTERM_MF_FAT nucleotide binding 263 2.00E-49 GOTERM_MF_FAT GTPase activity 31 4.50E-15
SP_PIR_KEYWORDS nucleotide-binding 182 3.70E-33 GOTERM_MF_FAT guanyl ribonucleotide binding 57 2.10E-14
GOTERM_MF_FAT purine nucleotide binding 201 3.20E-30 GOTERM_MF_FAT guanyl nucleotide binding 57 2.10E-14
GOTERM_MF_FAT ribonucleotide binding 194 1.00E-29 GOTERM_MF_FAT GTP binding 54 1.70E-13
GOTERM_MF_FAT purine ribonucleotide binding 193 2.80E-29 UP_SEQ_FEATURE nucleotide phosphate-binding region:GTP 43 1.40E-12
SP_PIR_KEYWORDS atp-binding 130 6.60E-21 SP_PIR_KEYWORDS gtp-binding 48 7.50E-11
GOTERM_MF_FAT nucleoside binding 159 2.80E-20 INTERPRO Small GTP-binding protein 20 8.60E-04
GOTERM_MF_FAT purine nucleoside binding 158 3.20E-20 Annotation Cluster 8 Enrichment Score: 10.85 Count P-value
GOTERM_MF_FAT adenyl nucleotide binding 155 9.70E-20 GOTERM_MF_FAT translation factor activity, nucleic acid binding 29 3.20E-16
GOTERM_MF_FAT adenyl ribonucleotide binding 147 7.30E-19 SP_PIR_KEYWORDS Initiation factor 20 7.00E-13
GOTERM_MF_FAT ATP binding 145 7.80E-19 GOTERM_MF_FAT translation initiation factor activity 20 2.70E-12
UP_SEQ_FEATURE nucleotide phosphate-binding region:ATP 66 8.00E-07 GOTERM_BP_FAT translational initiation 15 1.40E-09
Annotation Cluster 2 Enrichment Score: 16.42 Count P-value GOTERM_CC_FAT eukaryotic translation initiation factor 3 
complex
8 6.80E-07
SP_PIR_KEYWORDS protein biosynthesis 71 1.50E-40 Annotation Cluster 9 Enrichment Score: 9.43 Count P-value
GOTERM_BP_FAT translational elongation 45 1.00E-30 GOTERM_CC_FAT mitochondrial part 77 7.20E-14
GOTERM_BP_FAT translation 86 1.40E-26 GOTERM_CC_FAT mitochondrial membrane 57 2.70E-11
KEGG_PATHWAY Ribosome 39 4.10E-23 GOTERM_CC_FAT mitochondrial envelope 59 4.40E-11
SP_PIR_KEYWORDS ribonucleoprotein 55 4.40E-23 GOTERM_CC_FAT mitochondrion 130 9.00E-11
SP_PIR_KEYWORDS ribosome 35 7.20E-19 GOTERM_CC_FAT organelle envelope 72 2.40E-10
GOTERM_CC_FAT ribonucleoprotein complex 84 6.50E-18 GOTERM_CC_FAT envelope 72 3.30E-10
SP_PIR_KEYWORDS ribosomal protein 40 2.20E-14 GOTERM_CC_FAT organelle membrane 103 9.10E-10
GOTERM_CC_FAT cytosolic ribosome 22 2.80E-13 GOTERM_CC_FAT mitochondrial inner membrane 46 1.10E-09
GOTERM_CC_FAT cytosolic part 31 6.20E-13 GOTERM_CC_FAT organelle inner membrane 47 2.60E-09
GOTERM_MF_FAT structural molecule activity 75 7.80E-12 SP_PIR_KEYWORDS mitochondrion 60 3.60E-05
GOTERM_CC_FAT ribosomal subunit 25 4.10E-11 Annotation Cluster 10 Enrichment Score: 9.36 Count P-value
GOTERM_CC_FAT cytosolic small ribosomal subunit 15 1.00E-08 SMART RRM 37 8.00E-15
GOTERM_CC_FAT small ribosomal subunit 16 6.10E-08 INTERPRO RNA recognition motif, RNP-1 37 2.40E-13
GOTERM_MF_FAT structural constituent of ribosome 40 4.90E-07 INTERPRO Nucleotide-binding, alpha-beta plait 37 9.00E-13
GOTERM_CC_FAT ribosome 43 2.60E-06 UP_SEQ_FEATURE domain:RRM 2 16 6.90E-07
Annotation Cluster 3 Enrichment Score: 15.29 Count P-value UP_SEQ_FEATURE domain:RRM 1 16 6.90E-07
GOTERM_CC_FAT non-membrane-bounded organelle 201 1.70E-20 UP_SEQ_FEATURE domain:RRM 3 10 8.20E-06
GOTERM_CC_FAT intracellular non-membrane-bounded organelle 201 1.70E-20 Annotation Cluster 11 Enrichment Score: 8.28 Count P-value
GOTERM_CC_FAT cytoskeleton 112 5.70E-13 GOTERM_BP_FAT protein transport 73 1.90E-12
GOTERM_CC_FAT cytoskeletal part 84 4.30E-10 GOTERM_BP_FAT intracellular transport 68 2.10E-12
Annotation Cluster 4 Enrichment Score: 13.43 Count P-value GOTERM_BP_FAT establishment of protein localization 73 3.00E-12
GOTERM_CC_FAT pigment granule 36 4.70E-24 GOTERM_BP_FAT protein localization 76 5.70E-10
GOTERM_CC_FAT melanosome 36 4.70E-24 GOTERM_BP_FAT intracellular protein transport 42 1.10E-08
GOTERM_CC_FAT cytoplasmic membrane-bounded vesicle 68 1.10E-09 SP_PIR_KEYWORDS protein transport 45 5.60E-08
GOTERM_CC_FAT cytoplasmic vesicle 73 4.00E-09 GOTERM_BP_FAT cellular macromolecule localization 43 1.00E-07
GOTERM_CC_FAT vesicle 76 4.10E-09 GOTERM_BP_FAT cellular protein localization 42 2.40E-07
GOTERM_CC_FAT membrane-bounded vesicle 68 6.60E-09 SP_PIR_KEYWORDS transport 97 3.20E-02
Annotation Cluster 5 Enrichment Score: 13.11 Count P-value Enrichment Score: 7.62 Count P_Value
GOTERM_CC_FAT intracellular organelle lumen 147 2.70E-19 SP_PIR_KEYWORDS nucleotide binding 22 2.20E-10
GOTERM_CC_FAT membrane-enclosed lumen 153 3.70E-19 SP_PIR_KEYWORDS P-loop 22 6.80E-10
GOTERM_CC_FAT organelle lumen 150 4.60E-19 SP_PIR_KEYWORDS GTP binding 12 9.20E-05
GOTERM_CC_FAT nuclear lumen 95 1.20E-07
GOTERM_CC_FAT nucleoplasm 64 4.60E-04
Annotation Cluster 6 Enrichment Score: 12.85 Count P-value
SP_PIR_KEYWORDS Chaperone 32 6.50E-14
GOTERM_BP_FAT protein folding 33 8.50E-14
GOTERM_MF_FAT unfolded protein binding 26 5.20E-13
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Next, we asked if C8j specifically affects the protein binding of TDP-43 with 
other proteins that are involved in protein degradation or aggregate disassembly to reduce 
TDP-43 granules.  First, we searched the proteins that showed increased or decreased 
binding to TDP-43 with 24 hour C8j treatment in the triplicated mass spectrometry 
experiments, and identified 34 proteins with increased and 1 protein with decreased 
binding to TDP-43 upon 24-hour C8j treatment.  Using the list of proteins, we tested if 
those proteins were involved in specific biological functions or pathways using the 
DAVID bioinformatics approach.  The proteins were involved in cytoskeleton and non-
membrane bound organelle, translation initiation, protein modification, which includes 
protein phosphorylation, dephosphorylation, and degradation, and co-enzyme metabolism 
(Figure 28). 
The binding of previously known TDP-43 binding proteins, EIF3A, G3BP2, 
PHGDH, SRSF7 and STAU1, increased with 24 hour C8j treatment (Figure 28 
Boldface).  EIF3A, G3BP2, SRSF7 and STAU1 are RNA binding proteins that are 
involved in RNA metabolism, and the increase of their binding suggests C8j might 
regulate the formation of TDP-43 complex with those proteins under arsenite stress.  The 
binding of EIF3A and PSMD14, which were identified in MNI as potential C8j target or 
immediate mediator, increased with 24-hour C8j treatment (Figure 28 *), suggesting the 
high likelihood of their involvement in C8j mode of action.  The TDP-43 binding to two 
proteins, PHGDH and PSMB2, increased with 1 hour and 24 hour C8j treatment relative 
to the DMSO treat group, but not in the 1 hour sodium arsenite off group (Figure 28 ‡), 
suggesting the C8j specific response of those proteins.  PSMB2 is a subunit of 
		
127	
proteasome and increase of its binding to TDP-43 suggests the association of TDP-43 
with proteasome system might be facilitated with C8j treatment.  The proteins, AHCY, 
GLYR1, KRT1, PPP2CA, PSMB5, PSMD14 and STAU1, increased binding under all 
treatments (1 hour or 24 hour C8j, and 1hr arsenite off) (Figure 28 Red character), 
suggesting these proteins might be involved in the dissociation of TDP-43 granules upon 
removal of stress, such as sodium arsenite, as a normal recovery response in mammalian 
cells, and C8j might be mimicking the condition to reduce TDP-43 granules. 
These data indicates that the C8j increases the binding of proteins that are 
involved in cytoskeleton and non-membrane bound organelle, translation, post-
translational protein modification in the process of reducing the TDP-43 granules.   
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Table 23 The list of proteins with increased or decreased binding to TDP-43 with various treatments, including 
C8j. 
The TDP-43 binding proteins were co-immunoprecipitated with hTDP-43-EGFP and the increased or 
decreased binding to the human TDP-43 was detected with LC-MS/MS in triplicate experiments.  The 
binding of 25 proteins increased with 24 hr C8j treatment in all three replicated experiments.  PHGDH and 
PSMB2 increased binding to TDP-43 with 1 hr and 24 hr C8j treatment.  AHCY, GLYR1, KRT1, 
PPP2CA, PSMB5, PSMD14 and STAU1 increased binding under all treatments (1 hr or 24 hr C8j and 1hr 
arsenite off).  PGAM5 decreased binding with 24 hr C8j treatment.  EIF3A, PSMD14 & PPP2CA were also 
identified as potential C8 targets in t3, t6 & t24 of MNI analysis, respectively.  Previously known TDP-43 
binding proteins (EIF3A, G3BP2, PHGDH, SRSF7 and STAU1) are highlighted in magenta.	
Protein C8/DMSO (Fold)
Std 
Error
ACOT9 2.71 0.45
ANXA6 3.13 0.15
AP3B1 8.49 6.74
ARPC1B 2.97 0.39
CAP1 7.48 5.64
DLST 1.79 0.21
EIF3A 2.15 0.54
EIF3E 3.39 0.73
EIF3F 2.09 0.49
FV1 4.15 0.38
G3BP2 3.07 0.90
IDH2 3.35 1.12
ISYNA1 4.26 1.54
KRT7 2.64 0.71
MAP4 8.31 3.78
NEFM 3.73 1.78
PPP2R1A 3.68 0.88
PRKAR1A 4.06 0.38
SEC31A 2.22 0.05
SEPT11 2.53 0.52
SRSF7 2.48 0.37
STOM 4.70 2.36
SYP 3.46 1.24
TPM4 2.98 0.83
TXNDC5 3.27 1.28
Protein C8/DMSO (Fold)
Std 
Error
PHGDH 2.23 0.43
PSMB2 3.06 1.07
Protein C8/DMSO (Fold)
Std 
Error
AHCY 6.69 3.18
GLYR1 2.92 0.77
KRT1 2.28 0.28
PPP2CA 2.53 0.59
PSMB5 8.74 3.46
PSMD14 3.21 0.58
STAU1 4.43 1.61
Protein C8/DMSO (Fold)
Std 
Error
PGAM5 0.14 0.14
Increased after: 24 hr C8j Increased after: 1hr & 24 hr C8j
Increased after:
1hr & 24 hr C8j and 1hr Ars Off
Decreased after:
1hr & 24 hr C8j
MNI t3
MNI t6
MNI t24
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Figure 28. The functional annotation clustering of C8j-responding TDP-43 binding proteins. 
The hTDP-43-EGFP co-immunoprecipitated proteins with increased binding upon 24 hr C8j treatments 
were detected with LC-MS/MS in triplicate experiments.  The protein (PGAM5) with decreased binding 
with 24 hr C8j treatment is highlighted in blue.  The proteins (PHGDH and PSMB2) with increased binding 
specifically with 1 hr and 24 hr C8j treatment were marked with ‡.  The proteins (AHCY, GLYR1, KRT1, 
PPP2CA, PSMB5, PSMD14 and STAU1) with increased binding under all treatments (1 hr or 24 hr C8j 
and 1hr arsenite off) were highlighted in red.  Previously known TDP-43 binding proteins (EIF3A, G3BP2, 
PHGDH, SRSF7 and STAU1) were highlighted in boldface.  The candidate C8 targets that were identified 
in MNI (EIF3A, PSMD14 & PPP2CA) were marked with *.	 	
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Section Four: C8j Affects Enzymatic Activity of Kinases Involved in MAPK 
Pathways in vitro 	
The phosphorylation of TDP-43 has been shown as a key component of 
ALS/FTLD-U pathology (Arai et al., 2006; Neumann et al., 2006).  In previous 
experiments we showed the TDP-43 granule inhibitors reduces TDP-43 proteins that are 
phosphorylated at S409-S410 with immunoblots.  Additionally, we have showed the 
potential role of novel phosphorylation sites of TDP-43 at T103-S104 on the TDP-43 
granule formation.  Based on these findings, we questioned whether C8 directly binds to 
a specific kinase to affect its enzymatic activity, and as a result, reducing the 
phosphorylation of TDP-43 and subsequently the formation of intracellular TDP-43 
granules. 
To ask if C8 directly affect kinases and their enzymatic activity, we performed in 
vitro kinase profiling with C8j against 383 recombinant mammalian protein kinases out 
of 518 kinases from human kinome and atypical protein kinases.  The enzymatic activity 
of four kinases was either up or down regulated by more than 20% relative to the DMSO 
vehicle control in the in vitro assay.  Two kinases, TAO kinase 3 (TAOK3/JIK) for 42% 
and leucine-rich repeat kinase 2 (LRRK2) for 30%, were up-regulated with 5 µM C8j 
treatment relative to the DMSO vehicle controls (Table 24).  In addition, the C8j 
treatment also showed inhibitory effects on two kinases, mitogen-activated protein kinase 
kinase kinase 12 (DLK/MAP3K12) for 20% and FES proto-oncogene, tyrosine kinase 
(FES/FPS) for 21% relative to the control groups.  These data suggest C8j can modulate 
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the enzymatic activity of mammalian kinases in vitro, although the inhibition or 
activation is moderate presumably due to a weak association between the compound and 
the kinases. 
These results suggest the C8j might directly bind to the kinases and affect their 
enzymatic activity, further supporting a possible involvement of the TDP-43 granule 
inhibitor in the regulation of protein phosphorylation to reduce the TDP-43 granule 
formation, however the activation and inhibition of the kinase activity we observed were 
between 20 to 43% changes.  It is essential to test if the phosphorylation of downstream 
targets of those kinases is affected by the C8j treatment to draw a conclusion of the effect 
of the compound on the kinase activity.  
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Table 24. The list of protein kinases activated or inhibited by C8j in vitro. 
The 383 mammalian wild type protein kinases from the human kinome and atypical protein kinases were 
separately incubated with 5 µM C8j in vitro and their enzymatic activity was measured.  The table lists the 
kinases that showed C8-dependent increase or decrease on the enzymatic activity more than 20% relative to 
the DMSO control groups.  SEM, standard error of the mean.  P, P-value, **** P<0.0001 with Tukey’s test.	 	
Kinase KEGG Pathway % DMSO SEM P
TAOK3/JIK MAPK Signaling 142.8 6.0 ****
LRRK2 Parkinson’s Disease 130.0 4.3 ****
DLK/MAP3K12 MAPK Signaling 79.8 0.3 ****
FES/FPS Axon Guidance 79.3 0.3 ****
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Section Five: Drug Affinity Responsive Target Stability (DARTS) of C8 	
We demonstrated the biological effects of the TDP-43 granule inhibitors in 
different TDP-43 model organisms, but the direct binding target of the compound in cells 
is still unclear.  We asked if the granule inhibitor C8 directly binds to a target protein to 
inhibit the TDP-43 granule formation.  It has been shown that the binding of a small 
molecule to a target protein significantly improves its protein stability against proteases 
with a method called drug affinity responsive target stability (DARTS) assay (Lomenick 
et al., 2009).  To identify the direct protein target of C8 under stressed conditions, we 
prepared lysates from the inducible PC12 hTDP-43-EGFP cells that were treated with 
sodium arsenite.  The cell lysates were then incubated with C8 in vitro and were 
subjected to different concentration of proteases. 
First we tested the protection of C8 on target proteins against Pronase, a mixture 
of nonspecific endo- and exoproteases isolated from Streptomyces griseus, that robustly 
digests both denatured and naive proteins (Narahashi, 1970).  With the Pronase treatment 
the proteins that were visualized on acrylamide gel with SYPRO-Ruby stain appeared as 
a smear, and as the concentration of the proteases increased the smear shifted lower in the 
gel, indicating the robust digestion of the proteins due to the protease mix (Figure 29A).  
In these conditions, there was no obvious band that only existed in the C8-treated groups 
relative to the DMSO vehicle-treated controls, indicating the TDP-43 granule inhibitor 
did not protect the target proteins against Pronase. 
Next, we tested the target stabilization of C8 against Thermolysin, a more 
selective metallo endoprotease isolated from Thermolysin from Geobacillus 
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stearothermophilus, that only hydrolyzes denatured proteins, hence is less stringent than 
Pronase.  As we observed with Pronase, the protein bands that were visualized on 
acrylamide gel appeared as a smear with the protease treatment, but Thermolysin 
generated more distinct protein bands, confirming less stringent enzymatic activity of 
Thermolysin (Figure 29B).  The protein bands shifted lower as the concentration of 
Thermolysin increased generating new bands with smaller molecular weights.  In these 
conditions, no distinct band was observable in the C8 treated groups compared to the 
vehicle treated controls, indicating that the TDP-43 granule inhibitor does not sufficiently 
stabilize the target proteins against not only Pronase, but also less stringent protease 
Thermolysin. 
In addition to the target stabilization effect of C8 on total proteins, we then asked 
whether the TDP-43 granule inhibitor directly binds to TDP-43 and stabilizes it against 
proteases.  The immunoblotting of the arsenite-treated PC12 hTDP-43 cell lysates 
showed well-defined bands of the full-length exogenous and endogenous proteins at 70 
kDa and 43 kDa (Figure 29C and D).  In both Pronase and Thermolysin digested 
samples, those bands disappeared as the concentration of the proteases increased without 
leaving no distinct protein band in the C8 treated groups compared with the DMSO 
controls.  These results indicate that C8 does not sufficiently stabilize TDP-43 from 
proteases. 
As a summary, the results from DARTS assays show that the TDP-43 granule 
inhibitor C8 has no sufficient target protective effects on total proteins against proteases, 
suggesting the binding of the compound to the target proteins is possibly very weak and 
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not sufficient enough to protect the targets from the protease digestion.  The data also 
suggests the possibility of an alternative target of C8, other than proteins, that C8 directly 
binds in cells to inhibit the granule formation.   
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Figure 29. The visualization of protease-digested proteins after the incubation of cell lysates with C8. 
The lysates from the arsenite-treated inducible hTDP-43-EGFP cells were incubated with C8.  The lysates 
were then subjected with different protease-protein ratio of (A) Pronase or (B) Thermolysin and the 
undigested proteins were visualized with SYPRO-Ruby stain after SDS-PAGE.  The protease-treated 
lysates were separately immunoblotted with anti-TDP-43 antibody to visualize the protective effect of C8 
on TDP-43 against (C) Pronase and (D) Thermolysin.  D, DMSO vehicle control.  * and ** indicate the 
full-length hTDP-43-EGFP and endogenous TDP-43, respectively.  † indicates 35 kDa Thermolysin.	 	
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CHAPTER FIVE: DISCUSSION 
Section One: Cleaved TDP-43 	
Since the first SOD1 mutation was discovered to be associated with familial ALS, 
many additional genes with ALS/FTLD-U associated mutations have been identified.  
Interestingly, a profound number of those genes are involved in RNA metabolism (TDP-
43, FUS, ATXN2 and HNRNPA1), ubiquitin proteasome pathway (UBQLN2), 
autophagy (OPTN, SQSTM1, UBQLN2 and VCP) and neuroinflammation (TBK-1).  
Furthermore, the mutations in UBQLN2 and VCP, for example, result in the 
accumulation of TDP-43 cytoplasmic inclusions in the disease affected brain and spinal 
cord tissues, highlighting the widespread involvement of the TDP-43 granule formation 
in the ALS/FTLD-U pathology. 
Currently more than 40 disease-associated genetic mutations in TDP-43 have 
been reported thus far, and the majority of the mutations are located in the C-terminus 
end where the Glycine-rich (G-rich) prion-like domain is located.  The mutations in the 
G-rich domain have been shown to increase the aggregation propensity of the TDP-43 
protein.  Furthermore, the C-terminus fragments of protease-cleaved TDP-43, especially 
the fragments with 25 kDa molecular weight, are also more aggregate prone with the 
exposed beta-strands of RNA recognition motif that is responsible for homo-dimerization 
of TDP-43 and the C-terminus prion-like protein-protein interaction domain. 
The TDP-43 proteins are cleared by both ubiquitin-dependent proteasome system 
and autophagy, and the accumulation of TDP-43-positive inclusions in the disease-
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affected tissues may suggest compromised function of those proteostasis mechanisms in 
the neurons, especially under stressed conditions. 
In this study we demonstrated a chemical compound C8 and its analogs with 
similar backbone structure are able to reduce the TDP-43 proteins with different 
molecular weights, in addition to reducing the formation of the intracellular TDP-43 
granules in the mammalian cells.  Furthermore, the effect on the reduction was 
consistently more prominent on the fragmented 25 kDa and 35 kDa species with 65% and 
91% reduction, respectively, or high molecular weight TDP-43 with 73% reduction than 
the full-length with 51% reduction.  In imaging based analysis, we observed around 70% 
inhibitory effect with C8 and C8j.  It is likely that the reduction in the arsenite-induced 
TDP-43 granules are primarily due to the reduced level of the truncated and high 
molecular weight TDP-43, suggesting the presence of a specific biological mechanism of 
C8, such as UPS and autophagy, which selectively reduces the level of TDP-43 proteins 
with low and high molecular weights.  Further study using the co-treatment of the 
proteasome and autophagy inhibitors with C8 would elucidate the light of the potential 
biological mechanism through the proteostasis mechanisms. 
 
Section Two: Phosphorylated TDP-43 
 
Bioinformatics studies, large-scale mass-spectrometry analyses, or small-scale 
studies with anti-phospho antibodies and phospho-mimetic or null expression constructs 
have shown there are more than 30 amino acid residues that are phosphorylated in TDP-
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43.  Even though many of those phosphorylation sites are distributed throughout the 
protein, the majority of those sites (18 out of 33) are located in the C-terminus end where 
prion-line protein-protein interaction domain is located, suggesting the phosphorylation at 
those amino acid residues might alter the biochemical property of the domain and 
increase its aggregation propensity. 
In ALS/FTLD-U brain and spinal cord tissues, TDP-43 is often found in 
intracellular inclusions, and is hyper-phosphorylated at serine residues 409 and 410 
(S409p-S410p), further highlighting the role of the TDP-43 phosphorylation in the 
disease pathology.  In this study, we demonstrated C8 and C8j also reduce the TDP-43 
that is phosphorylated at S409-S410 for 48% and 64%, respectively, in addition to 
reducing the protein level of full-length, cleaved and high molecular weight TDP-43.  
These data suggest the TDP-43 granule inhibitor acts through reducing the amount of 
phosphorylated TDP-43 at S409-S410 to reduce the intracellular TDP-43 granules, 
however it is also possible that an additional mechanism is contributing to inhibit granule 
formation, since the inhibitory effect of C8 and C8j we observed in imaging based 
experiment was stronger than the effect we observed on the phosphorylation sites with 
the immunoblot experiments. 
We identified novel phosphorylation sites of TDP-43 threonine 103 and serine 
104 (T103-S104) with unbiased proteomics study, and demonstrated the phospho-
mimetic mutations of those residues to aspartic acid spontaneously induced intracellular 
inclusions in human neuroblastoma.  Furthermore, under arsenite-induced stress 
conditions the TDP-43 granule formation of the T103D-S104D variant was further 
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increased at the same degree with the wild type background without synergistical effect.  
Interestingly, the phospho-null mutation of T103-S104 to alanine did not abolish the 
TDP-43’s ability to form inclusions under arsenite-stressed conditions.  These data 
suggest the phosphorylation at those novel residues are not essential, but sufficient to 
induce the TDP-43 granules. 
In a pilot experiment, we tested if C8j acts through the novel phosphorylation 
sites T103-S104 of TDP-43 to reduce the inclusions, however under basal conditions we 
did not see a significant decrease in the spontaneously formed T103D-S104D 
intracellular granules.  On the other hand, the treatment with C8j reduced the cells with 
arsenite-induced TDP-43 granules, suggesting C8j might not strongly modulate the 
phosphorylation at T103-S104 to reduce the granules.  In this experiment, the fraction of 
cells with the spontaneously formed TDP-43 granules was lower than that from other 
experiments, pointing possible experimental variability.  Further investigations are 
necessary to study the interplay of C8j and the novel phosphorylation sites. 
The newly identified phosphorylation site T103-S104 is located in the N-terminus 
of TDP-43, between nuclear localization signal and the first RNA/DNA recognition motif 
(RRM1).  Even though our data suggest the phosphorylation at T103-S104 can be 
sufficient to induce intense TDP-43 inclusions, which is similar to the observation of 
S409-S410 phosphorylation sites, it is possible that the regulatory role of those sites in 
granule formation can be different due to the opposite location within the protein.  Since 
the T103-S104 is about five amino acid residues downstream of NLS, it is possible the 
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phosphorylation at those residues may be involved in the regulatory mechanism of TDP-
43 subcellular localization. 
 
Section Three: Ubiquitinated and Phosphorylated TDP-43 
 
In ALS/FTLD-U brain and spinal cord tissues, TDP-43 is often found in 
detergent-insoluble, ubiquitin-positive intracellular inclusions and also TDP-43 itself is 
highly ubiquitinated.  In this study we demonstrated the effect of the TDP-43 granule 
inhibitor C8 on the ubiquitinated TDP-43 protein level that appear as high molecular 
weight smear with immunoblotting under arsenite-stressed conditions. 
In induced pluripotent stem (iPS) cells from ALS patients and healthy individual, 
the expression of detergent-insoluble high molecular weight TDP-43 increases as they 
undergo differentiation process over time.  At later stage of differentiation we tested, both 
C8 and C8j reduce the detergent-insoluble high molecular weight TDP-43 in the iPS cells 
from ALS patients, in addition to the control cell line.  The patient derived iPS cells allow 
us to study the effect of C8 and C8j on the endogenous level of TDP-43 with ALS 
mutations, but we observed high variability between lines and experiments.  Further 
experiments should include the internal control cell lines that are derived from the patient 
iPS cells with genetically edited its ALS mutation to the wild type sequence. 
Our study showed 1-hour short-term treatment reduce the ubiquitinated TDP-43 
protein level with high molecular weight, even though we did not see an effect of the 
inhibitor on the ubiquitinated TDP-43 protein level in 24-hour time point.  The magnitude 
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of reduction of ubiquitinated TDP-43 with C8j treatment is less than we observed in the 
total protein samples or biochemically fractionated RIPA-insoluble TDP-43 with high 
molecular weight.  Furthermore, the reduction of TDP-43 granules with C8j is more 
prominent than the effect of the inhibitor on the ubiquitinated TDP-43, suggesting the 
effect of C8j on the reduction of the ubiquitinated TDP-43 might not be the only 
mechanism to reduce the TDP-43 granules and there might be other mechanisms, such as 
inhibition of TDP-43 translation or increased activities of disaggregases. 
In addition to phosphorylation, a number of large-scale mass-spectrometry studies 
have identified eleven potential ubiquitination sites in TDP-43 protein, all in the N-
terminus side and upstream of C-terminus region.  Among all putative ubiquitination 
sites, there are two lysine (K) residues that are in a pair with tandem amino acid residues 
that can be potentially phosphorylated by kinases (serine (S), threonine (T) or tyrosine 
(Y)): K102-T103-S104 and K114-T115-T116. 
In this study, we showed T103-S104 can be phosphorylated, and the modification 
increases in the TDP-43 granule formation.  In our mass-spectroscopy study, we also 
observed K102 was ubiquitinated under arsenite-treat conditions, where TDP-43 formed 
intracellular granules.  It is possible the phosphorylation at T103-S104 regulates the 
ubiquitination at K102, or vice versa, to regulate the localization of the protein through 
affecting the availability of NLS to regulatory proteins, such as importin and GTP-
binding nuclear protein Ran (Ran-GTP), which regulate the subcellular localization of 
proteins through binding to the localization signal, subsequently affecting the formation 
of TDP-43 granules. 
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Similar to T103-S104, the phosphorylation at T115-T116 has not been studied 
extensively; one study shows that T116 can be phosphorylated by casein kinase 1 (CK1), 
but there are no other reports of the phosphorylation at T115-T116.  More than sixty 
high-throughput studies, including ours mass spectrometry, have reported K114 can be 
ubiquitinated, but the interplay between the lysine residues and the immediate 
downstream phosphorylation sites T115-T116 remains unknown. 
In addition to K102 and K114, K408 is located in the TDP-43 C-terminus end 
right upstream of the phosphorylation sites S409-S410, which are the most studied post-
translational modification sites of TDP-43 especially in the context of ALS/FTLD-U 
pathology.  Even though the interplay of ubiquitination and phosphorylation at K408-
S409-S410 might hold a key role in the TDP-43 granule formation, no high-throughput 
experiments out of more than sixty studies have shown K408 is potentially modified with 
ubiquitination. 
Among all TDP-43 ubiquitination sites, at least 36 high-throughput studies, 
including our mass-spectrometry analysis have shown the modification at K102, and our 
study highlighted the potential phosphorylation and its affect at T103-S104 on TDP-43 
granule formation.  A number of studies have reported the potential ubiquitination sites of 
TDP-43, however, it is still not clear whether the modification affects the specific 
function of TDP-43 protein, such as pre-mRNA processing, protein-protein binding, or 
the TDP-43 granule and aggregate formation.  Further detailed studies are required to 
show the interplay between the ubiquitination and phosphorylation at K102-T103-S104, 
in terms of their role in TDP-43 subcellular localization and granule formation, and a 
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potential role of the TDP-43 granule inhibitor C8 through the modification of those 
residues. 
 
Section Four: TDP-43 Protein Turnover and Granule Formation 
 
The protein level of TDP-43 is tightly regulated through auto-regulation of its 
mRNA transcript by promoting RNA instability, and simply overexpressing the protein 
can induce intracellular granule formation.  Furthermore, the ALS-associated mutations 
of TDP-43 with increased aggregate formation can increase its protein half-life.  In our 
inducibly cell line model, overexpression of hTDP-43-EGFP induces approximately 20% 
cells with TDP-43 granules under basal conditions.  Furthermore, the EGFP-tagged 
protein showed increased stability relative to the endogenous TDP-43 under arsenite-
stressed conditions, recapitulating the phenotype of TDP-43 with disease-associated 
mutations. 
Our preliminary study showed the C8j had no effect on the rate of the exogenous 
hTDP-43-EGFP protein turnover, including that of the endogenous TDP-43 and beta-
actin observed with the similar slope of the graphs between DMSO and C8j groups.  On 
the other hand, we saw a trend in which the protein level of cleaved hTDP-25-EGFP 
declined over time where the slope of the DMSO-treated group stayed leveled, however 
further experiments are required to confirm the change with statistical analysis.  When 
the newly synthesized proteins were labeled with AHA, the cells were not treated with 
C8j and the protein synthesis or degradation was not potentially altered during this 
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period.  Hence, it is possible the observed reduction in the cleaved form might be due to 
the clearance of the protein that was stimulated by the C8j treatment, however additional 
experiments need to be performed to statistically analyze the data and draw the final 
conclusion of the experiments. 
In our PC12 hTDP-43-EGFP model system, the arsenite treatment induced TDP-
43 granule formation within three hours, and the effect reached to the plateau at around 
70% cells with granules in subsequent time points in live cell imaging.   In the condition, 
the fraction of cells with TDP-43 continuously decreased over time with the C8j 
treatment.  The effect of C8j on TDP-43 granules was similar to what we observed with 
the hTDP-25-EGFP protein level in the pulse-chase experiment, where the level of the 
cleaved fragment continued to decrease over time and reached at approximately 50% of 
the initial protein level after 24 hours.  In addition, our collaborator Dr. Yongjie Zhang at 
Dr. Leonard Petrucelli’s laboratory in Mayo Clinic (Jacksonville, FL) transiently 
overexpressed EGFP-hTDP-25, and observed 50% reduction of cells with TDP-43 
granules after 24 hours of 5 µM C8 treatment relative to the DMSO vehicle control 
(Personal Communication).  The longer 48-hour treatment reduced the cells with granules 
by 60%.  These data suggests that C8j might be acting on the degradation of the cleaved 
fragment to reduce the TDP-43 granule formation. 
We saw the decreased level of hTDP-25-EGFP with C8j, however it is also 
possible that C8j might be reducing the production of truncated TDP-43 by inhibiting 
proteases.  Further studies are required to elucidate the effect of C8j on the production of 
TDP-25 fragments. 
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Section Five: TDP-43 Protein Function 
In neurons TDP-43 is localized in both nucleus and cytoplasm, especially in the 
soma and dendrites, forming RNA granules, and it regulates neuronal plasticity and the 
ALS-associated mutations of TDP-43 reduce the dendritic branching.  TDP-43 also has 
been shown to regulate many mRNA transcripts that are involved in calcium ion 
signaling, synaptic functions and neuronal development, highlighting the crucial 
regulatory role of TDP-43 in neuronal functions. 
In mammalian primary neurons, the overexpression of mutant TDP-43 protein 
becomes toxic over time, although the mechanism is still not clear.  In our experiments, 
the overexpression of wild type TDP-43 protein shortened the total dendritic length of 
primary mouse hippocampal neurons.  In addition, the ALS-associated A317T and 
Q334R variants of TDP-43 also shortened the dendrites (Figure	25).  In all genetic 
backgrounds, the TDP-43 granule inhibitor C8j reversed the shortened dendrites that 
were induced by the overexpression of TDP-43.  Furthermore, the effect of C8j was 
specific to TDP-43, since we did not observe the elongation of dendrites with C8j in 
EGFP-expressing neurons, highlighting C8j can be active on the primary neurons and the 
effect is selective to the TDP-43 protein function or toxicity. 
In Drosophila melanogaster, on the other hand, the overexpression of human wild 
type TDP-43 protein promotes dendritic branching in sensory neurons.  Furthermore, the 
mutations of TDP-43 that are associated with ALS have decreased dendritic branching 
potential on those neurons, suggesting a loss-of-function phenotype of the mutations.  
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Our study demonstrated the TDP-43 granule inhibitor C8j is biologically active in 
Drosophila, and it is able to modulate the protein function of TDP-43 on dendritic 
branching of fly sensory neurons.  Furthermore, the data suggest the compound is able to 
ameliorate the loss-of-function phenotype of the ALS-associated Q331K TDP-43 protein 
in those neurons, and its effect was specific to the mutant protein.  At this stage, it is still 
not clear if the loss-of-function phenotype of Q331K in the Drosophila model is due to 
the loss of functional TDP-43 protein in neurons through intracellular aggregate 
formation.  Since observed the reduction TDP-43 granules in mammalian cells with the 
C8j treatment, it is possible the inhibitor is also rescuing the protein function through 
activating proteostasis mechanism and reducing those aggregates in the Drosophila 
neurons. 
 
Section Six: Mode of Action of C8 and C8j 
 
Many RNA binding proteins form intracellular inclusions depending on the 
cellular microenvironment, such as stress granules under stress conditions, to respond the 
new condition by rapidly consolidating the mRNA transcripts and associated translational 
machinery into the non-membrane bound granules, and funneling the cellular resources to 
the expression of essential stress-response proteins for survival.  In ALS/FTLD-U, many 
proteins that are associated with RNA metabolism, such as TDP-43, FUS, HNRNPA1, 
ATXN2 and MATR3, have been discovered to form inclusions in the disease-affected 
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neurons, and the known disease-associated mutations of those proteins have increased 
propensity to form those inclusions. 
It has been postulated that in the early stage of RNA granule formation, the main 
driving force of its mechanism is through diffusion, and increased local protein 
concentration is enough to form the granules in liquid-like state, especially with the 
dimerization domain and less-structured prion-like domain of RNA biding proteins.  As 
the duration of the granule formation persists, it is thought the granule’s state shift from 
the liquid-like dynamic state to more solid-like thermodynamically stable aggregates. 
The expression of TDP-43 protein level is tightly regulated in cells through auto-
regulation of the mRNA transcript stability.  In our PC12 cell hTDP-43-EGFP cell 
model, the overexpression of exogenous protein was sufficient to drive the formation of 
the intracellular TDP-43 granules with increased half-life of the protein.  In addition, the 
overexpression increased the truncated hTDP-25-EGFP protein with increased aggregate 
propensity with the exposed beta-strand in the second RNA recognition motif (RRM) and 
the prion-like C-terminus G-rich domain. 
The TDP-43 protein is degraded through ubiquitin proteasome system and 
autophagy depending on the soluble or aggregated state of the protein.  Similar to what is 
postulated with general RNA binding proteins, it is possible that TDP-43 granules are 
presumably in liquid-like, more dynamic state at earlier stage of stress, in which 
proteasome system can be the major mechanism to clear the TDP-43 protein, especially 
the truncated aggregate-prone species, upon the removal of the stress.  With increased 
duration of the stress conditions, TDP-43 granules may become less detergent soluble, 
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solid-like aggregated state, and the autophagy may be required to clear the aggregated 
TDP-43. 
The effect of the TDP-43 granule inhibitors C8 and C8j on the TDP-43 granule 
inhibition seems to be specific to TDP-43.  Matrin-3 (MATR3) is another ALS-
associated RNA biding protein that forms intracellular inclusions in the spinal cord 
tissue, and its mutations found in ALS increases nuclear and cytoplasmic MATR3.  The 
protein also responds to arsenite-insult by forming the intracellular inclusions, similar to 
TDP-43.  In our laboratory, we tested if C8j reduces the MATR3 granules, but the 
treatment did not decrease the granule formation, while the TDP-43 granules formation 
was reduced (Personal Contact).  In our experiments of C8 and C8j with the inducible 
PC12 cell system, we observed the reduction of full-length, truncated, high molecular 
weight, detergent-insoluble, phosphorylated, and ubiquitinated TDP-43 proteins in 
variable degrees, postulating the possibility of multiple biological targets of the 
inhibitors, but based on the data, their effect seems to be specific to the TDP-43 protein. 
Many genes identified in ALS/TFLD-U are involved in diverse array of biological 
processes, such as RNA metabolism, DNA-damage repair, ubiquitin proteasome 
pathway, and autophagy.  In our unbiased gene-expression and systems biology study 
with the TDP-43 granule inhibitors C8 and C8j, a profound number of candidate genes 
that were identified as potential targets or mediators of the TDP-43 granule inhibitors 
were from the proteostasis pathway, such as PSMC1, PSMD5 and PSMD6 that are 
component of cytosolic 26S proteasome subunits. 
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Furthermore, even though the degree of activation was weak in vitro, C8j 
increased the kinase activity of leucine-repeat rich kinase 2 (LRRK2), which is a well-
known contributor of another major neurodegenerative disease, Parkinson’s disease (PD).  
Our laboratory has shown LRRK2 is a positive regulator of autophagy, and the PD-
associated mutation G2019S of LRRK2 reduces its activator function.  In the study the 
expression of the wild-type LRRK2 was protective for C. elegans dopaminergic neurons 
against the insult of alpha-synuclein, an aggregate prone amyloidgenic protein in PD.  In 
addition, the data from our unpublished study suggests that the LRRK2 promote 
autophagy through directly interacting with histone deacetylase 6 (HDAC6), a protein 
deacetylase and a master regulator of autophagy. 
In addition to HDAC6, LRRK2 has been shown to phosphorylate the GTPase 
Rab5b, which regulates the trafficking of early endocytic vesicles and regulates the 
formation of autophagosome at an early stage of autophagy.  In neuronal culture, the 
overexpression or knocking down LRRK2 disrupts the vesicle endocytosis when the 
neurons are depolarized, suggesting the function of LRRK2 in cells is finely tuned and 
the slight modulation of its protein level or activity might be sufficient to induce the 
profound biological effects in endocytic trafficking and autophagy.  Thus, the moderate 
up regulation of LRRK2 with C8j might be sufficient to induce the activation of 
autophagy and the clearance of TDP-43 granules. 
One of the potential mechanisms of the C8 and C8j might be the direct activation 
of LRRK2 kinase activity by C8, and subsequent activation of autophagy through 
modulating the HDAC6 and Rab5b functions.  LRRK2 is a  
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It is interesting to see if C8 and its analogs are able to activate the autophagic influx using 
co-treatment with known autophagy inhibitors, such as 3-methyladenine and 
Bafilomycin, and see if the co-treatment will abolish the C8’ ability to reduce the TDP-43 
granules.   
In addition to the proteostasis pathway as a potential target of C8, our study 
showed other proteins or genes that are involved in biological mechanisms, such as signal 
transduction mechanisms.  Protein phosphatase 2 regulatory subunit B, alpha isoform 
(PPP2R2A) is thought to be responsible for the localization and specific activity of the 
protein phosphatase 2 (PP2A).  Even though mechanism is still unclear, it has been 
shown that the mutant TDP-43 reduces the activation of AMP-activated protein kinase 
(AMPK), dependent on PP2A by increasing the dephosphorylation of AMPK.  It is 
possible that TDP-43 is involved in the regulatory mechanisms of energy metabolism and 
stress induced pathways through AMPK, where C8 reduces the TDP-43 inclusions.  
TDP-43 might associate the regulatory subunit of PP2A, PPP2R2A, and the association 
of those proteins might be responsible for the change in the phosphorylation status of 
TDP-43.  Our bioinformatics study showed another subunit of protein phosphatase 2, 
PPP2CA, which can be a direct target or mediator of C8, although the direct 
dephosphorylation of TDP-43 by PP2A yet needs to be demonstrated.  We are currently 
performing further analysis of the mass spectrometry results to see the effect of C8j on 
the TDP-43 protein complex formation. 
In this study we did not see the protection of proteins by C8 after two different 
protease treatments.  It is possible the protein level of C8 target might be below the 
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detectable level with SYPRO Ruby stain.  In fact, mass spectrometry of a whole gel 
excise is often utilized to detect low abundant proteins that were targeted by studied 
compounds in DARTS.  Secondly, the binding of C8 might not be sufficient enough to 
protect the targeted proteins from the protease digestion.  It is possible the binding of the 
compound does not block the protease cleavage sites of C8 targets.  Finally, it is possible 
that C8 does not directly bind to proteins as a mode of action, but acting on other 
macromolecules within the cells affecting the biological processes such as energy 
metabolism or oxidation to reduce the formation of TDP-43 granules under stress 
conditions.  In fact, the oxidative state of TDP-43 that was detected by mass spectrometry 
was slightly lower with C8j treatment than the DMSO treated group, represented by the 
less number of oxidized sites in the peptides that were detected by the mass spectrometry. 
The C-terminally cleaved TDP-43, TDP-25, has higher propensity to form 
aggregates and the protein level is kept low in cells under basal conditions.  Under 
stressed conditions, such as arsenite treatment, the full-length TDP-43 is cleaved and 
produces TDP-25, which facilitates the formation of intracellular TDP granules with 
mRNA transcripts from house keeping genes, and allows the cells to response to the new 
environment by shuttling the cellular resources to express the translation of stress-
response proteins.  Those early stage TDP granules can be clear by proteasome pathway, 
but extended stress condition is thought to induce the further transition of those granules 
to less reversible TDP aggregates, which requires autophagy for clearance.  It is possible 
that the TDP-25 with its aggregate prone potential might be acting as a positive regulator 
of TDP-43 granule formation, and the protein level is tightly regulated by ubiquitin-
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dependent proteasome pathway or autophagy, depending on the duration of stress 
conditions.  Under stressed conditions, C8j might be acting through the protein 
translocation from nucleus to cytoplasm by modulating the phosphorylation status at 
T103-S104 near NLS, and also facilitating the degradation of the cleaved fragments.  It is 
possible that even the subtle change or dysregulation of the TDP-25 from the mutations 
in the G-rich domain or phosphorylation of the region might increase the risk of 
developing irreversible TDP-43 aggregates over long period of time, often found in the 
ALS pathogenesis with the disease onset in the later life stage.  C8j might reduce the 
aggregate prone TDP-25 by activating the cellular pathways that are involved in the 
reversal of aggregate formation or the clearance of the aggregated proteins through UPS 
or autophag.  
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Section Seven: Future Direction 	
In this study, we discovered the novel phosphorylation sites of TDP-43 at the 
residues T103-S104 that were not been previously described in a literature.  Furthermore, 
we demonstrated the potential role of the phosphorylation at T103-S104 on the TDP-43 
granule formation through the expression of phospho-null and mimetic variants in 
mammalian cell models.  We are currently testing if the treatment of C8j decreases the 
granules that are induced by the T103D-S104D phospho-mimetic mutations, especially 
under arsenite-stressed condition. 
In addition, we are producing anti-phospho-T103-S104 polyclonal antibody that 
can specifically detect the phosphorylation at those amino acid residues.  Using the 
purified antibody, we test if the phosphorylation at those novel residues are associated 
with ALS/FTLD-U pathology and it is specific to the aggregated form of TDP-43 in the 
brain and spinal cord tissues from disease affected patients. 
Furthermore, we highlighted the involvement of proteostasis pathway as a direct 
target or mediator of the granule inhibitor through the unbiased approaches.  Further 
detailed analysis of the data from gene-expression and proteomics results, especially from 
the early time points, is required to identify an upstream regulator of the homeostatic 
pathway that is regulated by C8 and its analogs.  Genetic knockdown or over-expression 
analysis of the regulator would elucidate the light to the biological effect of C8 to reduce 
TDP-43 granules. 
The mass spectrometry analysis highlighted the list of proteins of which binding 
to TDP-43 was increased under arsenite treated conditions.  We expect these proteins 
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might be involved in either clearance of TDP-43 granules through disassembly or 
degradation.  Especially EIF3A was highlighted both in MNI analysis and the mass 
spectrometry.  We plan to knockdown the protein to observe the effect on the TDP-43 
granule formations, and to test if the effect of C8j on TDP-43 granule inhibition is 
dependent on the protein. 
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